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Despite continuous exposure to various fungi, present as part of the commensal fl ora or present 
in our environment, healthy immune competent individuals exhibit a high innate resistance to 
 invasive fungal infection. In the early 1900s Aspergillus spp. infections were rare and of little clinical 
importance. This changed when aggressive immunosuppressive therapies were used to treat patients 
with cancer. Medical treatments that included cytotoxic chemotherapy, bone marrow transplantation 
or solid organ transplantation rendered a host susceptible to suff er an invasive fungal disease. This was 
acknowledged in the 1950’s and 1960’s when an increase in frequency in secondary mycoses was 
 observed.1 The striking increase in the incidence of candidiasis and aspergillosis appeared causally 
 associated with modern chemotherapy and secondary mycoses were recognized as an important 
 contributory cause of death in leukemia patients. Among those infections Candida spp. represents the 
most common fungal opportunistic pathogen and Aspergillus spp. represents the major air-born fungal 
opportunistic pathogen of invasive fungal disease. The clinical relevance of invasive aspergillosis (IA) as 
a complication of treatment was confi rmed by Young et al. who described a series of 98 patients with 
this disease between 1953 and 1970.2 Approximately 90% of the patients suff ered from  hematological 
disease and most cases were confi rmed postmortem. Among the Aspergillus spp.,  Aspergillus  fumigatus 
is the most frequently observed in IA.3 A. fumigatus is found ubiquitous in nature and has a wide 
 geographical distribution and the incidence of infection is related to several factors including the 
underlying conditions and the treatment regimens. 
The priest and botanist Pier Antonio Micheli was the fi rst in 1729 to describe a fungus in the book ‘Nova 
Plantarum Genera’ that he named Aspergillus due to its resemblance of its microscopical  morphology to 
an aspergillum, a brush or instrument that is used for sprinkling holy water. A. fumigatus is a  saprophytic 
fungus that plays an important role in recycling environmental carbon and nitrogen in the  composting 
procedure. It has thermotolerant properties and is one of the few fungi able to cope with the high 
temperature during composting.3 Aspergillus spp. exhibit typical morphological features that  enables 
diff erentiation from other fungi. Macroscopically they are characterized by rapid growth, with a  powdery 
texture and a variable color from white to various shades of green, or from brownish to black depending 
on the species and type of agar used. Microscopically Aspergillus spp. are characterized by the presence 
of narrow, dichotomously branched septate hyphae. The conidiophores are a branch of the  vegetative 
hyphae originating from the foot cell and ending with a vesicle (Figure 1). A. fumigatus  exhibits 
 columnar conidial heads with a fl ask-shaped vesicle, named phialides, and has rough conidia that 
are  macroscopically green. Recently, the taxonomy of A. fumigatus has been revised by  incorporating 
sequence-based information. At present, partial Beta-tubulin or calmodulin sequences are the most 
promising loci for Aspergillus identifi cation to the species level. Aspergillus section Fumigati, previously 
identifi ed as A. fumigatus based on macroscopic and microscopic morphology, now contains as many 
as 33 diff erent species, 10 anamorphs and 23 teleomorphs based on sequence-based identifi cation.4 
A.  fumigatus can cause a wide spectrum of diseases ranging from mild to severe life-threatening 
 symptoms. The primary route of infection of A. fumigatus is by inhalation of air-borne conidia and 
 therefore primarily aff ects the lungs, causing four main syndromes. These include the relative mild 
 syndromes;  allergic bronchopulmonary aspergillosis (ABPA) in patients with altered lung function such 
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as asthma and cystic fi brosis patients and chronic necrotizing pulmonary aspergillosis (CNPA) in patients 
with structural lung disease. The severe syndromes caused by A. fumigatus include aspergillomas in 
preexisting lung cavities such as in tuberculosis patients and invasive aspergillosis (IA) found in severely 
immunocompromised patients.5,6
A. fumigatus and the host response
Normally in immune competent individuals the fi rst line of host defense against conidia, that are 
not removed by mucociliary clearance, consists of the innate immune response by macrophages 
that  ingest and kill conidia and in response to this process produce cytokines and chemokines. Also 
 epithelial cells play an important role, they secrete soluble antimicrobial compounds that play a 
direct role in airway  defense and are likely to assist in initiating proinfl ammatory responses against 
A.  fumigatus conidia. In the lung, alveolar macrophages engulf and destroy conidia,  additionally 
 neutrophils form aggregates around conidia in the airways of immune competent mice in vivo.7  Recruited 
neutrophils  cooperate to inactivate conidia and, together with alveolar macrophages,  prevent conidial 
 germination in  immune-competent hosts.7 The ability of neutrophils to attack and kill A. fumigatus 
depends on the Toll like receptors TLR2 and TLR4 and the dectin-1 receptor, which  recognize  diff erent 
components of the fungal cell wall.8 Upon recognition the innate immune system  facilitates chemokine 
and  cytokine  production,  secretion of  antimicrobial compounds and stimulation of  phagocytosis. In 
immune  compromised individuals or when conidia outnumber the macrophages, conidia can evade 
 macrophage killing and germinate to produce hyphae. The second line of human antifungal defense 
consists of neutrophils that adhere to and kill the hyphae of the fungus.9 Neutrophils play an important 
role in the defense against fungi since patients undergoing periods of neutropenia are known to be 
at high risk of developing invasive  fungal infection. Neutrophils can rapidly degrade pathogens by 
 proteolitic enzymes and NADPH oxidase, which rapidly produces reactive oxygen species (ROS).10 
Figure 1. (A) Microscopic morphology of A. fumigatus structure. (B) Microscopic image of A. fumigatus, 100x magnifi cation (kindly 
provided by Ton Rijs).
A B
13
 1
Chronic granulomatous disease (CGD) patients have defects in the NADPH oxidase enzyme complex 
and are highly susceptible to bacterial and  fungal  infections.11 However, whether ROS is  essential 
for killing Aspergillus is still under debate. When the  immune system cannot stop or control hyphal 
growth, the hyphae can invade and destruct  surrounding tissue in order to obtain nutrients necessary 
for growth. Depending on the severity of  immune  suppression  A.  fumigatus may grow uncontrolled 
and may  disseminate.5 Although over 90% of IA cases involve the lung, other organs may be aff ected 
including the  sinuses and the brain. Aspergillus is an angiotrophic fungus and infection of the vessels is 
a characteristic  pathological feature in IA and when left untreated the disease may spread to any organ. 
The role of the adaptive  immune system in IA has not been fully elucidated yet. The daily clearance of 
conidia relies solely on the innate immune  system and the adaptive immune system is expected to 
play a role in an established IA. Aspergillus  specifi c antibodies have been detected in patients with IA 
but their functionality could not be determined and was considered to be minor.8 Animal experiments 
have shown that mice which lack the functional T cells or both T and B cells, are not more susceptible 
to IA than wild-type mice.7 In  contrast, adoptive transfer of Th1 cells and DC vaccination have both 
shown protective eff ects against IA.12,13 The innate and adaptive immunity are tightly controlled and 
interconnected, therefore this complex interplay needs further investigation to identify the key players 
in eliminating Aspergillus during invasive infection.
Epidemiology and Incidence of IA
The incidence rates of IA vary considerably in diff erent studies. There is an increasing immunocompromised 
patient population, and in addition to the well known risk groups, such as patients with certain 
hematological malignancies, new risk groups are emerging such as critically ill patients and patients 
with severe COPD.14 In patient populations with similar degree of immune suppression and underlying 
disease not all patients but only a subset will develop IA. Specifi c patient groups are at risk for IA with the 
most important clinical risk factor being a prolonged and profound neutropenia. Other important factors 
associated with an increased risk for IA are cancer and chemotherapy, administration of corticosteroid 
therapy, genetic background and immunosuppression to treat allograft rejection. The risk of IA depends 
further on the phase of the treatment of the underlying disease and a history of IA. The diagnosis of IA 
remains diffi  cult and therefore probably a signifi cant proportion of cases of IA remain undetected. A 
wide range of incidence numbers of IA are observed in diff erent centers, although the highest incidence 
rates, of 5 to 24% are observed in patients undergoing therapy for acute leukemia. For other patient 
groups lower incidence rates are reported, yet the mortality of IA remains signifi cant in all patient groups 
(Table 1).15
Diagnosis of IA
Table 1. Incidence and mortality rates of IA for diff erent patient groups.15 
Patients
Acute Leukemia 
Allogeneic haematopoietic stem cell transplantation
Solid organ transplantation
Other causes of immunosuppression* 
 *(burns, AIDS, intensive care unit)
Mortality (%)
30-40 
60
50-60
70-85
Incidence (%)
5-24
10 
11-14
4-7
14
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The route of infection of IA is most often via the lungs and symptoms observed can be fever, dyspnea 
and respiratory failure. Early diagnosis of IA increases the probability of a favorable outcome but 
clinical symptoms rarely allow for early diagnosis as they are not specifi c for IA. Due to the diagnostic 
uncertainty, consensus defi nitions have been proposed aimed at facilitating clinical research. The 
consensus defi nitions were fi rst published in 2002 and were recently revised.16 Briefl y, IA is categorized 
as possible, probable or proven depending on the level of evidence. The defi nitions depend on host 
factors, clinical factors and mycological evidence of infection.16 Important diagnostic tools in IA are 
the biomarkers galactomannan and 1,3 beta-D glucan, and the high-resolution CT scan (HRCT). In 
neutropenic patients nodular lesions, sometimes surrounded by a halo (halo-sign) are suggestive for 
an invasive fungal infection. The lesions are early markers of disease. An air-cresent sign is also highly 
suggestive of invasive fungal disease, but is not an early marker. HRCT proved to be superior to the 
traditional chest X-ray for detection of pulmonary lesions in neutropenic patients. Additionally, the 
use of HRCT led to earlier diagnosis of IA and improved survival when early diagnosis was combined 
with early surgical intervention.17 HRCT imaging may be combined with galactomannan monitoring. 
Galactomannan is a cell wall component that is released by aspergilli during infection. The antigen can 
be detected in serum and other biological specimens such as urine and in lavage fl uid obtained with 
bronchoscopy. Galactomannan has been shown to be an early marker of IA. This pre-emptive approach 
has been shown to be feasible in certain centers, but strategic studies are being performed to establish 
if this approach is safe and eff ective compared to the empiric treatment approach. Empiric therapy 
involves starting antifungal therapy in high risk patients who remain febrile despite treatment with 
broad-spectrum antibacterial agents. In this strategy it remains unclear if the patient had an invasive 
fungal disease and an etiological diagnosis is seldom obtained. Culture is positive in only 30 to 50% 
of patients, and becomes positive usually when the fungal burden is relatively high. Identifi cation of 
Aspergillus to the species level is relevant for the therapeutic management in IA. The clinical experience 
with 1,3 beta-D glucan in the management of IA is still limited. Circulating glucan was found in patients 
with IA, but the assay will also be positive in patients with other fungal diseases such as candidemia 
and infections due to certain fungi including due to Fusarium spp..18 Furthermore, 1,3-beta D glucan 
is not specifi c for fungi, as it can also be found in plants and bacteria.19 Clearly the role of glucan in 
the management of invasive fungal infections remains to be determined. Another potentially useful 
diagnostic tool for the diagnosis of IA that is still under development is nucleic acid detection of A. 
fumigatus. However, standardization and optimization are still under discussion.20,21 
Treatment of IA
An important advance in the treatment of IA has been made by the introduction of new compounds, 
mainly of the triazole class, and by the clinical trials that have been performed to provide evidence 
for their clinical use. On the basis of clinical evidence thus obtained treatment guidelines have been 
established.22 The treatment of IA is based on surgical intervention, antifungal therapy and reduction 
of immunosuppression if possible. Surgical removal of fungal debris or lesions should be performed 
when feasible and plays predominantly a role in the treatment of Aspergillus sinusitis and central 
15
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nervous system aspergillosis.23 In clinical practice, surgical intervention is not commonly used due to the 
propensity to bleeding in many patients. 
There are three classes of antifungal compounds that are clinically licensed for treatment of IA including 
the polyenes, azoles and echinocandins. The choice for a certain compound is primarily based on 
the evidence obtained in clinical trials, but also on the identifi cation of the fungus causing infection, 
if possible. An overview of the main properties of the diff erent antifungal compounds is depicted in 
Figure 2.
 
The most used polyene is amphotericin B that is available in diff erent formulations to improve effi  cacy and 
tolerability. The compound was originally extracted from Streptomyces nodosus, a fi lamentous bacterium, 
in 1955.24 The polyenes bind to ergosterol in the fungal cell membrane and forms membrane-spanning 
channels that cause leakage of cellular components and osmotic cellular lysis that can eventually lead 
to cell death. The second mechanism of action of the polyenes is the involvement of oxidative damage 
of the cell linked to its own oxidation.25 Conventional amphotericin B has long been the only antifungal 
drug available for treatment of IA. More recently, lipid-formulations were developed that reduced the 
toxicity, but retained the effi  cacy of the drug. The lipid-formulations of amphotericin B include liposomal 
amphotericin B (Ambisome), amphotericin B lipid complex (ABLC, Abelcet) and amphotericin B colloid 
dispersion (ABCD, Amphocil). Liposomal amphotericin B was shown to be eff ective for the primary 
treatment of IA and is considered an important drug for patients with IA who fail to voriconazole therapy 
or are intolerant to the drug. Due to the broad spectrum of the drug it also commonly used in patients 
suspected of invasive fungal disease, but without documentation of Aspergillus as cause.26
Antifungal azoles can be divided into two groups, the imidazoles which are mostly used topically and the 
Figure 2. Schematic overview of mechanisms of action of the antifungal drugs used for treatment of invasive aspergillosis (IA). 
Azoles and echinocandins both block formation of essential cell wall components by enzyme binding. Amphotericin B forms pores in 
the fungal cell membrane and thereby causes leakage of essential cellular components.
16
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triazoles which have greater affi  nity for fungal rather than mammalian CYP450 enzymes. Nowadays for 
treatment or prophylaxis of IA the azole compounds play the most important role with the exception of 
fl uconazole which exhibits no relevant activity against A. fumigatus. The azoles inhibit fungal cell growth 
by inhibiting an enzyme in the ergosterol pathway; lanosterol 14-alpha-demethylase encoded by the 
cyp51 gene in A. fumigatus. Azoles bind with their nitrogen group in the azole ring to the heme group 
located in the center of the CYP51 protein and thereby blocking sterol synthesis at the level of the sterol 
C-14-alpha demethylase. As a result it leads to the substitution of methylated sterols and ergosterol 
depletion in the fungal membrane as well as accumulation of toxic sterol intermediates that eventually 
cause inhibition of fungal cell growth.27,28 The azoles are the largest class of antifungal compounds and 
are relatively well tolerated, act fungistatic and can all be administered both intravenously and orally 
except for posaconazole which can only be administered orally. Voriconazole is an extended spectrum, 
synthetic azole derivative of fl uconazole and was shown to be superior to amphotericin B and other 
licensed antifungal therapy for the primary treatment of IA.29 This drug is used as fi rst line therapy for IA 
in many medical centers throughout the world, although it should be noted that due to its nonlinear 
pharmacokinetics drug monitoring is needed for optimal therapy.30 Posaconazole was shown to be 
eff ective for the prevention of invasive fungal diseases in neutropenic patients and in patients with 
severe graft-versus-host-disease.31,32 
The echinocandins are lipopeptides that were discovered when natural peptides were screened 
for antifungal activity in the 1970’s.33 There are three drugs of this group that have been developed 
now for parental administration only; caspofungin, micafungin and anidulafungin.34 By targeting the 
enzyme (1,3)-beta-D-glucan synthase that is absent in mammalian cells, the echinocandins interfere 
with the synthesis of the polysaccharide (1,3)-beta-D-glucan. This essential cell wall molecule forms a 
fi bril of three helically entwined linear polysaccharides and provides fungal cell wall integrity. Inhibition 
of the (1,3)-beta-D-glucan synthase results in fungal cell wall stress and loss of cell wall integrity. The 
echinocandin caspofungin has been investigated for its activity against Aspergillus spp. and the drug 
acts fungistatically by causing aberrant growth of hyphae at the apical tips and killing does not occur.35 
The drug is also eff ective as salvage therapy in IA and showed effi  cacy as alternative empiric therapy 
comparable to liposomal amphotericin B for certain patients.36,37
 
Epidemiological breakpoints of antifungal drugs
Although acquired resistance among Aspergillus spp. was long considered to be an uncommon 
phenomenon, the number of studies that report azole resistance in A. fumigatus has increased in recent 
years.38-44 Host factors play an essential role in the outcome of therapy, but there is increasing evidence 
that the susceptibility of the isolate also plays a role. Minimum inhibitory concentrations (MIC) testing of 
Aspergillus spp. is not routinely performed in most clinical microbiology laboratories. Furthermore, clinical 
breakpoints of antifungal drugs are lacking. MIC breakpoints can be established using an approach 
involving the epidemiological distribution of MICs, the pharmacokinetic and pharmacodynamic 
properties of the agent and results of clinical studies that correlate the MIC of the isolate with the 
outcome of the patient. To establish a clinically derived breakpoint for Aspergillus spp. several diffi  culties 
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are seen. These include a highly variable bioavailability of azoles, low frequency of positive cultures, a 
lack of markers for progression of disease and a substantial impact of the underlying condition of the 
patient. To use epidemiological distribution of MICs to derive breakpoints, suffi  cient wild-type isolates 
and those in the resistance range will be needed. However, determination of resistance genotype 
needs to be available and the impact of a particular mutation must be profound and unequivocal. Due 
to the diffi  culties in establishing clinical MIC breakpoints, epidemiological cut-off  values (ECVs) have 
been defi ned (Table 2).45-47 ECVs discriminate the wild-type strains from those with acquired resistance 
mechanisms if drugs display a bimodal MIC distribution. Diff erent methods for in vitro susceptibility 
testing are being used in clinical microbiology laboratories such as the assay published by the Clinical 
Laboratory Standard Institute (CLSI) and the European guidelines for in vitro susceptibility testing of 
antifungals against Aspergillus spp. and molds (EUCAST).48,49
Antifungal resistance in A. fumigatus
The molecular basis of the development of antifungal drug resistance is not well understood but is 
necessary in order to understand the impact and development of this phenomenon. For the antifungal 
class of polyenes, containing the antifungal compound amphotericin B, development of resistance 
by A. fumigatus is considered to be a rare phenomenon.50 For the echinocandins that have only been 
available recently, epidemiological data of resistance directed against this group is rare. However, a 
target mutation in the FKS1 gene and overexpression of the FKS1 gene have both been described to be 
related to echinocandin resistance.51,52 The most observed antifungal resistance is directed against the 
azole class compounds, also the class that is most often used during long term antifungal treatment. 
The consequences for treatment of IA with an azole resistant isolate are of great signifi cance. Alternatives 
are limited because the polyenes are highly nephrotoxic and the echinocandins have limited activity 
against A. fumigatus and are not available in an oral formulation. A. fumigatus is intrinsically resistant to 
fl uconazole and ketoconazole.53 Other primary resistance of A. fumigatus to antifungal agents has not 
been described, although reduced susceptibility has been described in sibling species within Aspergillus 
section Fumigati.54 These new species are morphologically very similar to A. fumigatus and are not 
common to be discriminated in the clinical microbiology laboratory. However, some of the new species 
were found to cause infections in humans and exhibit a more resistant phenotype in comparison with 
A. fumigatus. This was described for Neosartorya pseudofi scheri (anamorph A. thermomutatus), A. lentulus, 
and A. undagwae.55,56 As well as laboratory induced azole-resistant A. fumigatus strains, clinical azole- 
Table 2. Epidemiological cut-off  values for A. fumigatus and azole compounds, from Verweij et al.47
Compound
Itraconazole
Voriconazole
Posaconazole
Intermediate
(MIC; mg/l)
2
2
0.5
Susceptible
(MIC; mg/l)
< 2
< 2
< 0.5
Resistant
(MIC; mg/l)
> 2
> 2
> 0.5
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resistant A. fumigatus strains have also been described. Resistance of clinical A. fumigatus isolates has 
been reported in the past with a low frequency and is generally considered to be a rare phenomenon. 
However, the frequency of resistance could be underestimated because antifungal susceptibility testing 
is not performed as a routine standard in most clinical microbiology laboratories. Most studies only 
report individual cases of azole resistance and do not refl ect a large unselected population of fungal 
strains. Nevertheless several studies have been published over time that screened collections of 
A. fumigatus isolates for azole resistance (Table 3).
Although the frequency of azole resistance in A. fumigatus has remained low for many years, we 
recently observed multi-azole resistance (MAR) in A. fumigatus in the Netherlands.44 Patients with MAR 
aspergillosis presented with primary IA or with breakthrough infection while receiving itraconazole 
or voriconazole. The patients were from six diff erent hospitals in the Netherlands, and there was no 
evidence for spread of a single clone. The isolates were highly resistant to itraconazole and showed 
elevated minimum inhibitory concentrations (MICs) of voriconazole, posaconazole and the experimental 
azole ravuconazole.44 A substitution of leucine 98 for histidine in the cyp51A gene, together with two 
copies of a 34 bp sequence in tandem in the gene promoter (TR/L98H), was found to be the dominant 
resistance mechanism. 
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Table 3. Epidemiological studies of azole resistance in A. fumigatus.
# Isolates
107
130
156
170
17
200
331
40
374
393
292
519
637
181
159
230
Resistance 
phenotype
ITC
VCZ > 4 μg/ml
ITC > 16 μg/ml
ITC
ITC ≥ 4 μg/ml
ITC
ITC
ITC ≥ 2 μg/ml
VCZ
ITC ≥ 16 μg/ml
VCZ ≥ 2 μg/ml
ITC
ITC ≥ 2 μg/ml
ITC ≥ 4 μg/ml
PSC > 0.25 μg/ml
ITC ≥ 4 μg/ml 
# Resistant
isolates
3
1
4
3
11
ND
ND
2
ND
32
1
34
43
1
1
62
Country
Sweden
Netherlands
France
Netherlands
United Kingdom
France, Italy
Worldwide
Taiwan
Spain
Spain, Netherlands, United Kingdom, France
North America
United Kingdom
Worldwide
North America
Portugal
United Kingdom
Reference
Chryssanthou et al. 199775
Verweij et al. 199876
Dannaoui et al. 199977
Verweij et al. 200278
Mosquera et al. 200279
Dannaoui et al. 200450
Pfaller et al. 200580
Hsueh et al. 200581
Guinea et al. 200882
Rodriguez-Tuleda et al. 200846
Espinel-Ingroff  et al. 200883
Howard et al. 200940
Pfaller et al. 200984
Baddley et al. 200985
Amorim et al. 201045
Bueid et al. 201039
ITC; itraconazole, VCZ; voriconazole,PSC; posaconazole, ND; no azole resistance detected. 
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Azole resistance and target mutations
Resistance development in micro-organisms is a well known phenomenon especially in viruses and 
bacteria but generally not in fungal pathogens. However, in the mid-1990’s C. albicans isolates became 
resistant in roughly 30% of the oropharyngeal infections in AIDS patients, indicating that fungi are 
capable of acquiring mechanism that confer to antifungal drug resistance.57 These fi ndings indicated 
that under the appropriate conditions susceptible fungal isolates could develop resistance mechanisms 
to survive upon exposure to antifungals. Generally it was thought that these resistant isolates gained 
their resistance mechanisms under pressure of antifungal compounds within an individual patient as 
pathogenic fungi cannot transfer resistance by horizontal transfer.58 In fungi mechanisms of resistance 
described in literature can be divided in two general types; drug effl  ux mechanisms and modifi cation 
of the target enzyme by specifi c mutations or overexpression.59 For Aspergillus spp. genes encoding for 
effl  ux transporters are present abundantly. The genome of A. fumigatus is predicted to contain at least 49 
ABC family transporter and 278 major facilitator superfamily (MFS) genes.59 By overexpression of a drug 
transporter pump azoles can be actively removed from the fungal cell, preventing it to inhibit the sterol 
14-alpha-demethylase enzyme. Some genes have been investigated in azole resistant isolates in which 
drug resistance was related to overexpression of a certain gene involved in effl  ux of antifungals. However 
very few genes have been investigated so far and these genes have not been shown to be upregulated 
in other azole resistant isolates.60-64 In addition to the two generally described mechanisms of resistance 
in fungi new genes have been recently identifi ed in antifungal drug resistance. In A. fumigatus a sterol-
regulatory element binding protein, SrbA and a major transcriptional regulator of the unfolded protein 
response, the HacA gene have been described to be involved in antifungal resistance mechanisms.65,66
Many studies have shown a positive correlation between specifi c point mutations in the cyp51A gene 
and azole resistance in A. fumigatus. In A. fumigatus two distinct but closely related cyp51 genes were 
found (cyp51A and cyp51B) that share 63% sequence identity and encode for two diff erent cyp51 
proteins.53,67 A double knockout of the cyp51 genes was not obtained and therefore thought to be lethal. 
A targeted gene disruption of the cyp51A gene only resulted in unchanged ergosterol content and no 
increased expression of cyp51B. Azole susceptibility increased however with 17- and 40-times more 
sensitive to fl uconazole and ketoconazole.68,69 Azole binding studies showed that fl uconazole has the 
weakest binding with CYP51A and CYP51B proteins, which can be confi rmed by the lack activity of 
fl uconazole against A. fumigatus isolates. Furthermore CYP51B showed more tight bindings with azoles 
compared to CYP51A and is generally more susceptible to azole compounds compared to CYP51A.53 
It has been postulated that the cyp51A gene encodes for the major 14-alpha-demethylase enzyme 
activity required for growth and the cyp51B gene encodes for alternative functions for particular 
growth conditions or even being functionally redundant.53 This provides a possible explanation to why 
mutations in azole-resistant A. fumigatus isolates are predominantly detected in the cyp51A gene and 
only rarely in the cyp51B gene.53,70 Also in cyp51B no mutations have yet been proven to be correlated 
to azole resistance. In eukaryotes cyp genes are thought to encode for proteins that are bound to the 
endoplasmatic reticulum (ER) or inner mitochondrial membranes.71 The N terminus of the 14-alpha-
20
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demethylase in Candida albicans is thought to act as membrane-spanning domain that anchors the 
protein to the cytoplasmic face of the ER, which shows a high homology and similar hydrophobicity 
profi le with the A. fumigatus cyp51A and suggesting a similar role.72,73 Three diff erent studies adapted 
the X-ray crystallography of Mycobacterium tuberculosis protein to develop an A. fumigatus CYP51A 3-D 
protein model.69,74 All models show that two ligand entry channels can be identifi ed in the CYP51A 
protein. The ligand access channels immersed in the ER membrane would allow highly lipophilic 
sterol substrates as well as azole compounds to dock into the channels and restrict access of other 
metabolites.53 The azole compounds can bind to the active heme molecule located in the center of the 
CYP51A protein and thereby inhibiting its enzyme function. Diff erent amino acid substitutions at codon 
54, 98, 138, 220 and 448 are related to resistance against one or more azole compounds found in clinical 
or laboratory induced azole resistant A. fumigatus isolates (Table 4). Codon 54 and 220 are thought to 
interfere with the entry of azole compounds into the hydrophobic access channel because they are 
located in the opening of one of the ligand access channels. A tandem repeat in the promoter region 
has been described in several plant pathogenic fungi to be correlated to azole resistance, which is also 
found in the A. fumigatus promoter region combined with a L98H mutation. The duplication of a 34 bp 
sequence in the promoter region signifi cantly increases the expression of CYP51A which for one part 
provides an explanation for the decrease in azole susceptibility. Recombinant analysis showed that the 
34 bp TR alone is not suffi  cient for the full azole-resistant phenotype. The same is true if isolates only 
harbor the L89H mutation only. Recombinant experiments showed that only when both mutations 
were introduced the MAR phenotype was observed.42 
Table 4. Mutations in the cyp51A gene of A. fumigatus resulting in azole resistance.
Origin of
 isolate
Clinical
Clinical
Laboratory
Laboratory
Laboratory
Clinical
Clinical
Laboratory
Clinical
Clinical
Clinical
Laboratory
Amino acid 
change
G54E
G54Q, -R or -W
G54W
G54E, -R
G54E, -K or -R
34 bp TR and L98H
G138C
G138R
M220V, -K or -T
M220I and G54R
G448S
G448S
Underlying 
condition
HIV, unknown
Unknown
-
-
-
Invasive Aspergillosis
Aspergilloma
-
Unknown
Aspergilloma
Invasive Aspergillosis
-
Resistant 
phenotype
ITC
ITC
ITC + PCZ
ITC + PCZ
ITC
Multi-azole
Multi-azole
VCZ + RCZ
Multi-azole
Multi-azole
VCZ + PCZ
Multi-azole
Azole exposure
Unknown
Unknown
Exposed to PCZ
Unknown
Exposed to ITC
Naive and exposed to ITC or VCZ
Exposed to ITC and VCZ
Unknown
Unknown
Exposed
Unknown
Unknown
Reference
70
73
73
86
62
44
87
86
41
88
89
86
ITC; itraconazole, VCZ; voriconazole, PCZ; posaconazole, RCZ; ravuconazole, TR; tandem repeat.  
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Outline of this thesis
Clinical azole compounds became widely available in the 1990s and are nowadays used as primary 
therapy against aspergillus disease in most medical centers worldwide. The azoles exhibit good 
activity against A. fumigatus, are available in oral and IV formulations and are generally well 
tolerated. Azole resistance has long been considered to be an uncommon phenomenon in A. fumigatus. 
Nevertheless, a new dominant resistance mechanism, the TR/L98H, was observed in the Netherlands in 
six diff erent hospitals without evidence for clonal spread in the year 2007. This led to the investigation of 
the Nijmegen culture collection in which all A. fumigatus isolates between 1994 and 2007 were analyzed 
for azole resistance which is described in chapter 2. To investigate whether the TR/L98H mutations 
were also present in environmental azole resistant A. fumigatus isolates, the studies to investigate 
azole resistant isolates from the environment, the comparison of the antifungal susceptibility testing, 
resistance mechanisms and genetic relatedness with those collected from clinical isolates are described in 
chapter 3. The results from chapter 2 and 3 led to the hypothesis that the TR/L98H mutations could 
be possibly linked by the agricultural fungicide use and the collected evidence for this is discussed in 
chapter 4. In chapter 5 the link between intensive use of fungicides and induction of the dominant 
TR/L98H azole resistance mechanism is studied by in vitro susceptibilty testing of azole fungicides, docking 
studies, induction experiments and tracking of evolution. A homology model of the CYP51A protein was 
developed and in chapter 6 it is studied whether this model can be used to predict the potential 
correlation of a mutation in the cyp51A gene to azole resistance. In chapter 7 studies in which the 
molecular mechanism by which the TR/L98H mutation in the cyp51A gene can confer azole resistance 
are investigated. This was done by molecular dynamics simulations and the development of a new site-
directed mutagenesis system. Finally, all the studies presented in this thesis are discussed in chapter 8.
22
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Abstract
Resistance to triazoles was recently reported in Aspergillus fumigatus isolates cultured from patients with 
invasive aspergillosis. The prevalence of azole resistance in A. fumigatus is unknown. We investigated 
the prevalence and spread of azole resistance using our culture collection that contained A. fumigatus 
isolates collected between 1994 and 2007. We investigated the prevalence of itraconazole (ITZ) resistance 
in 1,912 clinical A. fumigatus isolates collected from 1,219 patients in our University Medical Centre 
over a 14-y period. The spread of resistance was investigated by analyzing 147 A. fumigatus isolates 
from 101 patients, from 28 other medical centres in The Netherlands and 317 isolates from six other 
countries. The isolates were characterized using phenotypic and molecular methods. The electronic 
patient fi les were used to determine the underlying conditions of the patients and the presence of 
invasive aspergillosis. ITZ-resistant isolates were found in 32 of 1,219 patients. All cases were observed 
after 1999 with an annual prevalence of 1.7% to 6%. The ITZ-resistant isolates also showed elevated 
minimum inhibitory concentrations of voriconazole, ravuconazole, and posaconazole. A substitution of 
leucine 98 for histidine in the cyp51A gene, together with two copies of a 34 bp sequence in tandem 
in the gene promoter (TR/L98H), was found to be the dominant resistance mechanism. Microsatellite 
analysis indicated that the ITZ-resistant isolates were genetically distinct but clustered. The ITZ-sensitive 
isolates were not more likely to be responsible for invasive aspergillosis than the ITZ-resistant isolates. 
ITZ resistance was found in isolates from 13 patients (12.8%) from nine other medical centres in The 
Netherlands, of which 69% harboured the TR/L98H substitution, and in six isolates originating from 
four other countries. Azole resistance has emerged in A. fumigatus and might be more prevalent than 
currently acknowledged. The presence of a dominant resistance mechanism in clinical isolates suggests 
that isolates with this mechanism are spreading in our environment.
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism 
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Introduction
The saprophytic mould Aspergillus is known to cause a spectrum of diseases in humans including 
allergic syndromes, non-invasive infections as well as invasive aspergillosis. The morbidity and mortality 
associated with invasive aspergillosis is high, although the mortality rate appears to be improving partly 
due to the use of eff ective antifungal agents, most notably the triazoles.1 Voriconazole was superior to 
amphotericin B for the treatment of invasive aspergillosis and has become the primary choice to treat this 
condition.2 Recently, another triazole, posaconazole, was reported to be highly eff ective in preventing 
invasive aspergillosis in neutropaenic patients with acute myeloid leukaemia and myelodysplastic 
syndrome and in patients with graft-versus-host-disease.3,4 As a consequence, the role of the class of 
azole compounds will further increase in the management of invasive aspergillosis.
We recently observed the emergence of multiple-triazole-resistance (MTR) in A. fumigatus, the primary 
cause of invasive aspergillosis.5 Patients with MTR aspergillosis presented with primary invasive 
aspergillosis or with breakthrough infection while receiving itraconazole (ITZ) or voriconazole. The 
patients were from six diff erent hospitals in the Netherlands, and there was no evidence for spread 
of a single clone.5 The isolates were highly resistant to ITZ and showed elevated minimum inhibitory 
concentrations (MICs) of voriconazole, posaconazole and the experimental azole ravuconazole.5,6
The emergence of MTR in A. fumigatus might have signifi cant impact on the role of azoles in the 
management of invasive aspergillosis, but the impact of resistance on the role of azoles will greatly 
depend on the prevalence of MTR and the ability to detect MTR isolates at diagnosis.7 However, the 
prevalence of MTR is currently unknown, although the number of patients with a MTR isolate was 
found to be signifi cantly higher than in a previously conducted surveillance study in the Netherlands.5,8 
We investigated the prevalence of azole resistance in A. fumigatus in a prospectively collected fungus 
culture collection over a period of 14 year. We also investigated the spread of resistance by analysing 
isolates in our collection, obtained from other hospitals in the Netherlands and other countries.
Materials and Methods
Setting and strain selection
The Radboud University Nijmegen Medical Centre is a tertiary care hospital with beds for 950 patients. 
The medical microbiology laboratory receives specimens from patients admitted to the hospital as 
well as those seen as outpatient. The mycology unit of the laboratory has the policy to routinely store 
fungal isolates from patients with fungal diseases admitted to the hospital or seen as outpatient. For 
Aspergillus species every isolate, irrespective of its clinical signifi cance, was stored. In addition, fungi that 
were cultured from the hospital environment or those sent to the laboratory for identifi cation, in vitro 
susceptibility testing or as part of research collaboration, were stored. From the isolates a spore 
suspension was made in glycerol 10% and stored at –80°C.
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The fungus culture collection was searched for A. fumigatus isolates. To investigate the prevalence of azole 
resistance we used the A. fumigatus isolates that were cultured from patients that had been admitted 
to our hospital or were seen as outpatient. The spread of azole resistance was investigated by analysing 
isolates that had been cultured at other hospitals centres in the Netherlands and sent to our laboratory 
for identifi cation. The isolates in our collection obtained from other countries were also screened for 
azole resistance. All A. fumigatus isolates were originally identifi ed by experienced technicians on the 
basis of macroscopic colony morphology, microscopic morphology of conidia and conidia-forming 
structures, and the ability to grow at 48°C. The selected A. fumigatus isolates were cultured on Sabouraud 
slants for 7 days and subsequently subcultured on Sabouraud slants supplemented with itraconazole at 
a concentration of 8 mg/l, and incubated at 35°C.
Phenotypic analyses
For phenotypic comparisons, for every patient from our hospital with an A. fumigatus isolate that grew 
in the presence of 8 mg/L of itraconazole (ITZ+), two control patients were randomly selected with an 
isolate that failed to grow on the itraconazole containing slants (ITZ-): one in the four weeks preceding 
the ITZ+ A. fumigatus culture date and one in the four weeks after the culture date. In addition, one 
control patient was randomly selected for every remaining month for each year in which a patient with 
an ITZ+ isolate was identifi ed. All ITZ+ and ITZ- A. fumigatus control isolates were investigated for their 
antifungal susceptibility of ITZ, voriconazole, ravuconazole, posaconazole, amphotericin B, terbinafi ne 
and caspofungin using the CLSI M38-A broth micro dilution reference method.9
Genotypic analyses
For genotypic comparisons, isolates were randomly selected from the ITZ- control patients in a 1:1 ratio 
with the ITZ+ patients. For ITZ+ and ITZ- isolates the full coding sequence of both strands of the cyp51A 
gene was determined by PCR amplifi cation and analysed to detect mutations.6,10 Molecular identifi cation 
was performed by sequencing of parts of the highly conserved Beta-tubulin and calmodulin gene, as 
described previously,11-13 in order to rule out any species within the Aspergillus section Fumigati, which are 
closely related to A. fumigatus, but are diffi  cult to discriminate based on morphological features alone.12 
The neighbour-joining (NJ) method was used for phylogenetic analysis. Sequences were compared 
with those of A. fumigatus, A. lentulus, A. viridinutans, A. brevipes, A. novofumigatus, A. fumigatiaffi  nis and 
Neosartorya species all obtained from the CBS Fungal Biodiversity Centre, Utrecht, the Netherlands.14
Microsatellite genotyping was used to determine the genetic distances between the ITZ+ and ITZ- 
A. fumigatus isolates and analysed, as described previously.15,16 Allele sharing distance matrices were 
generated,17 and these matrices were used as input to the Neighbor program of the PHYLIP software 
package to produce the dendrograms.18
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Patient characteristics
The electronic patient fi les were searched for clinical information on the patients with an ITZ-resistant 
A. fumigatus isolate and from the controls. Information collected included the sample from which the 
A. fumigatus isolate was cultured, the underlying condition of the patients and the presence of invasive 
aspergillosis. Invasive aspergillosis was classifi ed according to the EORTC/MSG consensus defi nitions.19 
Human experimentation guidelines from the Committee on Research Involving Human Subjects 
Arnhem–Nijmegen were followed in the conduct of this research.
Statistical analysis
To test whether ITZ+ isolates had been present throughout the observation period (1994-2007) we 
calculated the probability that the onset date of fi nding an ITZ+ was as late as we found it to be. For the 
phenotypic analysis we used t tests on the natural logarithm of the MIC’s and for the genotypic analysis 
we used a chi-square test. For the patient characteristics, the exact chi-square test was used, because of 
the low expected numbers in certain cells.
Results
Prevalence of ITZ+ A. fumigatus isolates
The fungal culture collection included 12,645 isolates that had been collected between 1994 and 2007. 
Of these, 2,683 were identifi ed as A. fumigatus, and 1,912 were cultured from patients admitted to our 
hospital or seen as outpatient. These isolates were cultured from 1,219 patients, with a median number 
of patients of 92.5 per year (range 48 to 138), which corresponded with a median of 130 A. fumigatus 
isolates per year (range 72 to 215). All isolates were revived and subcultured on Sabouraud slants 
containing 8 mg/L of ITZ at 35°C and 1,871 isolates failed to grow under these conditions. However, 41 
isolates from 32 patients were able to grow on the itraconazole-containing agar. An ITZ+ A. fumigatus 
isolate was cultured for the fi rst time on June 15, 2000. All 674 consecutive clinical isolates from 462 
patients cultured in the 6.5 year before this date did not grow on the ITZ-containing Sabouraud agar. 
From 2000 onwards, patients were observed every year with an ITZ+ A. fumigatus isolate, with a maximum 
prevalence of 6.0%. Under the assumption of a random distribution of all ITZ+ isolates over the complete 
set of n observations, the probability of fi nding the fi rst of k occurrences at observation number o or later 
is equal to (n - o + 1) over k divided by n over k. For the observations at hand this probability is so small 
(p < 0.001), that we can conclude that the ITZ+ isolates are not randomly distributed over all observations: 
ITZ+ isolates started to occur after a given time point notably after 1994, but before or equal to June 15, 
2000 (Figure 1).
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Phenotypic analysis
For phenotypic comparisons, the fi rst ITZ+ isolate of each of the 32 identifi ed patients, was compared 
with those of the control group. The control group consisted of 115 patients with one ITZ- A. fumigatus 
isolate per patient, representing at least one patient and isolate from every calendar month between 
January 1, 2000 and December 31, 2007. The phenotypes of the 32 ITZ+ isolates and the 115 ITZ- 
control isolates for the azole compounds are shown in Figure 2. All ITZ+ isolates also showed reduced 
susceptibility to voriconazole, ravuconazole, and posaconazole in comparison with the ITZ- controls 
(t-test, p < 0.0005). No signifi cant diff erences were observed for amphotericin B (t-test, p = 0.892), terbinafi ne 
(t-test, p = 0.591), and caspofungin (t-test, p = 0.816) (unpublished data).
Figure 1. Epidemiology of ITZ resistance in the A. fumigatus isolates.
Blue bars represent the number of patients with a positive A. fumigatus culture (left y-axis) and the red line represents the percentage of 
those patients with an ITZ+ isolate (right y-axis). The x-axis is the year.
Figure 2. Distribution of proportions of MICs of 32 ITZ+ A. fumigatus isolates (blue Bars) and 115 ITZ- controls (red Bars) of ITZ (left upper 
panel), voriconazole (right upper panel), ravuconazole (left lower panel), and posaconazole (right lower panel) Left x-axis represents the 
proportion of isolates and on the right x-axis the MIC distribution is shown. 
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Genotypic analysis
For genotypic comparisons the fi rst ITZ+ A. fumigatus isolate from 32 patients was compared with those 
of 32 randomly selected control patients. The dominant genetic changes in the ITZ+ isolates in the 
cyp51A gene were a point mutation at t364a, leading to the substitution of leucine 98 for histidine, 
together with the presence of two copies of a 34 base pair sequence in tandem in the promoter of cyp51A 
gene (TR/L98H), as previously found.5 These changes were present in 30 of 32 (94%) ITZ+ isolates and 
these isolates exhibited the previously reported MTR phenotype. In one ITZ+ isolate an a729g change 
was found to be responsible for the substitution at codon 220 of methionine by valine (M220V) and in 
the other no mutations in the cyp51A gene were found. In all 32 A. fumigatus ITZ- control isolates, the 
TR/L98H changes were not observed. To test the relation between an itraconazole resistant phenotype 
and the presence of TR/L98H a chi square test was performed, and there was a signifi cant relation 
between the two factors (χ2 = 50.143, df = 1, p < 0.0001). No changes were found in the cyp51A gene 
of control isolates, except for three isolates, with mutations that were not associated with a resistant 
phenotype. The 64 ITZ+ and ITZ- isolates could be classifi ed as A. fumigatus based on sequence analysis 
of parts of the Beta-tubulin and calmodulin genes. Three clades were formed based on the NJ analysis 
of the microsatellite typing; the ITZ+ isolates were genetically diff erent but clustered together in a 
single clade (Figure 3). Four ITZ+ isolates were clustered within the ITZ- clades, two with the TR/L98H 
substitution and the others with other or unknown mutations. The branches of the ITZ+ isolates had 
shorter genetic distances than those within the ITZ- isolate clades.
Figure 3. Genotypic relatedness of 32 ITZ+ A. fumigatus isolates and 32 ITZ- controls. 
The numbers are the identifi cation numbers of the individual isolates. The ITZ+ A. fumigatus with the L98H substitution 
and a tandem repeat in the promoter region of the cyp51A gene are underlined and printed in red. The ITZ+ isolates 
with other or unknown resistance mechanisms are underlined and printed in blue. The ITZ- isolates are printed in black.
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Table 1. Classifi cation of the underlying conditions in 32 patients with an ITZ+ A. fumigatus isolate and 115 ITZ- controls.
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Table 2. Clinical characteristics of nine patients with invasive aspergillosis and an azole-resistant A. fumigatus isolate.
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Table 3. Characteristics of clinical A. fumigatus isolates present in the fungus culture collection cultured from other hospitals in 
the Netherlands and from other countries.
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Patient characteristics
In 17 of 32 patients (53%) the ITZ+ isolate was cultured from a respiratory specimen (ten sputum 
specimens, four bronchoalveolar lavage fl uids and three bronchial secretions), which was not signifi cantly 
diff erent to 78 of 115 patients (68%) with an ITZ- isolate (41 sputum, 22 bronchoalveolar lavage fl uids 
and 15 bronchial secretions). A wide variety of underlying diseases and conditions were present (Table 
1), most notably patients with chronic lung diseases or cancer. Invasive aspergillosis was diagnosed in 
nine of 32 patients (28.1%) with an ITZ+ isolate (three proven, three probable and three possible cases) 
compared to 25 of 115 (21.7%) in the control group (seven proven, 12 probable and six possible cases), 
which was not diff erent. The characteristics of the nine cases with an ITZ+ isolate are shown in Table 2.
Spread of azole resistance
Our culture collection contained 149 A. fumigatus isolates from 28 other hospitals from 20 diff erent 
cities in the Netherlands. These isolates had been cultured from 101 patients with aspergillus disease 
and had been sent to our laboratory between 1994 and 2006. Of these, 22 (14.5%) isolates grew on the 
ITZ-containing Sabouraud slants. The ITZ+ isolates had been cultured from 13 patients (12.8%) from nine 
diff erent hospitals from seven cities in the Netherlands (Table 3). The fi rst resistant isolate was cultured 
in 1998, and all others after 2000. The TR/L98H changes were present in nine of 13 (69%) ITZ+ isolates 
(Table 3).
Our culture collection contained 317 A. fumigatus isolates from six European countries: Belgium, France, 
United Kingdom, Sweden, Norway and Greece. These isolates had been cultured between 1994 and 
2002 as part of research collaborations. Six isolates were resistant to itraconazole, originating from France, 
Sweden, Norway and the United Kingdom, some of which have been reported previously (Table 3).6,20-
22 The isolate obtained from the United Kingdom was originally cultured from a patient in the United 
States in 1989.22 All azole-resistant isolates from this group were cultured before 2000, except for the 
isolate from Norway, which was the only isolate with TR/L98H (Table 3). 
Discussion
Emergence of azole resistance was observed in all three sets of A. fumigatus isolates. Besides our hospital, 
azole-resistant isolates were found in nine other hospitals in the Netherlands, and in four other countries. 
The prospectively collected isolates from our hospital indicated that resistance had emerged since 2000 
with a prevalence between 1.7% and 6%. Therefore, azole resistance in A. fumigatus is not uncommon 
and probably more widespread than currently acknowledged.
Recently, taxonomic changes have been proposed for Aspergillus section Fumigati, with the description 
of several new species that are closely related to A. fumigatus.12 Since some of these new species 
appear to be more resistant to antifungal compounds than A. fumigatus,23 and species demarcation 
by morphologic features alone is not reliably possible,24 we took great care to correctly identify the 
species. Based on sequence-based analysis, we can be confi dent that the observed azole resistance has 
emerged in A. fumigatus.
Acquired resistance against azoles develops in response to exposure of fungi to azole compounds. 
Azole resistance has been shown to develop following exposure in the patient and in agricultural 
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settings.25-28 Favourable conditions for the development of azole resistance include long duration of 
drug exposure and high numbers of reproducing microorganisms.29 In patients with aspergillus disease, 
these conditions are present primarily in those with cavities, such as aspergilloma, and indeed numerous 
resistance mechanisms have been described in isolates obtained from this patient group.25-27 Among 
those, changes at codon 220 have been identifi ed, which were also found in isolates in our study. 
However, isolates that develop azole resistance during patient therapy are unlikely to cause further 
transmission. 
Person-to-person transmission in aspergillus disease is very uncommon, reported only through direct 
donor-to-recipient contact 30 and through infected wounds.31 Generally, a patient who responds to 
therapy overcomes the infection and transmission of the infecting isolate is prevented. The alternative 
outcome is that a patient fails to therapy, which commonly results in death. Transmission of any isolate 
after death appears to be unlikely. Acquisition of azole resistance in patients, therefore, is characterized 
by a high variety of resistance mechanisms and lack of spread. 
However, the pattern that we observed in the collection of isolates from our hospital was quite diff erent, 
with the dominance of the TR/L98H resistance mechanism in clinical isolates from epidemiologically 
unrelated patients. Furthermore, microsatellite typing showed that the genetic distances between 
the TR/L98H isolates was shorter than for other azole-susceptible and azole-resistant isolates. These 
observations suggest that the TR/L98H isolate is not transmitted from person-to-person, but might 
be present in our environment. The presence of Aspergillus species in the environment is considered 
the most important risk factor for invasive aspergillosis, and if TR/L98H is present in our environment 
resistant conidia will be dispersed into the ambient air and may cause infection through inhalation. 
A. fumigatus resistant to medical azoles has been recovered from the environment, indicating that 
this mode of transmission is feasible.32 Furthermore, azole-resistant aspergillosis due to TR/L98H was 
observed in azole-naïve patients which supports an environmental origin.5 
It remains unclear how azole resistance develops in A. fumigatus in the environment. We hypothesize that 
resistance in A. fumigatus could be caused by the use of azole fungicides. Fungicides, including triazoles, 
are widely used for both plant protection and material protection.33 As A. fumigatus is a saprophytic 
mould, environmental azole exposure could lead to the development of multiple resistant mutants. 
The dominance of the TR/L98H substitution is diffi  cult to explain, but could be due to the procedure we 
used to select azole-resistant isolates, to selective pressures in the environment or to properties of these 
isolates that allow better survival and spread in the environment than isolates with other mutations.
We believe that the distribution of resistance mechanisms within the sets of isolates that we investigated, 
refl ects these two modes of resistance development (patient versus environment). Variable resistance 
mechanisms were dominant in the resistant isolates from other countries, consistent with development 
of resistance in individual azole-treated patients. The TR/L98H substitution was the dominant change 
in the isolates cultured from our hospital, which included all Aspergillus isolates recovered from clinical 
specimens irrespective of clinical signifi cance, refl ecting acquisition from the environment. The isolates 
sent to us from other Dutch hospital were exclusively from patients with aspergillus diseases and 
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therefore refl ect a mixture of the two modes of resistance development. 
Our study was limited by the fact that the isolates from other countries were not collected with the 
intention to study the epidemiology of resistance. An accurate estimate of the spread of resistance 
therefore could not be obtained, which would require prospective surveillance studies. Another limiting 
factor was that we were unable to reliably determine clinical factors that might predispose for azole 
resistant aspergillosis. This was beyond the primary focus of our study and would require a prospective, 
multi-centre study.
Given the recent and rapid emergence of the TR/L98H resistance mechanism in A. fumigatus, we 
believe that further studies are urgently warranted. The reasons for development of resistance and 
their transmission should be investigated by sampling of the environment and, if resistance is found, 
establishing a link with azole exposure. In addition, international surveillance studies are required to 
determine the prevalence and spread of TR/L98H in other countries. Our study does indicate that the 
TR/L98H substitution has spread to other countries as one isolate from Norway possessed the TR/L98H 
substitution. In addition, TR/L98H isolates have been reported from Spain,6 Belgium34, France and the 
United Kingdom. One possible scenario might be that TR/L98H isolates have arisen from a single source 
and are subsequently spreading in the environment across countries. This might be the beginning of the 
global spread in our environment of azole resistance in A. fumigatus.
It is important to explore the clinical factors that might be associated with the acquisition of TR/L98H 
isolates and associated disease, and to determine the drug of choice for treatment of patients with 
azole-resistant aspergillosis. Our data indicate that the activity of voriconazole and posaconazole is 
reduced against the ITZ-resistant isolates compared with the control isolates. While awaiting the results 
of confi rmative international surveillance studies, we believe that clinical microbiology laboratories 
should determine the activity of azoles at least in those isolates that are cultured from patients that fail 
to respond to azole therapy. 
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Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles
Abstract
We reported the emergence of resistance to medical triazoles of Aspergillus fumigatus isolates from 
patients with invasive aspergillosis. A dominant resistance mechanism was found, and we hypothesized 
that azole resistance might develop through azole exposure in the environment rather than in azole-
treated patients. We investigated if A. fumigatus isolates resistant to medical triazoles are present in our 
environment by sampling the hospital indoor environment and soil from the outdoor environment. 
Antifungal susceptibility, resistance mechanisms, and genetic relatedness were compared with those 
of azole-resistant clinical isolates collected in a previous study. Itraconazole-resistant A. fumigatus 
(fi ve isolates) was cultured from the indoor hospital environment as well as from soil obtained from 
fl ower beds in proximity of the hospital (six isolates) but never from natural soil. Additional samples 
of commercial compost, leaves and seeds obtained from a garden center and a plant nursery were 
also positive (four isolates). Cross-resistance was observed for voriconazole, posaconazole, and the azole 
fungicides metconazole and propiconazole. Molecular analysis showed the presence of the dominant 
resistance mechanism, which was identical to that found in clinical isolates, in 13 of 15 environmental 
isolates, and it showed that environmental and clinical isolates were genetically clustered apart from 
nonresistant isolates. Patients with azole-resistant aspergillosis might have been colonized with azole-
resistant isolates from the environment. 
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Introduction
Invasive aspergillosis is a fungal disease caused by Aspergillus species that primarily aff ects 
immunocompromised patients such as those treated for hematological malignancy. Patients may 
become infected by inhalation of ambient air that contains fungal spores. The Aspergillus conidia can 
penetrate into the alveoli, and if not eff ectively removed, may germinate and proliferate and cause 
invasive aspergillosis. Mortality and morbidity due to invasive aspergillosis remain a signifi cant problem. 
Triazoles, such as itraconazole (ITZ), voriconazole and posaconazole, are used increasingly in the 
management of patients with this disease. Although the risk of resistance due to the increased use of 
triazoles is considered low1, we recently observed ITZ resistance rapidly emerging in clinical Aspergillus 
fumigatus isolates.2-5 Azole resistance was observed in up to 6% of patients in our hospital and in up to 
14% of isolates sent to our laboratory from other hospitals in the Netherlands, which were obtained from 
patients with aspergillus disease.2 Furthermore, azole resistance has been reported in other European 
countries.2,6,7 The ITZ-resistant isolates also showed signifi cantly reduced susceptibility to the other 
mold-active medical triazoles voriconazole and posaconazole.2 A substitution of leucine for histidine at 
codon 98 (L98H), combined with a 34 bp tandem repeat (designated TR) in the promoter region of the 
cyp51A gene (TR/L98H), which is the target for antifungal azoles, was found in 94% of isolates.2,5,8 
Azole resistance can develop through the exposure of the fungus to azole compounds, which may occur 
in azole-treated patients or through the use of azole compounds in the environment. The dominance 
of a single resistance mechanism is diffi  cult to explain by resistance development in individual azole-
treated patients, as one would expect multiple resistance mechanisms to develop. Also spread by 
person-to-person transmission of any Aspergillus isolate is highly unlikely. As inhalation of airborne 
aspergillus spores is the common route of infection in aspergillus diseases, we hypothesized that the 
dominance of a single resistance mechanism in clinical ITZ-resistant isolates was more consistent with 
acquisition from a common environmental source.2 If azole-resistant A. fumigatus is present in our 
environment patients could inhale resistant spores and subsequently develop azole-resistant disease. 
Indeed, azole-resistant aspergillosis was reported in azole-naïve patients, indicating that resistance does 
not exclusively develop during azole therapy.5 Favorable conditions for resistance development are 
exposure to azole compounds and the presence of reproducing fungus.9 A. fumigatus is abundantly 
present in our environment as saprophytic, reproducing fungi, most notably in soil and compost. 
Furthermore, azoles are commonly used for plant protection as well as material preservation. Therefore, 
it appears that resistance development in A. fumigatus is feasible in the environment, and isolates that 
develop resistance to fungicides might be cross-resistant to medical triazoles. 
We investigated if A. fumigatus isolates that are present in our environment are resistant to medical 
triazoles and if they are cross-resistant to azole fungicides. Furthermore, we characterized the isolates by 
microsatellite typing in order to determine if they were genetically related to clinical A. fumigatus isolates 
previously obtained from patients cared for in our University Medical Centre. 
48
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles
Material and Methods
We searched our private fungus culture collection for A. fumigatus isolates that had been cultured from 
the hospital indoor environment. Most indoor environment isolates were obtained from air sampling 
of patient rooms. These isolates had been stored in glycerol 10% at –80°C. In addition, samples were 
collected from soil sampled from the direct surroundings of the University Medical Centre, from soil 
obtained from plant nurseries and from leaves, seeds and compost obtained from a garden center. 
Environmental sampling was carried out in the months July and August of 2007. 
To recover A. fumigatus isolates from the outdoor environment, 2 g of soil, pulverized leaves or 
pulverized seeds was dissolved in 8 ml 0.2 M NaCl 1% Tween20. From this suspension, 100 μl was plated 
on Sabouraud dextrose agar, and plates supplemented with 4 mg/l of ITZ, and incubated at 37°C. For 
each A. fumigatus isolate that grew on the ITZ-containing agar (ITZ+), an azole susceptible A. fumigatus 
isolate (ITZ-) that had been cultured from the same environment (outdoor and indoor) was selected.
Isolates were tested for their antifungal susceptibility of ITZ, voriconazole, posaconazole, amphotericin B, 
terbinafi ne and caspofungin using the CLSI M38-A broth microdilution reference method.10 In addition, 
the activity of fi ve azole fungicides, including cyproconazole, metconazole, thiabendazole, tebuconazole, 
and penconazole, was determined using the same method.
Molecular methods were used for strain identifi cation, determination of the resistance mechanism, 
and for genotyping. For this conidia from each strain were inoculated into 15 ml of GYEP medium (2% 
glucose, 0.3% yeast extract, 1% peptone) and grown for 48h at 37°C. Mycelial mats were recovered, dried, 
and subjected to a DNA isolation protocol.11 In order to rule out any cryptic species within the Aspergillus 
section Fumigati, molecular identifi cation was performed by amplifi cation of parts of the Beta-tubulin 
gene and calmodulin gene.12,13 DNA sequences were determined using a BigDye Terminator v3.1 cycle 
sequencing kit (ABI) and an ABI 3100 DNA sequencer. Sequence alignments were performed using 
CLUSTAL-X and the neighbourjoining (NJ) method was used for the phylogenetic analysis.2,14 Sequences 
were compared with those of A. fumigatus, A. lentulus, A. viridinutans, A. brevipes, A. novofumigatus, A. 
fumigatiaffi  nis and Neosartorya species all obtained from the CBS Fungal Biodiversity Centre, Utrecht, 
The Netherlands. The full coding sequence of the cyp51A gene was determined by PCR amplifi cation 
and subsequent sequencing.15 For analysis the cyp51A sequence under accession number AF338659 in 
GenBank was used for comparison to detect mutations. 
Microsatellite genotyping was used to determine the genetic relatedness between the environmental 
isolates described for A. fumigatus with a short tandem repeat A. fumigatus assay.16 From six loci, consisting 
of three tri- and three tetranucleotide repeats, fragments were amplifi ed by using fl uorescently labeled 
primers.16 The sizes of the fragments were determined by addition of the GeneScan LIZ[500] marker 
and subsequent analysis of the fragments on the Applied Biosystems 3730 DNA analyzer. Assignment 
of repeat numbers in each marker was determined from the Genescan data by using the Peak Scanner 
version 1.0 software (Applied Biosystems). The repeat numbers of the environmental isolates were 
compared to those of our previously analyzed collection of 32 ITZ+ and 32 ITZ- clinical A. fumigatus 
isolates cultured between 2000 and 2007.2 Allele-sharing distance matrices were generated from the 
tandem repeat numbers and were used as input to the Neighbor program of the PHYLIP version 3.6 
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software package to produce dendrograms.2,17 To test for signifi cant diff erences between antifungal 
susceptibilities, the t test was used on the natural logarithm of the minimum inhibitory concentrations 
(MICs).
Results
A total of 248 A. fumigatus isolates, cultured from the hospital indoor environment, were present in our 
fungus culture collection. These isolates had been cultured between 1995 and 2007 and fi ve isolates 
grew on the ITZ-containing agar slants (ITZ+): three isolates from air sampling of patient rooms in the 
hematology ward in 2002, 2003 and 2005, and two from hospital water in 2007 (Table 1). 
Table 1. Characteristics of 15 ITZ+ and 15 ITZ- environmental A. fumigatus isolates. 
Category
ITZ+
ITZ-
Source of isolate
Air sample, patient room
Air sample, patient room
Air sample, patient room
Water fi lter sample
Water fi lter sample
Soil
Soil
Soil
Soil
Soil
Soil
Seeds 
Compost
Soil
Air sample, patient room
Air sample, patient room
Air sample, patient room
Water fi lter sample
Water fi lter sample
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Isolate 
no.
V17-24
V22-76
V37-56
V61-56
V61-57
V61-50
V61-79
V62-05
V62-09
V62-10
V62-14
V62-48
V62-63
V62-79
V04-22
V22-74
V22-80
V57-35
V57-53
V62-04
V62-06
V62-07
V62-12
V62-13
V62-23
V63-01
V63-03
V63-04
V63-05
Year of 
isolation
2002
2003
2005
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
2000
2003
2003
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
cyp51A substitution
TR  Codon 98 Other(s)
+    L98H S297T, F495I
+    L98H 
+    L98H 
+    L98H 
+    L98H 
+    L98H 
+    L98H 
+    L98H 
+    L98H Q141H
+    L98H 
—  
+    L98H S52T
+    L98H 
—  
—  
—  
—  
—  
—  
—  
—              F46Y, M172V, E472K
— 
—              F46Y, M172V, E472K
—  
—  
—  
—  
— 
—
ITZ
>16
16
>16
>16
>16
>16
>16
>16
>16
>16
>16
>16
>16
>16
0.25
0.25
0.25
0.25
0.25
0.25
1
0.5
0.5
1
0.25
0.25
0.25
0.25
0.5
VCZ
1
16
2
4
4
4
8
8
4
4
4
4
>16
0.5
0.5
0.5
0.5
0.5
0.5
1
4
0.5
4
2
1
0.5
1
0.5
4
POS
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.25
0.25
0.5
0.5
0.25
0.063
0.031
0.031
0.031
0.063
0.125
0.25
0.125
0.25
0.25
0.063
0.031
0.063
0.063
0.25
AMB
0.5
0.5
1
0.5
0.5
0.5
1
0.5
1
1
1
0.5
1
0.5
1
1
1
1
0.5
0.5
1
1
1
1
1
0.5
1
0.5
0.5
TER
0.031
0.031
0.125
0.25
0.063
0.25
0.016
0.125
0.063
0.125
0.063
0.25
0.031
0.5
0.063
0.063
0.5
0.063
0.016
0.25
0.5
0.063
0.031
0.5
0.25
0.125
0.063
0.016
0.5
CAS
0.25
0.25
0.25
1
0.5
>32
0.5
0.25
1
0.5
1
1
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
1
1
1
0.5
0.5
0.5
0.5
0.5
MIC (mg/liter)
ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; AMB, amphotericin B; TER, terbinafi ne; CAS, caspofungin
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A. fumigatus was also cultured from 49 of 79 outdoor environmental samples. Culture of soil samples 
taken from the direct proximity of the hospital showed the presence of ITZ+ A. fumigatus isolates in six 
samples obtained from fl ower beds. Cultures from natural soil were A. fumigatus positive, but these were 
never ITZ resistant. Following this observation, we cultured compost used in the fl ower beds as well 
as seeds, leaves, and compost that we obtained from a garden center and from a plant nursery, both 
located in towns other than the hospital. ITZ+ isolates were recovered from seeds (one isolate), compost 
from the plant nursery (one isolate) and commercial compost from the garden center (two isolates). 
Control isolates (ITZ-) were matched 1:1 to the environment from which an ITZ+ isolate was cultured. All 
15 ITZ+ isolates were confi rmed to be highly resistant to ITZ (MIC of >16 mg/liter) and showed reduced 
susceptibility to voriconazole (median MIC of 4 mg/liter; range of 0.5 to >16 mg/liter) and posaconazole 
(median MIC of 0.5 mg/liter; range of 0.25 to 1 mg/liter) compared to the ITZ- control isolates (p < 0.005). 
The median MICs for ITZ- isolates were 0.25 mg/liter for ITZ, 0.5 mg/liter for voriconazole, and 0.063 for 
posaconazole (Table 1). No signifi cant diff erences in MICs were observed for amphotericin B (p =0.285), 
terbinafi ne (p =0.909), and caspofungin (p =0.610). Three fungicides: cyproconazole, thiabendazole, 
and penconazole showed no in vitro activity against the ITZ- and ITZ+ A. fumigatus isolates (Figure 1). 
Metconazole and propiconazole showed activity against ITZ- isolates with median MICs of 0.25 mg/liter 
and 2 mg/liter, respectively. These compounds were signifi cantly less active against ITZ+ isolates, with 
the median MIC shifting to 1 mg/liter for metconazole and to >16 mg/liter for propiconazole (p <0.005, 
Figure 1). 
Figure 1.  In vitro activity of fi ve azole fungicides against 15 ITZ-resistant (black bars) and ITZ-susceptible (grey bars) A. fumigatus isolates. 
The number of isolates is given on the y axis and the MIC (mg/liter) on the x axis. Those isolates that were not inhibited by a concentration 
of 16 mg/liter were assigned to the >16 mg/liter category.
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Sequencing of the cyp51A gene showed the presence of two alterations, a 34 bp tandem repeat in the 
promoter region combined with the presence of a mutation that led to a substitution at codon 98 of 
leucine to histidine (TR/L98H), in 13 of 15 (86%) ITZ+ isolates, which was identical to the mechanism 
previously observed with the majority of resistant clinical isolates.2 No changes were found in the cyp51A 
gene of the two other ITZ+ isolates, indicating another yet unknown mechanism of resistance, and the 
TR/L98H alterations were absent in all of the 15 matched ITZ- control isolates.
All ITZ+ and ITZ- isolates were identifi ed as A. fumigatus by sequence analysis of the Beta-tubulin and 
calmodulin genes. Microsatellite typing of six STR loci showed that all isolates were genetically unique. 
Comparing the genetic relatedness by generating dendrograms of the STR profi les showed that the 
ITZ+ environmental isolates clustered apart from ITZ- environmental isolates. Furthermore, the ITZ+ 
environmental isolates were found to cluster with the previously analyzed azole-resistant clinical isolates. 
Likewise the ITZ- environmental isolates clustered together with the azole-susceptible clinical isolates in 
the remaining clusters. Two out of the three azole-resistant isolates without the dominant TR and L98H 
mutations clustered in azole-susceptible clusters (Figure 2).2
Figure 2. Genotypic relatedness of clinical and environmental azole resistant A. fumigatus isolates. 
The fi gure shows genetic distances of 15 environmental ITZ-resistant A. fumigatus isolates (blue squares, fi lled), 15 
environmental control A. fumigatus isolates (blue squares, open), 32 clinical ITZ-resistant A. fumigatus isolates (red 
circles, fi lled) and 32 clinical control A. fumigatus isolates (red circles, open). All resistant isolates were found to have the 
L98H substitution and a tandem repeat in the promoter region of the cyp51A gene, except for the underlined isolates.
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Discussion
Our study provides for the fi rst time evidence that patients with invasive aspergillosis due to azole-
resistant A. fumigatus might acquire the fungus from the environment. We were able to culture 
A. fumigatus isolates, resistant to ITZ, from the indoor environment as well as the outdoor environment, 
with soil and air samples from patient rooms, being positive. The emergence of resistant isolates in 
the hospital environment coincided with that observed in clinical isolates, i.e., after the year 1999.2 
The majority of indoor and outdoor environmental azole-resistant isolates exhibited a phenotype and 
mechanism of resistance that were identical to the main type found for resistant isolates recovered from 
clinical samples of patients admitted to our hospital. Also, microsatellite typing of the isolates showed 
that the environmental and clinical azole-resistant isolates clustered together, indicating genetic 
relatedness and possibly a common ancestor.
We used ITZ-containing Sabouraud agar to select for resistant isolates, which possesses the theoretical 
risk of induction of resistance in the A. fumigatus isolates due to exposure to ITZ. However, we regard 
this as highly unlikely, as the incubation (exposure) period was short, i.e., a maximum of 48 h, and 
most resistant isolates contained two genomic changes, both of which are required for the resistant 
phenotype.8 We have never found either of these changes separately in azole-susceptible isolates. In 
addition, we have performed induction experiments in wild-type isolates by repeated exposure to ITZ 
but thus far have been unsuccessful in inducing laboratory mutants containing the TR/L98H resistance 
mechanism (unpublished observations), which is similar to the experience reported by others.18 
Detection of resistance mechanisms directly with the original sample, i.e., soil or compost, for instance, 
by a specifi cally designed PCR, would overcome a selection step that involves exposure of the isolates 
to azole compounds.
The dominance of a single resistance mechanism and the genetic relatedness between clinical and 
environmental isolates indicate that acquisition of azole-resistant isolates from the environment is the 
most important infection route, more important than the generally recognized mode of resistance 
development during azole therapy of patients with aspergillus disease. The presence of A. fumigatus 
resistant to medical triazoles in our environment yields a major threat for immunocompromised patients, 
as it is unclear if (further) spread of resistant isolates can be prevented and alternative treatment options 
are limited, especially in invasive disease that has spread to the central nervous system.19 
An important question is how resistance to medical triazoles arises in environmental isolates. Although 
our study does not address this issue, we have previously suggested the use of azole fungicides for plant 
protection and material preservation as a possible cause.2,5 Azoles are widely used preharvest in grain-
growing and grass-growing environments as well as postharvest to prevent spoilage.1 Also, azoles are 
used for preservation of materials, such as in paints, and coatings, wall paper pastes, and are routinely 
applied to mattresses in order to prevent fungal growth. In the present study, the azole-resistant 
A. fumigatus isolates that we cultured from the outdoor environment were found exclusively in soil from 
fl owerbeds. In natural soil, A. fumigatus was recovered, but azole resistance was never observed. Since 
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the fl owerbeds contained both compost and cultivated plants, we went on to culture seeds, leaves, and 
compost which we obtained from a plant nursery and a garden center and which were also found to 
contain azole-resistant isolates. Fungicides are used during the production of plants, and residues might 
be present in organic matter that is used for composting. Azole fungicides are recognized to have the 
potential to persist in soil 20-22, and fungicide residues have been detected in compost.23 Furthermore, 
resistance to azole fungicides has been reported for numerous plant pathogenic molds, such as 
Mycosphaerella graminicola.24 As A. fumigatus is a thermotolerant fungus and readily grows in compost 
heaps, resistance to azole fungicides might arise under these conditions. Stepwise increased exposure 
of the maize pathogen Colletotrichum graminicola, a fungus also capable of causing cutaneous mycosis 
and keratitis in humans, to the fungicide tebuconazole showed loss of activity to this triazole as well as 
to ITZ and voriconazole, indicating that fungicides are capable of inducing resistance to medical azoles.25 
If fungicides are responsible for the emergence of resistance to medical triazoles in A. fumigatus, a 
resistance mechanism would have developed that causes primarily resistance to the fungicide. Resistance 
to other azole compounds, such as medical triazoles, can be expected if these compounds share the 
same target or have a similar molecule structure. The suspected fungicide or group of fungicides will 
be active against ITZ- isolates but will exhibit reduced activity against ITZ+ isolates. Among the fi ve 
fungicides that we have investigated in this study, three exhibited no activity, while two were active 
against the ITZ- isolates. Both of these, metconazole and propiconazole, were less active against the 
ITZ+ isolates indicating that the TR/L98H substitution results in a cross-resistant phenotype, which 
supports a possible role for fungicides in resistance development. As azole fungicides have been used 
for many decades further studies are required to understand their role in the emergence of resistance. 
It is important to investigate the temporal relationship between the year of introduction of fungicides 
and the presence of cross-resistance with medical triazoles. This would require to test all azole fungicides 
licensed for use in the Netherlands, prior to the emergence of azole resistance in A. fumigatus in the year 
2000. Also, laboratory experiments that determine the ability of azole fungicides to induce mutations in 
the cyp51A gene, most notably the TR/L98H substitution, would prove such a relationship. We therefore 
believe that our fi ndings could be explained by a relation between environmental azole use and 
development of cross-resistance to medical triazoles. The intensive use of triazole fungicides creates 
an environment that allows the TR/L98H strains to survive in our environment. Spread of the TR/L98H 
and possibly other azole resistance mechanisms cannot be excluded. In addition to abovementioned 
research and international surveillance studies of clinical isolates, environmental sampling is required in 
order to determine and track the spread of azole resistance in the environment. 
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Abstract
Invasive aspergillosis due to multi-azole-resistant Aspergillus fumigatus has emerged in the Netherlands 
since 1999, with 6 to 12.8% of patients harbouring resistant isolates. The presence of a single resistance 
mechanism (denoted by TR/L98H), which consists of a substitution at codon 98 of cyp51A and a 34 bp 
tandem repeat in the gene-promoter region, was found in over 90% of clinical A. fumigatus isolates. 
This is consistent with a route of resistance development through exposure to azole compounds in the 
environment. Indeed, TR/L98H A. fumigatus isolates were cultured from soil and compost, were shown 
to be cross-resistant to azole fungicides, and genetically related to clinical resistant isolates. Azoles are 
abundantly used in the environment and the presence of A. fumigatus resistant to medical triazoles is a 
major challenge because of the possibility of worldwide spread of resistant isolates. Reports of TR/L98H 
in other European countries indicate that resistance might already be spreading.
Azole resistance in Aspergillus fumigatus: a side-eff ect of environmental fungicide use?
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Introduction
Invasive aspergillosis is an infectious disease that is diffi  cult to manage. Patients become infected 
by inhaling airborne Aspergillus spp. conidia that are released by saprophytic moulds that inhabit 
the environment. Despite preventive measures in hospitals, aimed at reducing the levels of airborne 
fungal spores, specifi c patient populations remain at risk. These include patients with haematological 
malignancy, pulmonary diseases (e.g. chronic obstructive pulmonary disease), solid organ transplant 
recipients and patients treated with corticosteroids. The incidence rates vary from below 1% in autologous 
haematopoietic stem-cell transplant (HSCT) recipients to up to 27% in allogeneic HSCT patients.1 The 
incidence in critically ill patients was found to be 2.7 – 6.3%.1 In most high-risk patients, deposition 
of aspergillus spores and even subclinical infection probably happen in the community with invasive 
aspergillosis becoming clinically detectable after immunosuppressive treatment during admission to 
hospital.2-4 Patient-to-patient transmission of invasive aspergillosis is extremely uncommon, and only 
reports of two clusters have been published (transplantation of a contaminated allograft and a surgical 
wound infection).5,6 
Starting adequate antifungal treatment early is thought to improve outcome. Voriconazole is 
recommended for the primary therapy of invasive aspergillosis,7 and another triazole, posaconazole, 
was shown to reduce the number of invasive fungal infections in neutropenic patients with acute 
myeloid leukemia, myelodysplastic syndrome and in patients with severe graft-versus-host disease 
when administered prophylactically.8,9 The role of azoles has therefore increased in the management of 
patients with invasive fungal diseases, most notably of invasive aspergillosis. 
The increasing role of azoles might be threatened by the acquisition of resistance by opportunistic 
moulds. Evolution of drug resistance seems to be less prominent in fungi than in bacteria, in which 
horizontal transfer of genes and accessory genetic elements across taxa provides a major source of 
genetic variation.10 In fungi the evolution of drug resistance is more likely to proceed by the sequential 
accumulation of adaptive mutations.10 However, fungi are capable of rapidly adapting in response to 
environmental challenges by antifungal drugs. In the setting of infection in individuals coinfected with 
HIV, Candida albicans has evolved various resistance mechanisms in response to short periods of azole 
exposure. Acquired resistance was also seen in Aspergillus fumigatus isolates cultured from patients with 
aspergilloma during treatment with azoles.11-13
We recently reported the rapid emergence of azole resistance in A. fumigatus isolates cultured from 
patients with invasive aspergillosis.14,15 Azole resistance has emerged since 1999 in clinical A. fumigatus 
isolates from Dutch Hospitals and between 6% and 12.8% of patients were found to harbour an azole-
resistant isolate.14-16 The phenotype of the resistant isolates was characterized by in vitro resistance 
to itraconazole, and reduced activity of voriconazole and posaconazole, compared with wild-type 
isolates.14,15 Patients with azole-resistant invasive aspergillosis presented with primary or breakthrough 
infection, and failed to respond to itraconazole or voriconazole treatment.14,15,17-20 We believe that in 
addition to resistance development in azole-treated patients, resistance in A. fumigatus could also 
develop in our environment. An environmental route of resistance development confronts us with a 
major challenge with worldwide dimensions, because effi  cient reproduction and spread of resistant 
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fungus in the environment can be anticipated. We discuss the evidence that supports an environmental 
route of resistance development in A. fumigatus. 
Resistance development through patient exposure
Resistance has been shown to develop in patients with aspergilloma and cavitary lung disease who have 
been treated with azoles.11-13 Because in vitro susceptibility testing of aspergilli is not routinely done in 
many clinical microbiology laboratories, the prevalence of azole resistance is probably underestimated. 
Recently Howard and colleagues13 reported an increasing frequency of resistance in A. fumigatus in 
predominantly azole-treated patients with aspergilloma. Pathogenesis involves infection of the patient 
with an azole-susceptible A. fumigatus isolate that becomes resistant due to azole pressure. Importantly, 
the risk of development of phenotypic resistance seems to be dependent on the mode of reproduction 
of the moulds. Development of resistance might happen in patients with aspergilloma as aspergilli grow 
within the lung cavity by asexual reproduction through sporulation which allows multiple generations 
to form. This facilitates adaptation of the mould to the selective pressure of azoles.21 
In patients with acute invasive aspergillosis, asexual reproduction by sporulation does not happen, and 
the infection progresses through hyphal elongation. Spontaneous mutations are likely to happen in 
nuclei within the hyphae. For example, in Aspergillus niger, stress (ie, high temperature or ultraviolet light) 
increases the mutation frequency.22 Since the human body can be thought to be a hostile environment 
for any fungus because of exposure to host defences and antifungal drugs, mutations can be expected 
to happen during invasive fungal infection. However, the hyphae will contain millions of nuclei. 
Azole resistance in Aspergillus fumigatus: a side-eff ect of environmental fungicide use?
Figure 1. Relation between mutations and phenotypic expression in aspergillus. 
Hyphal growth, as present in invasive aspergillosis. Mutations will happen that have limited or no eff ect on the phenotype because they are 
vastly outnumbered by wild-type nuclei (A). From the hyphae, asexual propagative structures might be formed by which conidiospores (conidia) 
are produced via mitosis. This might happen in patients with aspergilloma. Mutations are expressed in conidia and in colonies from conidia (B). 
After germination of the conidia (C), hyphae and colonies with a susceptible (blue nuclei) or a resistant (brown nuclei) phenotype are formed.
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Therefore, mutations might have little eff ect on the phenotype of the fungus even if the mutation results 
in a gain of function, primarily because the mutated genes in the pool would be vastly outnumbered 
by wild-type genes (Figure 1). However, mutations would be expressed in uninucleate conidia and in 
all colonies that develop from those conidia. Therefore, asexual reproduction seems to be essential for 
phenotypic expression of mutations, including those predisposing for resistance.22 As a consequence, 
development of phenotypic resistance during treatment of patients with acute invasive aspergillosis 
should be seen as highly unlikely, unless the fungus undergoes asexual reproduction, for instance when 
the infection progresses to a cavitary lesion. 
Alternative sources of patient exposure to azoles include absorption of azole residues that are present 
in food. Several studies have investigated the presence of azole residues in food, most notably wines, 
because grapes are especially vulnerable to fungal infection and azole fungicides are intensively used in 
vineyards. Azole residues were found in more than 75% of wines, but all concentrations were below the 
required maximum residue concentrations.23 Although long-term exposure of consumers could happen 
if food contains azole residues, in general, the risk of exposure of consumers is thought to be negligible 
in high-income countries.24 Therefore, development of resistance to medical triazoles in A. fumigatus is 
unlikely to be caused by azole residues in foods.
Resistance development through environmental exposure
Our hypothesis focuses on another route of resistance development through exposure of A. fumigatus 
to azole compounds in our environment. Exposure of saprophytic fungi to azole compounds could take 
place in agriculture, where such compounds are commonly used for plant protection. The fungicides 
are applied repeatedly over a long period of time and could thereby create a persistent pressure of azole 
compounds on saprophytic fungi. We previously suggested that an environmental route of resistance 
development in A. fumigatus should be considered because a single mechanism of azole resistance 
was found in 94% of clinical isolates from diff erent hospitals in the Netherlands.14 The presence of such 
a dominant resistance mechanism is diffi  cult to explain if resistance had developed exclusively through 
treatment of epidemiologically unrelated patients, because we would expect multiple mechanisms 
of resistance to develop. Substantial diversity of cytochrome P450 14-alpha sterol demethylase gene 
(cyp51A)-related resistance mechanisms was noted in the study by Howard and colleagues13, which was 
shown to be associated with azole therapy and suggests a diff erent mode of resistance development than 
that seen in the Netherlands. Furthermore, spread of resistance is highly unlikely in invasive aspergillosis, 
because person-to-person transmission is very uncommon and a patient will either respond to therapy 
(precluding spread of the isolate) or the treatment will fail.14 In the latter case the (resistant) fungus 
might survive, but its spread directly to another patient or through the environment seems to be highly 
unlikely. However, our fi nding of a dominant resistance mechanism could be explained by resistance 
development in the environment as the saprophytic growth of aspergilli enables the phenotypic 
expression and spread of mutations. 
Furthermore, an environmental route of resistance development would be in line with the fi nding of 
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primary invasive aspergillosis due to azole-resistant A. fumigatus in azole-naïve patients.10,14 Breakthrough 
aspergillosis in patients on azole prophylaxis would also be consistent with an environmental route: 
patients would inhale both azole-susceptible and azole-resistant conidia, but the resistant conidia would 
have a selective advantage, thus allowing germination in the lungs and subsequent invasive disease.10,14 
Use of azoles as pesticides
Fungicides are widely used for plant protection in the European Union. At present, slightly less than 
half of the total European Union acreage under cereals and grapevine are treated yearly with azole 
fungicides.25 This compares to less than 5% of the total crop area treated yearly in the USA.25 Azole 
fungicides, also referred to as demethylation inhibitors, inhibit the biosynthesis of fungal ergosterol 
by inhibition of cytochrome P450 14-alpha sterol demethylase. The most important demethylation 
inhibitors used in agriculture are imidazoles and triazoles. Related groups of compounds that are used 
to a much less extent are derivatives of piperazines, pyridines, and pyrimidines.26 The mode of action of 
these compounds is similar to that of azoles.27 However, the azoles are the only class of compounds that 
are used both in agriculture and in clinical medicine. 
Although the overall use of pesticides in most European Union member states has declined over the 
past decades, the usage of fungicides has remained stable in the Netherlands in the recent years. 
However, the volume of triazole fungicides sold has almost doubled between 1995 and 2007 (Figure 2). 
For example, the volume of azoles and azole-like agricultural fungicides that was used in the Netherlands 
in 2004 was about 320-times higher than that of mould-active azoles used in clinical medicine (about 
130 000 kg vs 400 kg). Because plant pathogenic moulds share their natural environment with 
A. fumigatus, both are exposed to a strong and persistent pressure from azole fungicides.
Azole resistance in Aspergillus fumigatus: a side-eff ect of environmental fungicide use?
Figure 2. Total volume of fungicides and triazoles sold in the Netherlands between 1995 and 2007.
Data from the Dutch Foundation for Phytofarmacy (Nefyto, Nederlandse Stichting voor Fytofarmacie).
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Mechanisms of azole resistance
Resistance to fungicides is well-known in agriculture and is often fi rst recognised when expected levels 
of disease control are no longer achieved. Depending on the mechanism of resistance, complete failure 
of disease control can happen, as has been found in benzimidazole fungicides, and a more gradual 
loss of control, which has been reported for the triazoles. This failure of control corresponds with a 
sensitivity shift among plant pathogens towards reduced susceptibility to triazoles, which is thought to 
be happening in all European countries. Moreover, fi eld isolates that develop resistance in response to 
exposure to a triazole commonly show a multi-azole-resistant phenotype.28
Mechanisms of azole resistance that have been described in many plant pathogens include amino 
acid substitutions in the cyp51A gene or the presence of transcriptional enhancers, which cause over 
expression of the cyp51A gene (Table 1).12,13,28-44 The cyp51B gene of A. fumigatus has not been shown to 
be a target for substitutions that are associated with resistance. The described mechanisms of fungicide 
resistance represent a stable, heritable trait in plant pathogenic moulds and have no apparent adverse 
eff ect on the fi tness of the fungus.
In clinical A. fumigatus isolates multiple amino acid substitutions in the cyp51A gene have been 
described that correspond to azole resistance (Figure 3).45 Specifi c mutations in cyp51A have been 
associated with diff erent susceptibility profi les in A. fumigatus: cross-resistance to itraconazole and 
posaconazole has been associated with aminoacid substitutions at glycine-54 (G54),34 and a pattern 
of itraconazole resistance and Increased minimum inhibitory concentrations for other azoles has been 
linked to diff erent aminoacid substitutions at methionine-220 (M220).41 Single mutations at codon 138, 
which was associated with an amino acid substitution (G138C), and at codon 448 were also seen in a 
clinical A. fumigatus isolate that had a multi-azole-resistant phenotype.12,13,40
The dominant azole-resistant phenotype of the A. fumigatus isolates reported in Dutch hospitals was 
associated with a diff erent resistance mechanism, which consisted of an amino acid change in the 
cyp51A gene and the presence of a tandem repeat in the gene promoter (TR/L98H; Figure 3).14,42 Both 
alterations were shown to be necessary to display the azole-resistant phenotype, with the tandem 
repeat acting as a transcriptional enhancer.42 
Figure 3. Aspergillus fumigatus cyp51A-related resistance mechanisms to azole antifungals. 
The position of the diff erent mutations are shown with the associated phenotypes. MIC=minimum inhibitory concentration. TR=tandem repeat. 
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Table 1. Main resistance mechanisms to azole fungicides found in plant pathogens and clinical Aspergillus fumigatus isolates.
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The resistance mechanism seems to be indicative of the mode of resistance development. The 
resistance mechanism found in isolates thought to have become resistant through azole treatment 
consist of point mutations, whereas the presence of a tandem repeat is an important mechanism found 
in plant pathogenic moulds that develop resistance through exposure to azole fungicides (Table 1). 
The insertion of a tandem repeat might happen more readily during sexual reproduction of the mould 
compared with asexual reproduction. Sexual reproduction was recently described in A. fumigatus,46 but 
this mode of reproduction is rarely associated with fungal diseases in human beings, unlike asexual 
reproduction. As a consequence, the development of the 34 bp tandem repeat in A. fumigatus is 
most likely to be an event that has taken place in the environment. The second alteration found in the 
TR/L98H isolates, the substitution at codon 98, probably arose through a separate event.
The risk of opportunistic fungi becoming resistant because of azole antifungal use for plant protection 
has been acknowledged by investigators,47,48 and by governmental authorities such as the Scientifi c 
Steering Committee of the Health and Consumer Protection Directorate-General of the European 
Commission,25 but there has been little evidence to support a direct link between environmental and 
clinical resistant isolates. The reports were published when azole resistance in fungi was restricted 
to Candida spp., and was clearly associated with repeated azole treatment of immunocompromised 
patients with oropharyngeal candidiasis. Since then, a Swiss study has reported susceptibility to azoles 
used in clinical medicine of A. fumigatus isolates from compost sites, vineyards, and crop areas. Among 
150 environmental isolates, 32 showed increased minimum inhibitory concentrations of azoles, but 
no triazole cross-resistant isolates were identifi ed.49 However, we recently reported the presence of 
A. fumigatus resistant to medical triazoles in the indoor hospital environment as well as in outdoor 
soil samples.50 Azole-resistant isolates were never found in natural soil, only in cultivated soil samples. 
Furthermore, isolates resistant to medical triazoles were recovered from commercial compost and seeds 
obtained from a garden centre and plant nursery.50 13 of 15 (86%) environmental resistant isolates 
harboured the same resistance mechanism as found in clinical isolates, and genetic typing confi rmed 
that these environmental and clinical resistant isolates were clustered.50 This provides evidence that 
patients might become colonized and subsequently infected by resistant isolates originating from the 
environment.
A new route of antifungal drug-resistance development?
We believe that evidence is accumulating that resistance to medical triazoles might develop because of 
exposure of A. fumigatus to azole fungicides in the environment. This mode of resistance development 
would imply that resistance development against azole fungicides causes cross-resistance to 
medical triazoles. The principle has been shown for the maize pathogen Colletotrichum graminicola, 
which developed cross-resistance to itraconazole and voriconazole after exposure to the fungicide 
tebuconazole.51 Preliminary studies with TR/L98H isolates from clinical and environmental origins 
indicate that these isolates are cross-resistance to tebuconazole and metconazole, again supporting a 
role for fungicides in resistance development.50 
We seem to be at the verge of a new era in resistance development in moulds, although many questions 
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remained unanswered. The recent emergence of azole resistance in clinical A. fumigatus isolates (after 
1999) is diffi  cult to explain by environmental exposure because azole fungides have been used for several 
decades. A possible explanation might be that the early azole fungicides showed no activity against 
A. fumigatus, and that only recently have new compounds been introduced that have activity against 
A. fumigatus. However, the time between exposure and phenotypic resistance development is unknown, 
although the polyallelic nature of the TR/L98H resistance mechanism suggests a multistep development 
process. The dominance of the TR/L98H resistance mechanism is also unexplained because one would 
expect that azole exposure in the environment would result in multiple resistance mechanisms to 
emerge. Maybe the TR/L98H isolates have an advantage with respect to fi tness compared with other 
mutated isolates, which would facilitate its survival and spread in the environment. 
Compost may play a key role in the development and spread of azole resistance. Compost is an 
ecologic niche for A. fumigatus, and azole residues have been reported to be present in commercial 
compost.52 Compost, which is used in domestic gardens and for indoor plants, would also provide a 
mode of exposure of susceptible hosts. If the environmental route of resistance development proves 
to be correct, we anticipate that azole resistance in A. fumigatus is only the fi rst of many, with multiple 
yet unknown resistance mechanisms having developed in other Aspergillus spp. and in other clinically 
relevant moulds. 
Future directions
To prove a relation between the use of demethylation inhibitors and resistance development in 
A. fumigatus, all azole fungicides need to be tested for activity against A. fumigatus isolates that are 
susceptible and resistant to medical triazoles, and against isolates harbouring diff erent resistance 
mechanisms. The year of fi rst fi eld use of each fungicide will help to establish temporal relations 
between use of a specifi c fungicide and the recorded emergence of resistance in clinical isolates. For 
those fungicides that show cross-resistance, induction experiments should be done to establish whether 
resistant mutants show cross-resistance to medical triazoles. The ability of demethylation inhibitors to 
select the TR/L98H resistance mechanism in A. fumigatus would prove such a relation. This will also allow 
us to identify which compounds are responsible for resistance development. However, even if a relation 
between the use of azole fungicides and the development of resistance in A. fumigatus is proven, 
whether we can prevent further development and spread remains unclear, because resistant isolates are 
already present in the environment. Limiting the use of those fungicides that induce resistance might 
prevent the development of azole resistance, but preventing further spread of the TR/L98H resistance 
mechanism might not be feasible. Spread already seems to be happening, and TR/L98H has been found 
in other European countries such as Norway,14 United Kingdom,13,53 Belgium,54 France and Spain.42 This 
may be the fi rst sign of the global spread of azole resistance in aspergilli.
67
4
References 
1.  Lass-Florl, C. 2009. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52:197-205.
2.  Einsele, H. et al. 1998. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract  
 before marrow transplantation. Lancet 352:1443.
3.  Patterson, J. E. et al. 1997. Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics  
 and the utility of antigen detection. Infect. Control Hosp. Epidemiol. 18:104-108.
4.  Sarfati, J. et al. 2006. Recombinant antigens as diagnostic markers for aspergillosis. Diagn. Microbiol. Infect. Dis.  
 55:279-291.
5.  Keating, M. R. et al. 1996. Transmission of invasive aspergillosis from a subclinically infected donor to three 
 diff erent organ transplant recipients. Chest 109:1119-1124.
6.  Pegues, D. A. et al. 2002. Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of  
 person-to-person airborne transmission. Clin. Infect. Dis. 34:412-416.
7.  Walsh, T. J. et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society  
 of America. Clin. Infect. Dis. 46:327-360.
8.  Cornely, O. A. et al. 2007. Posaconazole vs. fl uconazole or itraconazole prophylaxis in patients with neutropenia.  
 N. Engl. J. Med. 356:348-359.
9.  Ullmann, A. J. et al. 2007. Posaconazole or fl uconazole for prophylaxis in severe graft-versus-host disease.   
 N. Engl. J. Med. 356:335-347.
10.  Cowen, L. E. 2001. Predicting the emergence of resistance to antifungal drugs. FEMS Microbiol. Lett. 204:1-7.
11.  Chen, J. et al. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus 
 serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37.
12.  Howard, S. J. et al. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob.Agents 28:450-453.
13.  Howard, S. J. et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with  
 treatment failure. Emerging Infectious Diseases 15:1068-1076.
14.  Snelders, E. et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance  
 mechanism. PLoS Med 5:e219.
15.  Verweij, P. E. et al. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
16.  Verweij, P. E. et al. 2002. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical  
 Aspergillus fumigatus isolates cultured between 1945 and 1998. J. Clin. Microbiol. 40:2648-2650.
17.  Hodiamont, C. J. et al. 2009. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with 
 chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med 
 Mycol. 47:217-220.
18.  Van Der Linden, J. W.M. et al. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 
 48:1111-1113.
19.  van Leer-Buter, C. et al. 2007. Aspergillosis--and a misleading sensitivity result. Lancet 370:102.
20.  Warris, A. et al. 2002. Multidrug resistance in Aspergillus fumigatus. N. Engl. J. Med. 347:2173-2174.
21.  Anderson, J. B. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fi tness. 
 Nat. Rev. Microbiol. 3:547-556.
22.  Lamb, B. C. et al. 2008. Diff erences in spontaneous mutation frequencies as a function of environmental stress  
 in soil fungi at “Evolution Canyon,” Israel. Proc. Natl. Acad. Sci. U.S.A 105:5792-5796.
23.  Trosken, E. R. et al. 2005. Quantitation of 13 azole fungicides in wine samples by liquid chromatography-
 tandem mass spectrometry. J. Chromatogr. A 1083:113-119.
24.  Oestreich, A. et al. 1997. Biological monitoring of the fungicide epoxiconazol during application. Arch. Environ. 
 Contam Toxicol. 33:329-335.
25.  Scientifi c Steering Committee and European Commission Health & Consumer protection directorate-general-  
 opinion on azole antimycotic resistance. 2002. 
68
Azole resistance in Aspergillus fumigatus: a side-eff ect of environmental fungicide use?
26.  www.lei.wur.nl. Land & Tuinbouwcijfers, The Hague, LEI, Rapport PR.04.02. 2004. 
27.  Ji, H. et al. 2000. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its   
 interaction with azole antifungals. J. Med Chem. 43:2493-2505.
28.  Hamamoto, H. et al. 2000. Tandem repeat of a transcriptional enhancer upstream of the sterol 14alpha-
 demethylase gene (CYP51) in Penicillium digitatum. Appl. Environ. Microbiol. 66:3421-3426.
29.  Albertini, C. et al. 2003. Polymorphism of 14 alpha-demethylase gene (CYP51) in the cereal eyespot fungi   
 Tapesia acuformis and Tapesia yallundae. European Journal of Plant Pathology 109:117-128.
30.  Butters, J. A. et al. 2000. The mechanism of resistance to sterol 14 alpha demethylation inhibitors in a mutant 
 (Erg 40) of Ustilago maydis. Pest Management Science 56:257-263.
31.  Cools, H. J. et al. 2006. Impact of changes in the target P450 CYP51 enzyme associated with altered triazole-  
 sensitivity in fungal pathogens of cereal crops. Biochem. Soc. Trans. 34:1219-1222.
32.  Delye, C. et al. 1997. A mutation in the 14 alpha-demethylase gene of Uncinula necator that correlates with 
 resistance to a sterol biosynthesis inhibitor. Appl. Environ. Microbiol. 63:2966-2970.
33.  Delye, C. et al. 1998. PCR cloning and detection of point mutations in the eburicol 14alpha-demethylase   
 (CYP51) gene from Erysiphe graminis f. sp. hordei, a “recalcitrant” fungus. Curr. Genet. 34:399-403.
34.  Diaz-Guerra, T. M. et al. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to  
 itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
35.  Fraaije, B. A. et al. 2007. A novel substitution I381V in the sterol 14alpha-demethylase (CYP51) of Mycosphaerella  
 graminicola is diff erentially selected by azole fungicides. Mol. Plant Pathol. 8:245-254.
36.  Ghosopha J.M. et al. 2007. Imazalil resistance linked to a unique insertion sequence in the PdCYP51 promoter  
 region of Penicillium digitatum. Postharvest Biology Technology 44:9-18.
37.  Leroux, P. et al. 2007. Mutations in the CYP51 gene correlated with changes in sensitivity to sterol 14 alpha-  
 demethylation inhibitors in fi eld isolates of Mycosphaerella graminicola. Pest. Manag. Sci. 63:688-698.
38.  Luo, C. X. et al. 2008. Occurrence and detection of the DMI resistance-associated genetic element ‘Mona’ in   
 Monilinia fructicola. Plant Disease 92:1099-1103.
39.  Ma, Z. et al. 2006. Overexpression of the 14alpha-demethylase target gene (CYP51) mediates fungicide 
 resistance in Blumeriella jaapii. Appl. Environ. Microbiol. 72:2581-2585.
40.  Manavathu E, Baskaran I., Krishnan S., Alangaden G., and Chandrasekar P. 43rd Interscience Conference on 
 Antimicrobial Agents, Abstract M-471: Cytochrome P450 14-alpha-Sterol Demethylase Mutation Dependent  
 Triazole Cross-Resistance in Aspergillus fumigatus. ICAAC 43rd . 2003. 
41.  Mellado, E. et al. 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (cyp51A) of 
 Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents 
 Chemother. 48:2747-2750.
42.  Mellado, E. et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to  
 azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
43.  Schnabel, G. and A. L. Jones. 2001. The 14alpha-Demethylasse(CYP51A1) Gene is Overexpressed in Venturia 
 inaequalis Strains Resistant to Myclobutanil. Phytopathology 91:102-110.
44.  Wyand, R. A. and J. K. Brown. 2005. Sequence variation in the CYP51 gene of Blumeria graminis associated with  
 resistance to sterol demethylase inhibiting fungicides. Fungal Genet.Biol. 42:726-735.
45.  Verweij, P. E. et al. 2009. Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resist. 
 Updat. 12:141-147.
46.  O’Gorman, C. M. et al. 2009. Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus 
 fumigatus. Nature 457:471-474.
47.  Hof, H. 2001. Critical annotations to the use of azole antifungals for plant protection. Antimicrob. Agents 
 Chemother. 45:2987-2990.
48.  Hof, H. 2008. Is there a serious risk of resistance development to azoles among fungi due to the widespread   
 use and long-term application of azole antifungals in medicine? Drug Resist. Updat.
69
49.  Meneau, I. and D. Sanglard. 2005. Azole and fungicide resistance in clinical and environmental Aspergillus 
 fumigatus isolates. Med. Mycol. 43 Suppl 1:S307-S311.
50.  Snelders, E. et al. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles.  
 Appl. Environ. Microbiol. 75:4053-4057.
51.  Serfl ing, A. et al. 2007. Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole 
 causes cross-resistance to medical azoles and potentiates caspofungin effi  cacy. Antimicrob. Agents 
 Chemother. 51:3672-3676.
52.  Vanni A et al. 2004. Occurrence of dicarboximide fungicides and their metabolites’ residues in commercial 
 compost. Argonomie 24 (1):7-12.
53.  Howard, S. J. et al. 2010. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis.  
 Clin. Microbiol. Infect. 16:683-688.
54.  Lagrou K, De Vleeschouwer J, Meerseman W, and et al. Triazole resistance among clinical Aspergillus fumigatus  
 isolates. 13rd Advances Against Aspergillosis, Miami, USA, Abstract 33. 2008. 
4

Snelders E*, Camps SMT*, Karawajczyk A, Schaftenaar G, Kema GHJ, Van der Lee HA, 
Klaassen CH, Melchers WJG, Verweij PE
*contributed equally to this publiclation
PLoS One,2012; in press
Triazole fungicides can induce cross-resistance to 
medical triazoles in Aspergillus fumigatus 
5
72
Abstract
Azoles play an important role in the management of aspergillus diseases. Azole resistance is an 
emerging global problem in Aspergillus fumigatus, and may develop through patient therapy. In 
addition, an environmental route of resistance development has been suggested through exposure to 
14 alpha-demethylase inhibitors (DMIs). The main resistance mechanism associated with this putative 
fungicide-driven route is a combination of alterations in the cyp51A-gene (TR34/L98H). We investigated if 
TR34/L98H could have developed through exposure to DMIs. Thirty-one compounds that have been 
authorized for use as fungicides, herbicides, herbicide safeners and plant growth regulators in the 
Netherlands between 1970 and 2005, were investigated for cross-resistance to medical triazoles. 
Furthermore, CYP51-protein homology modeling and molecule alignment studies were performed 
to identify similarity in molecule structure and docking modes. Five triazole DMIs, propiconazole, 
bromuconazole, tebuconazole, epoxiconazole and difenoconazole, showed very similar molecule 
structures to the medical triazoles and adopted similar poses while docking the protein. These DMIs 
also showed the greatest cross-resistance and, importantly, were authorized for use between 1990 and 
1996, directly preceding the recovery of the fi rst clinical TR34/L98H isolate in 1998. Through microsatellite 
genotyping of TR34/L98H isolates we were able to calculate that the fi rst isolate would have arisen in 1997, 
confi rming the results of the abovementioned experiments. Finally, we performed induction experiments to 
investigate if TR34/L98H could be induced under laboratory conditions. One isolate evolved from two 
copies of the tandem repeat to three, indicating that fungicide pressure can indeed result in these genomic 
changes. Our fi ndings support a fungicide-driven route of TR34/L98H development in A. fumigatus. Similar 
molecule structure characteristics of fi ve triazole DMIs and the three medical triazoles appear the 
underlying mechanism of cross resistance development. Our fi ndings have major implications for the 
assessment of health risks associated with the use of triazole DMIs. 
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus
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Introduction
Aspergillus fumigatus is the most frequent cause of aspergillus diseases in humans, which include allergic 
syndromes, aspergilloma and chronic or acute invasive aspergillosis. Antifungal agents of the azole class 
play a prominent role in the management of aspergillus diseases. Three medical triazoles, itraconazole, 
voriconazole and posaconazole, are clinically licensed for the prevention and treatment of aspergillus 
diseases.1 It has become apparent that A. fumigatus can develop resistance to the medical triazoles. 
Azole resistance is commonly due to mutations in the cyp51A-gene, encoding the target enzyme of 
antifungal azoles, and both preclinical evidence and clinical experience suggests that reduced in vitro 
susceptibility is associated with increased probability of failure to azole therapy.2–4 Azole resistance 
may develop during azole therapy, which has been primarily reported in patients with aspergilloma or 
other Aspergillus cavities that received long-term azole therapy.5 This route of resistance development is 
characterized by recovery of azole-resistant A. fumigatus isolates exclusively from patients receiving azole 
therapy and by a high diversity of resistance mechanisms. Sometimes multiple resistance mechanisms 
were found in diff erent A. fumigatus colonies recovered from a single patient.5 The morphotype of 
A. fumigatus appears to be important as the fungus commonly sporulates in cavities, thus creating 
spores that harbor cyp51A-mutations.7
In the Netherlands, we observed azole resistance in A. fumigatus isolates from azole-naïve patients 
and in patients with invasive aspergillosis, which is characterized by hyphal growth in the absence of 
asexual reproduction. One explanation for this observation could be that a second route of resistance 
development may exist through environmental exposure of A. fumigatus to 14 alpha-demethylase 
inhibitors (DMIs).4,6,7 DMIs are abundantly used for crop protection against phytopathogenic molds, for 
prevention of spoilage post harvest and for preservation of materials. Evidence that supports such a 
route of resistance development is the dominance of a single resistance mechanism in over 90% of 
Dutch azole-resistant A. fumigatus isolates, recovered from epidemiologically unrelated patients.6–8 This 
mechanism consists of a 34 bp insertion in the promoter region of the cyp51A gene combined with 
a substitution at codon 98 of leucine to histidine (TR34/L98H).
9 TR34/L98H isolates were cultured from 
patients that were azole-naïve as well as those with previous azole exposure, and were also recovered 
from the environment.10 Genetic analysis showed clustering of clinical and environmental TR34/L98H 
isolates compared to wild-type controls.6,10 TR34/L98H isolates exhibit a multi-azole-resistant phenotype 
and azole-resistant invasive aspergillosis was associated with a high mortality rate of 88%.8,11 In the 
Netherlands the fi rst TR34/L98H isolate was cultured in 1998 and since then the prevalence of clinical 
isolates harboring TR34/L98H has increased over time.
6,8 
Theoretically there are signifi cant risks associated with the environmental route of resistance 
development in fungi. First there is the potential of migration of the resistance trait through sexual or 
asexual reproduction. It has been shown for phytopathogens that resistance mechanisms may develop 
locally and subsequently spread across countries.12 There are early indications that suggest that migration 
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is occurring in TR34/L98H as isolates harboring this resistance mechanism have now been reported in 
other European countries,13 and more recently in azole-resistant isolates in China.14 The other risk of the 
environmental route of resistance development is the emergence of multiple resistance mechanisms 
over time due to continued azole pressure. There are recent reports that indicate that in addition to 
TR34/L98H other ‘environmental’ resistance mechanisms may be emerging.
15,16  
Therefore, it is of great importance to explore the relationship between the use of DMIs and the 
emergence of TR34/L98H in A. fumigatus as this may enable eff ective measures to be taken that prevent 
further increase of TR34/L98H isolates or of the emergence of new resistance mechanisms. The aim of our 
current research was to determine if route of TR34/L98H development could have been fungicide driven. 
Our hypothesis was that cross-resistance could develop if DMIs and medical triazoles share similar 
molecule characteristics. This was investigated through molecule alignment and docking studies using 
a homology model of the CYP51A protein. Furthermore, temporal relationships between DMI exposure 
and TR34/L98H emergence were investigated. Finally, we investigated if the TR34/L98H substitutions 
could be induced through DMI-exposure under laboratory conditions. We were able to identify fi ve 
triazole DMIs that exhibit highly similar molecule characteristics to medical triazoles and could have 
caused the emergence of TR34/L98H in A. fumigatus. 
Material and Methods
Susceptibility testing
A collection of 25 clinical wild-type A. fumigatus isolates, 25 clinical azole-resistant TR34/L98H isolates, 17 
environmental wild-type isolates, and 13 environmental TR34/L98H isolates were selected for investigation 
of the in vitro activity of fungicides. In addition, two clinical isolates were included that have a tandem 
repeat as underlying resistance mechanism similar to TR34/L98H: one isolate harbored a 53 bp tandem 
repeat and the other a 46 bp tandem repeat in combination with two substitutions in the cyp51A-gene 
at codons 121 and 289. Finally, four isolates were included that had a resistance mechanism that arose 
through azole therapy, consisting of point mutations in the cyp51A-gene. All isolates were previously 
identifi ed by sequencing parts of the Beta-tubulin gene and the calmodulin gene. Furthermore, the 
full coding sequence and promoter region of the cyp51A-gene was sequenced and microsatellite 
genotyping was performed.6 Sequences were aligned with a reference cyp51A sequence (GenBank 
accession no. AF338659) to identify mutations. All isolates were stored in 10% glycerol at -80°C and 
subcultured on Sabauroud slants at 37°C. 
Between 1970 and 2005 33 compounds were authorized by the Dutch Board for the Authorization 
of Plant Protection Products and Biocides for use as fungicides, herbicides, herbicide safeners and 
plant growth regulators, in The Netherlands. Of these 31 were available for testing including: amitrole, 
benomyl, biteranol, bromuconazole, carbendazim, cyazofamide, cyproconazole, difenoconazole, 
epoxiconazole, fenamidone, fenarimol, fenchlorazole-ethyl, fuberidazole, imazamethabenz-methyl, 
imazilil, metconazole, myclobutanil, nuarimol, paclobutrazole, penconazole, prochloraz, propiconazole, 
prothioconazole, pyrimethanil, tebuconazole, thiabendazole, thiophanate-methyl, triadimefon, 
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triademinol I, triademinol II, trifl umizole (Sigma Aldrich). The compounds were dissolved in DMSO and 
autosterilized for 30 minutes at room temperature. The minimal inhibiting concentration (MIC) was 
determined using a microbroth dilution format according to the CLSI M38-A2 reference method.17 
Docking studies
The structure of wild-type CYP51A protein A. fumigatus was derived from the crystal structure of human 
(PDB code: 3I3K) and Mycobacterium tuberculosis (Mt) (PDB code: 1EA1) lanosterol 14 alpha-demethylase 
by homology modeling. Both proteins share 38% and 24% sequence identity with CYP51A of 
A. fumigatus, respectively and contain ligands in the active site bound to heme. The three-dimensional 
structures have been predicted by YASARA’s homology modeling experiment (http://www.yasara.org). 
The experiment consists from building four models based on diff erent alignment variants. The missing 
loops were modeled and optimizations of structures ware performed. The model with the best Z-score 
derived from the crystal structure of human lanosterol 14 alpha-demethylase was used for the presented 
studies.
In a recent publication by Fraczek et al. the Mycobacterium and human structures were also both 
compared and confi rmed the choice for the human lanosterol 14 alpha-demethylase as the best 
template for the A. fumigatus model.18 The structures of tested fungicides and medical triazoles (Table 1) 
were downloaded from PubChem (http://pubchem.ncbi.nlm.nih.gov/). We used FlexX for the docking 
experiment.19,20 The coordination of ligands to the iron atom of heme was treated as pharmacophore 
during the docking procedure. The water molecule present in the active site according to the crystal 
structure of 1EA1 was treated dynamically. The program checked automatically whether the presence 
of the water molecule had favorable contribution to the docking pose and only in such a case the water 
molecule was reported back, otherwise it was neglected. The fl exibility of hydrogen atoms of Y107, 
Y121 and S297 was introduced to fi nd an optimal docking pose for the ligand. Docking the respective 
compounds back into their crystal structure validated the docking procedure. The root mean square 
deviation (RMSD) of the positions for fl uconazole (PDB code 1EA1) was 0.28 Å and for ketoconazole 
(PDB code 313K) 0.44 Å. All the binding modes present in the crystal structures were conserved.21,22
Microsatellite genotyping
Microsatellite genotyping was used to determine the genetic distances between TR34/L98H 
A. fumigatus isolates. A collection of 144 consecutive TR34/L98H isolates were used that originated from 
two prospective surveillance studies that were performed in the Netherlands. The fi rst study included 
A. fumigatus isolates that were collected in Dutch hospitals between 1994 and 2007. A total of 1,912 
A. fumigatus isolates were obtained from 1,219 patients from the Radboud University Nijmegen Medical 
Centre.6 In addition, 147 A. fumigatus isolates from 101 patients, from 28 other medical centers in the 
Netherlands were collected.4,6 The second culture collection included 1,792 A. fumigatus isolates that 
were collected from 1,192 patients in seven University Medical Centers in the Netherlands between 2007 
and 2009.8 Both studies included an unselected collection of A. fumigatus isolates (clinically relevant as 
well as colonizing isolates) and used agar supplemented with itraconazole to detect for azole-resistance. 
From six loci, consisting of three tri- and three tetranucleotide repeats, fragments were amplifi ed by 
76
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Table 1. Antifungal susceptibilities of medical triazoles and compounds used as fungicide, herbicide, herbicide safener and 
plant growth regulator.
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5
using fl uorescently labeled primers. The sizes of the fragments were determined by addition of the 
GeneScan LIZ[500] marker and subsequent analysis of the fragments on the Applied Biosystems 3730 
DNA analyzer. Assignment of repeat numbers in each marker was determined from the GeneScan 
data by using the Peak Scanner version 1.0 software (Applied Biosystems).23 By plotting the number 
of observed new genotypes versus the time on a semi-logarithmic scale, the year that the fi rst new 
genotype emerged in The Netherlands was calculated with a 95% confi dence interval by using the 
software package GraphPad Prism v5.00.
Induction experiments
Induction experiments were performed with the medical triazole itraconazole (5 mg/l), the triazole 
DMIs bromuconazole (8 mg/l), difenoconazole (8 mg/l), epoxiconazole (16 and 32 mg/l), propiconazole 
(32 mg/l) and tebuconazole (8 mg/l) and all fi ve DMIs combined together in concentrations ranging 
between 0.063 – 4 mg/l of each DMI. Wild-type isolate CM237 and akuBKU80 as well as recombinant 
A. fumigatus isolates akuBKU80-TR3 containing the 34 bp tandem repeat and akuBKU80-L98H2 containing 
the L98H substitution were used. A solution of 1x106 of conidia was spread on a GYEP agar plate 
(glucose 2%, yeast extract 0,3%, peptone 1% and agar 2%) containing one or a combination of DMIs 
and subsequently passaged on GYEP agar slants with the same concentration of DMI(s). Agar plates and 
slants were incubated at 37°C, and isolate akuBKU80-TR3 was also incubated at 25°C and 48°C. After 10 
passages sequencing of the cyp51A promoter and full coding gene was performed to detect mutations.
Statistical analysis
In order to express diff erences in MIC50 between wild-type and TR34/L98H for the diff erent compounds 
we fi rst log transformed the MIC50 data and then computed point biserial correlations as correlation 
eff ect sizes (r).24 Values of r=0 indicate similarity between MIC50’s and values of r=1 indicate the largest 
relative dissimilarity. These correlation eff ect sizes cannot be computed in cases where all samples have 
identical MIC50 values, such as with compounds that show no in vitro activity against both wild-type and 
TR34/L98H isolates. In those cases the correlation eff ect size was considered r=0.
Results
Activity of fungicides against A. fumigatus
In the Netherlands 33 compounds have been authorized by the Dutch Board for the Authorization of 
Plant Protection Products and Biocides for use as fungicides, herbicides, herbicide safeners and plant 
growth regulators, between 1970 and 2005, of these 19 were DMIs (Table 1; Figure 1; Figure 2A). We 
were able to obtain 31 of these compounds as dry powder and investigated the in vitro activity against 
38 TR34/L98H A. fumigatus isolates from clinical and environmental origin and 42 wild-type controls. In 
addition, two azole-resistant isolates from environmental origin that harbor a transcriptional enhancer 
as a resistance mechanism and four isolates with point mutations in the cyp51A-gene that arose 
through patient therapy were also tested (Table 2). Diff erences in MIC50 between the wild-type and 
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Figure 1.Chemical structures of antifungal compounds. 
Three medical antifungal compounds and 31 compounds that were authorized by the Dutch Board for 
the Authorization of Plant Protection Products and Biocides for use as fungicides, herbicides, herbicide 
safeners and plant growth regulators. The compounds are presented according to structural group.
TR34/L98H against all diff erent compounds were computed as correlation eff ect sizes (r). The correlation 
coeffi  cient is used as a measure of the size of an eff ect with a value of -1 indicating a negative correlation 
between the two variables, a value of 0 indicating no correlation and a value of 1 indicating a positive 
correlation. For the medical triazoles the eff ect sizes were 0.99 for itraconazole, 0.82 for voriconazole 
and 0.85 for posaconazole representing a positive correlation of dissimilarity between the MIC50’s of 
the wild-type and TR34/L98H isolates. Dissimilarity between the MIC50’s was found for 20 compounds, 
with the greatest diff erences (r>0.90) found for propiconazole, difenoconazole, epoxiconazole (r=0.96), 
bromuconazole (r=0.95), metconazole (r=0.94), imazalil (r=0.94), and tebuconazole (r=0.93) (Figure 
2B). These compounds were DMIs from the triazole class, with the exception of imazalil. Isolates with a 
46 bp or 53 bp tandem repeat insertion showed similar correlation eff ect sizes as TR34/L98H isolates (data 
not shown), while isolates that had become resistant through patient azole therapy generally showed 
lower r-values (Table 1).25
Molecule alignments and docking
We used a homology model of the A. fumigatus CYP-protein to predict the preferred orientation of 
DMI-compounds to form a stable complex with the 14 alpha-lanosterol demethylase enzyme. A crystal 
79
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*Correlation eff ect sizes could not be computed if in at least one of the two groups all variables were constant. This was the case with compounds 
that showed no in vitro activity against both wild-type and TR34/L98H A. fumigatus isolates, and the correlation eff ect size was considered 0.
Figure 2. Overview of introduction of the 31 compounds by year and correlation eff ect sizes.
A) Overview of compounds by year of authorization by the Dutch Board for the Authorization of Plant 
Protection Products and Biocides (data from the Dutch Foundation for Phytofarmacy, Nefyto). The fi ve 
triazole DMIs that exhibited the most identical docking by molecule alignment are underlined in blue. 
B) Correlation eff ect sizes (r) of compounds and medical triazoles comparing diff erences in the median MIC of wild-type and TR34/L98H 
isolates. The fungicides are represented by grey dots and those belonging to the DMIs by black dots. The medical triazoles are indicated 
by red dots, and the fi ve triazole DMIs that exhibited the most identical docking by molecule alignment are indicated by blue dots.
A
B
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Table 2. Activity of medical triazoles and fi ve DMIs against clinical and environmental A. fumigatus isolates with diff erent 
cyp51A-mediated resistance mechanisms. 
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structure of the A. fumigatus CYP51A protein is not available, therefore to see structural similarities in 
CYP51s for azole inhibition we superimposed the fl uconazole-bound Mycobacterium tuberculosis 
(Mt) structure (PDB code 1EA1), the ketoconazole-bound human structure (PDB code 313K) and 
ketoconazole-bound A. fumigatus homology structure. Both fl uconazole and ketoconazole bind to the 
heme iron via the nitrogen of an azole ring. The dihalogenated phenyl group, a common structural 
moiety of ketoconazole and fl uconazole, occupied the same spaces at the active site of the heme 
molecule but interacts with the binding pockets lined by diff erent residues when the human CYP51, 
the Mt CYP51 and the A. fumigatus CYP51 homology model are aligned. In human and A. fumigatus 
CYP51, residues Y145 and Y121, respectively formed van der Waals contacts with the dichlorophenyl 
group of ketoconazole, whereas their side-chain hydroxyl group made hydrogen bonds to the D-ring 
propionate (C2H5COO
-) of the heme. Residue Y131 (PDB code 313K) that is located in the B’ helix of the 
homology structure (Y107) is invariant in the CYP51 family and involved in hydrogen-bond formation 
with heme A-ring propionate in all three structures. In the Mt structure, Y145-corresponding F89 is away 
from the active site due to the conformational fl exibility of the B–C–helix region. Instead, R95 and R96 
of Mt CYP51 are near the heme and fl uconazole difl uorophenyl group (Figure 3). Thus, ketoconazole 
could bind to Mt enzyme, utilizing the same space as fl uconazole for the dihalogenated phenyl ring, 
while the remainder of ketoconazole would occupy the access channel observed in the human enzyme 
although the channel would have to be open by relocation of some of the side chains like F78 and 
M433 (grey structure Figure 3). In the Mt structure, the hydroxyl group of fl uconazole made a water-
mediated hydrogen bond to the heme A-ring propionate. This water molecule is not observed in the 
human structure because the cycle ether group of ketoconazole fi lled in the space of water. In addition, 
in Mt and A. fumigatus CYP51s an invariant H259/H296 residue from helix I is pointed into the active 
site, whereas the confi rmation of the corresponding H314 in human CYP51 prevents its interaction 
with the inhibitors. The itraconazole, posaconazole and voriconazole molecules were docked into the 
A. fumigatus homology structure. They showed the same binding pattern as described for the crystal 
structures and were able to align to the presented poses of fl uconazole (representative of voriconazole) 
and ketoconazole (representative of itraconazole and posaconazole). The compounds from the groups 
of imidazoles, pyrimidines and triazoles adopted similar poses upon docking in the active site of the 
A. fumigatus as those observed for the medical triazoles. The largest dissimilarities were in the cases 
of compounds that lack a phenyl group next to the 5- or 6-member aromatic ring that coordinates to 
the iron center. We performed a fl exible alignment of the compounds on the structure of voriconazole 
in order to fi nd the most similar compounds. The pharmacophores used as a fi lter for the alignment 
that consist of 5/6-member aromatic ring containing at least one nitrogen atom, a hydrogen-bond 
donor or acceptor and the aromatic functional group (Figure 4). The structures classifi ed to groups of 
benzimidazoles, cyaninoimidazoles together with prochloraz, imazamethabenz from imidazolinone, 
and pyrimethanil from pyrimidines and fenamidone and amitrole from triazoles were fi ltered out from 
the set of the ligands as not similar to the voriconazole molecule. The remaining 20 of 31 structures were 
considered to be similar to the medical triazoles. We focused our analysis of the docking poses on the 
compounds that satisfi ed the given pharmacophores for alignment. 
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Figure 3. 3D representation of three aligned structures of CYP51 with the ligands in their active site, constructed by using the Yasara software. 
In green human CYP51 bound with ketoconazole from PDB: 3I3K; in grey Mt bound with fl uconazole from PDB: 1EA1; in cyan A. fumigatus
bound with ketoconazole from the homology model. The ligands are represented in balls and sticks, only the residues important for binding a 
particular ligand are depicted in the picture and represented in sticks. Numbering of the residues corresponds with their colors to the models.
Figure 4. Two-dimensional structure of voriconazole with indicated pharmacophores that were used to align and fi lter the 31 compounds 
(Table 1). The fi gure was constructed by using Marvin Sketcher form ChemAxon (www.chemaxon.com). 
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Docking poses of fungicides similar to medical triazoles
The triazole DMIs that have three nitrogen atoms in the aromatic ring coordinated to the iron atom 
of heme made a hydrogen bond contact to residue S297, present in the active site of the A. fumigatus 
CYP51 homology model. Residue H296, also present in the active site, interacted with most of the 
fungicides with the exception of imazalil, trifl umizole, fenarimol, nuarimol, penconazole, metconazole 
that instead interacted with a bridging water molecule. Propiconazole, myclobutanil, difenoconazole 
lack any interaction with residue H296 or a bridging water molecule. Most of the DMIs share the core 
structure with medical triazoles and due to this similarity they adopt much the same poses in the active 
site of A. fumigatus as the medical triazoles. Propiconazole and bromuconazole exhibit the most alike 
poses with the core structure being the most similar to itraconazole and posaconazole (Figure 5A). 
Tebuconazole and epoxiconazole also adopted the most alike poses being most similar to voriconazole, 
except they interacted with residue H296 in the active site (Figure 5B). The analysis of the top three 
poses proposed by the docking program showed that these compounds were able to adopt also poses 
where they interacted with a bridging water molecule instead of H296. This makes the binding modes of 
propiconazole, bromuconazole, tebuconazole and epoxiconazole most identical to those represented 
by the medical triazoles. Difenoconazole (Table 1) was diff erent in structure from the rest of the cross-
resistant DMIs. Instead of one aromatic ring (Figure 5A and 5B) it has a biphenyl moiety, upon docking 
this part was placed into the access channel where the long tail of medical azoles is normally located. 
The above mentioned fi ve triazole DMIs were also among the compounds with the highest r-value and 
showed complete loss of in vitro activity against A. fumigatus isolates harboring TR34/L98H (Figure 2B, 
Table 1). Moreover, these fi ve DMIs were authorized for use in the Netherlands between 1990 and 1996 
(Figure 2A), which preceded the fi rst known isolation of a clinical TR34/L98H isolate in 1998.
6 
Figure 5. Analysis of most modes binding modes compared to the medical triazoles. 
A) Binding modes of propiconazole. This fungicide exhibits the most similar binding modes compared to the medical triazoles located 
in the active site of human and A. fumigatus CYP51. 
B) Binding modes of tebuconazole. This fungicide exhibits the most similar binding modes compared to the medical triazoles located in 
the active site of Mt CYP51. The main diff erence between A and B is the interactions with residue H296 in the active site, which is lacking in A. 
A B
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Imazalil and metconazole also showed a high correlation eff ect size (Figure 2A), but, unlike the fi ve 
abovementioned triazole DMIs, retained in vitro activity against TR34/L98H isolates (median MIC of 2 
mg/l) (Table 1). Docking studies and molecule alignments showed that imazalil and metconazole were 
less similar to the medical triazoles and therefore less likely to have caused the emergence of TR34/L98H 
in A. fumigatus.
Microsatellite genotyping
A. fumigatus isolates from two Dutch surveillance studies were used to investigate the evolution of 
TR34/L98H genotypes over time.
6,8 The collections were obtained prospectively over a 16 year period and 
included 3,847 isolates from 2,512 patients. All isolates were screened for azole resistance by subculture 
on agar supplemented with itraconazole. The collections included 144 consecutive TR34/L98H isolates 
which were genetically characterized by short tandem repeat genotyping.23 By plotting the number 
of observed new genotypes versus time on a semi-logarithmic scale, we calculated a rate of change 
of 1.37±0.05 genotype-1.year-1. Using the rate of change to calculate the year of fi rst emergence of 
TR34/L98H, indicated that TR34/L98H had developed in the year 1997 (95% CI: 1993.7-1999.7) (Figure 6).
Figure 6.The evolution of new microsatellite genotypes over time based on short tandem repeat typing of 144 TR34/L98H A. fumigatus 
isolates, cultured between 1998 and 2009 in the Netherlands. By plotting the number of observed new genotypes versus time on a semi-
logarithmic scale, a rate of change of 1.37±0.05 genotype-1.year-1 was calculated. As the fi rst TR34/L98H isolate was cultured in 1998, the 
rate of change indicates that the fi rst strain would have emerged around 1997 (95% CI: 1993.7-1999.7). This analysis also indicates that 
TR34/L98H had developed from a single ancestor. 
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Induction of TR34/L98H
We investigated if the TR34/L98H substitutions could be induced during exposure to DMIs under laboratory 
conditions. A wild-type A. fumigatus isolate and recombinants containing either the 34 bp insertion or 
the L98H substitution were exposed to itraconazole, bromuconazole, difenoconazole, epoxiconazole, 
propiconazole, tebuconazole or a mixture of these DMIs. The induction experiments generally resulted 
in a resistant phenotype within three passages. In three out of twelve clones of A. fumigatus cultured 
under itraconazole pressure, cyp51A-substitutions G138C or P216L were detected. These substitutions 
have been reported in patients who developed azole-resistant aspergillus disease during itraconazole 
therapy.5 TR34/L98H was not found in any of the clones that were exposed to itraconazole, single DMI 
compounds or to a mixture of DMIs. However, following exposure of the A. fumigatus conidia containing 
the 34 bp insertion in the cyp51A-gene promoter to 8 mg/l of tebuconazole resulted in one clone in 
which after three passages a triplicate of the 34 bp sequence was detected in the promoter region.
Discussion
Although the hypothesis of a fungicide-driven route of azole resistance development in A. fumigatus is 
controversial,26 we provide evidence that such a route may exist. Five triazole DMIs were identifi ed that 
exhibited very similar molecule characteristics to the medical triazoles, resulting in the most identical 
binding modes and the greatest level of cross-resistance. These fi ve DMIs were authorized for use 
between 1990 and 1996, which was in keeping with our calculated date of origin of TR34/L98H based 
on microsatellite typing, and precedes the fi rst clinical TR34/L98H isolate in 1998. Continued triazole DMI 
pressure and lack of an apparent fi tness cost in TR34/L98H isolates are probably important factors that 
have facilitated the ability of TR34/L98H to sustain in the fi eld in competition with wild-type isolates. 
Although the relation between the use of antimicrobial agents outside human medicine and the 
development of resistance to clinically used compounds has been shown for bacteria, we show for 
the fi rst time evidence that the same principle may occur in molds. Culture-based surveillance studies 
increasingly report TR34/L98H in clinical and environmental isolates in Europe and, most recently, 
in China.14 Moreover, there is very recent evidence that two new ‘environmental’ azole resistance 
mechanisms have emerged in A. fumigatus in the Netherlands, of which one has rapidly migrated 
across the country similar to TR34/L98H.
27 However, surveillance studies based on positive cultures 
may underestimate the prevalence of resistance. Detection of azole resistance mechanisms directly 
in clinical specimens from patients with chronic lung diseases showed that in culture-negative, PCR-
positive samples cyp51A-mutations were detectable in as many as 55.1% of respiratory samples.28 These 
observations indicate that we are just beginning to understand the scale of the problem, but it suggests 
that azole resistance in A. fumigatus has become a public health problem and threatens an increasing 
population of (immunocompromised) patients.
Our study was limited by the fact that we were unable to induce the full TR34/L98H resistance mechanism 
during DMI-pressure under laboratory conditions, using an isolate that is defi cient in DNA break repair. 
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Previously, microsatellite genotyping showed shorter genetic distances for TR34/L98H isolates compared 
with wild-type isolates,10 which suggests that TR34/L98H isolates may have originated from a common 
ancestor. If this would be the case, the development of TR34/L98H would be extremely infrequent in the 
environment and would explain why we were unable to induce TR34/L98H under laboratory conditions. 
However, this may point to other reasons for the emergence of TR34/L98H. TR34/L98H isolates may have 
other properties, such as increased fi tness or virulence, or high sporulation effi  cacy, that have made 
isolates harboring TR34/L98H more successful in the fi eld than wild-type A. fumigatus. However, at 
present there is no evidence that supports increased virulence in TR34/L98H isolates. Animal studies 
indicate that the virulence of TR34/L98H is similar to that of wild-type isolates, although only one 
TR34/L98H isolate was used.
3 An alternative explanation for our inability to induce TR34/L98H could be that 
this resistance mechanism developed through sexual or parasexual reproduction rather than asexual 
reproduction, which was not tested in the laboratory. However, we did observe one isolate in which 
two copies of the tandem repeat evolved into three, supporting the role of DMIs in inducing genomic 
changes in cyp51A of A. fumigatus. Another limiting factor of our studies was the lack of sequence-based 
evolutionary analysis. In A. fumigatus no genes have been described that are suitable for this type of 
analysis and therefore we used microsatellite data.
The relation between the use of the triazole DMIs and cross-resistance to medical triazoles in A. fumigatus 
has major implications for the assessment of health risks associated with the use of DMIs. Molecule 
structure similarity and activity of triazole DMIs against A. fumigatus appear to be the key features 
that cause cross-resistance to medical triazoles. Further research should be aimed at understanding 
the conditions under which resistance mechanisms develop in the environment and which Aspergillus 
morphotype is most prone to develop resistance mechanisms. Reversal of resistance development 
may be achievable by restriction of certain triazole DMIs, but laboratory population studies and genetic 
mapping would be required to predict the impact of changes in DMI-pressure. In addition, there is 
limited insight in the use of fungicides for agricultural and non-agricultural applications. 
The continued use of DMIs with activity against opportunistic human fungal pathogens is a risk for the 
management of fungal diseases caused by these pathogens. The number of classes of drugs available 
for treating non-invasive and invasive fungal diseases is limited and the triazoles are the only class of 
antifungal agents that can be administered orally. A fungicide-driven route of resistance development 
in TR34/L98H could indicate that such mechanisms may also occur in other Aspergillus species or other 
opportunistic fungi. It is therefore of great importance to perform abovementioned research as it may 
allow the implementation of evidence-based strategies aimed at elimination of the fungicide-driven 
route of azole resistance development in opportunistic fungi. 
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Abstract
Molecular studies have shown that the majority of azole resistance in Aspergillus fumigatus is associated 
with amino acid substitutions in the cyp51A gene. To obtain insight into azole-resistant mutations, the 
cyp51A gene of 130 resistant and 76 susceptible A. fumigatus isolates was sequenced. Out of 130 azole-
resistant isolates, 105 contained a tandem repeat of 34 bp in the promoter region and a leucine to 
histidine substitution in codon 98 (designated TR/L98H). Additionally in 12 of these TR/L98H resistant 
isolates, the mutations S297T and F495I were found, and in one isolate the mutation F495I was found. 
In eight azole-resistant isolates, known azole-resistant mutations were detected in codons G54, G138 
or M220. In three azole-susceptible isolates the mutation E130D, L252L or S400I was found and in 13 
azole-susceptible isolates but also in one azole-resistant isolate, the mutations F46Y, G98G, M172V, 
N248T, D255E, L358L, E427K and C454C were found. All the nonsynonymous mutations, apart from 
the mutations in codon G54, G138 and M220 and L98H, were located at the periphery of the protein, 
as determined by a structural model of the A. fumigatus CYP51A protein and were predicted neither 
to interact with azole compounds nor to aff ect structural integrity. Therefore, this wide diversity of 
mutations in the cyp51A gene in azole-susceptible A. fumigatus isolates is not correlated with azole 
resistance. Based on the CYP51A protein homology model, the potential correlation of a mutation to 
azole resistance can be predicted.
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Introduction
Aspergillus fumigatus is the etiological agent of a range of clinical syndromes, most notably invasive 
aspergillosis (IA), which is associated with signifi cant morbidity and mortality. Advances in the management 
of IA have been made in recent years by imaging techniques, by the use of non-culture-based diagnostic 
tools, by improvement in management of patients with IA, and by the use of more eff ective antifungal agents, 
especially the azole compounds.1 Azole resistance in clinical A. fumigatus isolates has long been considered 
to be an uncommon phenomenon, but recently multi-azole-resistance (MAR) has been reported to be 
emerging and is increasingly recognized as cause of treatment failure.2-4 Resistance signifi cantly complicates 
patient management, given the limited number of alternative agents with evidence-based effi  cacy in 
aspergillus diseases and the fact that the azoles are the only class that can be administered orally. Azoles bind, 
with one of their nitrogen atoms of the azole ring, to the iron atom of the heme group located in the center 
of the CYP51 protein and thereby probably blocking the access of lanosterol to the active site where its C14 is 
demethylated.5 This leads to the substitution of methylated sterols and ergosterol depletion in the fungal cell 
membrane, as well as to the accumulation of toxic sterol intermediates that eventually causes inhibition of 
fungal cell growth.6 Molecular studies have shown that in the majority of cases azole resistance in A. fumigatus 
is associated with mutations in the azole drug target enzyme encoded by the cyp51A gene. This has been 
described for azole-resistant A. fumigatus clinical isolates, as well as for laboratory-induced azole-resistant 
A. fumigatus mutants.7 Mutations at codon G54 are related to cross-resistance to the azoles itraconazole 
and posaconazole.8 Also diff erent mutations in codon M220 have been described in clinical strains that are 
correlated to itraconazole resistance combined with diff erent patterns of elevated MICs of the other azole 
drugs.9 Azole-resistant A. fumigatus isolates have been found that showed a glycine to cysteine substitution in 
codon 138 and exhibited a pan-azole resistant phenotype.10 In codon 488, a mutation from glycine to serine 
was correlated with resistance to voriconazole and itraconazole.11 A recent survey of MAR clinical isolates in 
the Netherlands showed over 90% dominance of a resistance mechanism consisting of a tandem repeat of 
34 bp in the promoter region combined with a leucine to histidine substitution at codon 98 (TR/L98H).3,4,12-14 
The cyp51A sequence of Mycobacterium tuberculosis shows 28% sequence identity over 464 residues with 
the cyp51A sequence of A. fumigatus. Therefore, it was possible to derive the structure of wild-type CYP51A 
protein of A. fumigatus from the crystal structure of M. tuberculosis by homology modeling.15,16 The carefully 
optimized and checked structure of the protein was used to characterize the mutations in the CYP51A 
homology model. Two ligand access channels were previously identifi ed in the model which probably not 
only accommodate the natural substrates but are also used by the azole compounds for docking.15,16 The aims 
of our study were to obtain insight into the distribution of mutations in the cyp51A gene and to correlate the 
presence of cyp51A mutations with the phenotype regarding their susceptibility to azole compounds by 
using the CYP51A protein homology model.
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Materials and Methods
The department of Medical Microbiology of the Radboud University Nijmegen Medical Centre has a 
policy of routinely storing all Aspergillus isolates cultured from clinical specimens irrespective of its clinical 
signifi cance. In addition, Aspergillus species cultured from the indoor or outdoor hospital environment or 
as part of research collaborations are stored.
For several research studies performed in our centre, 2,925 A. fumigatus isolates were screened for 
resistance to itraconazole by subculturing of the isolates on Sabouraud agar slants that contained 4 or 8 
mg/l itraconazole. For isolates that grew on itraconazole-containing agar (ITZ+), the in vitro activities of 
amphotericin B, itraconazole, voriconazole, posaconazole, and caspofungin were determined by using 
the Clinical and Laboratory Standards Institute M38-A reference method.17 For classifi cation of the MICs, 
the recently proposed interpretative breakpoints were used.21 Isolates resistant to more than one azole 
compound but not all of them were designated MAR, while isolates with MICs in the resistant range for 
all clinically licensed mould-active azoles were designated pan-azole resistant.18
Of a total of 2,925 A. fumigatus isolates, 130 isolates were able to grow on itraconazole containing agar. 
If resistance to itraconazole was confi rmed, the cyp51A gene was fully sequenced. From isolates that 
failed to grow on itraconazole-containing agar (ITZ-), controls were selected. In total 76 ITZ- isolates 
were randomly selected and matched on the basis of (i) underlying disease of the patient, (ii) temporal 
relation to an ITZ+ isolate or (iii) to sample type (Figure 1). 
All isolates were identifi ed to the A. fumigatus species level by macroscopic and microscopic morphology, 
the ability to grow at 48°C, and sequencing of the Beta-tubulin gene. PCR amplifi cation and subsequent 
sequencing of the Beta-tubulin gene were performed by using forward primer 5’-aattggtgccgctttctg-3’ 
and reverse primer 5’-agttgtcgggacggaatag-3’. Cycling and sequencing conditions were the same 
as those described for the amplifi cation of the cyp51A gene. Sequences were compared with those 
of Aspergillus fumigatus, Aspergillus lentulus, Aspergillus viridinutans, Aspergillus brevipes, Aspergillus 
novofumigatus, Aspergillus fumigatiaffi  nis, and Neosartorya species, all obtained from the CBS Fungal 
Biodiversity Centre, Utrecht, The Netherlands, by using the neighbourjoining (NJ) method for 
phylogenetic analysis.3 For selected isolates, the full sequence of the cyp51A gene was determined. 
For this, conidia from each strain were inoculated into 15 ml of GYEP medium (2% glucose, 0.3% yeast 
extract, 1% peptone) and grown for 48 h at 37°C. Mycelial mats were recovered, dried, and subjected 
to a DNA isolation protocol as described previously.3 PCR amplifi cation and subsequent sequencing of 
the cyp51A gene was performed by using forward primer 5’-atggtgccgatgctatgg-3’ and reverse primer 
5’-ctgtctcacttggatgtg-3’. Cycling conditions were as follows: 95°C for 5 min, 40 cycles of 94°C for 30 s, 
58°C for 45 s and 72°C for 2 min, followed by a fi nal extension at 72°C for 7 min. All DNA sequences 
were determined using a BigDye Terminator version 3.1 cycle sequencing kit (ABI) and an ABI 3100 DNA 
sequencer. Sequences were aligned to a reference cyp51A sequence (GenBank accession no. AF338659) 
to identify mutations. 
A homology model of the A. fumigatus cyp51A gene was built using the crystal structure of M. tuberculosis 
CYP51A as a template (PDB-code 1e9x). The two proteins show 28% sequence identity over 464 residues. 
The WHAT IF web server (http://www.swift.cmbi.ru.nl) was used for model building, and Yasara was used 
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for energy minimization and analysis. The structure was initially optimized in vacuum with all backbone 
atoms fi xed. The locations of the mutations were pinpointed, and they were introduced into the CYP51A 
homology model by using the VMD software.19 Furthermore, the mutations were investigated for their 
potential interactions with azole compounds by considering the ligand binding residues, the reported 
substrate access channel residues, and known mutation hot spots.10,16     
Figure 1. Procedure for selection of ITZ-resistant and -susceptible A.fumigatus isolates for sequencing of the cyp51A gene.
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Results and Discussion
A total of 206 A. fumigatus isolates, 130 ITZ+ and 76 ITZ-, were analyzed for mutations in the cyp51A gene. 
A wide variety of mutations was found in the cyp51A gene of ITZ+ and ITZ- isolates, both known and not 
known from the literature to be correlated with azole resistance (Table 1). In 113 ITZ+ isolates, cyp51A 
mutations known to be correlated with azole resistance were found. In 105 ITZ+ isolates, a tandem 
repeat of 34 bp in the promoter region and a leucine to histidine substitution at codon 98 (TR/L98H) 
were found, and in eight ITZ+ isolates other known mutations were found.12  
In 19 isolates that contained the TR/L98H mutations, additional mutations in the cyp51A gene (S297T, 
F495I, S52T, Q88H, N125I, Q141H, A284A, and L339L) were found. In one ITZ+ isolate, the mutations F46Y, 
G98G, M172V, N248T, D255E, L358L, E427K, and C454C were found, and in 16 ITZ+ isolates, no mutations 
were found in the cyp51A gene. In 13 ITZ- isolates, combinations of the mutations F46Y, G98G, M172V, 
N248T, D255E, L358L, E427K, and C454C were found, and in three ITZ- the mutations, E130D, L252L, and 
S400I were found. In 60 ITZ- isolates, no mutations were found in the cyp51A gene.
ITZ+ isolates
Cyp51A mutations known to be correlated with azole resistance
In eight ITZ+ isolates, mutations changing amino acid G54, G138, or M220 in the cyp51A-encoded 
protein were detected (Table 1). These mutations were all known to be correlated to azole resistance.8-10 
The amino acids in codon G54, G138 and M220 were all located in close proximity to the opening of one 
of the two ligand access channels of the protein (Figure 2). The ligand access channels are thought to be 
used by the azole compounds to enter the active site of the protein, and alterations of these openings 
of these channels due to amino acid changes probably disturb the docking of azole molecules. The 
G138C mutation was located in a helix of channel 1 close to the heme cofactor, and isolates harboring 
this mutation show a pan-azole resistance phenotype (Figure 2). This was also described previously 
for G138R, in which the arginine was predicted to clash with one of the heme’s side chains and with 
the side chains of the neighboring residues.16 Amino acid G54 and M220 are located in loops in close 
proximity to the opening of channel 2. The M220R, -I, and -V mutations produced an itraconazole 
resistance phenotype combined with an increased MIC of voriconazole, while M220K produced an 
itraconazole and posaconazole resistance phenotype. The mutation G54W produced an itraconazole 
and posaconazole resistance yet voriconazole susceptibility phenotype. As glycine is replaced with the 
larger and hydrophobic tryptophan residue, it might suffi  ciently close the entrance of access channel 2 
to disturb the docking of large molecules such as those of itraconazole and posaconazole. The long tails 
of itraconazole and posaconazole need to make interactions along the opening and within the channel 
for stable docking toward the heme center. The voriconazole molecule, however, is much smaller than 
those of itraconazole and posaconazole since it lacks a long tail. It does not need to make interactions 
at the entrance surface of the channel. Therefore, changes in residues in codon 54, which is located at 
the entrance of the channel, do not aff ect voriconazole but do have a dramatic eff ect on the docking of 
itraconazole and posaconazole.
Azole resistance profi le of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling
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Table 1.Mutations found in the cyp51A gene of A. fumigatus and azole susceptibility phenotypes.  
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Furthermore, the G54E mutation produced only an itraconazole resistance phenotype. The main 
diff erence in structure between posaconazole and itraconazole is the presence of the hydroxyl group 
at the end of the long tail of posaconazole that may create a hydrogen bond interaction on the surface 
of the protein. Moreover, it is not clear whether an additional oxygen atom in the core scaff old of 
itraconazole plays any role in preventing the drug from accessing the active site in the presence of 
the G54E mutation. Therefore, not only the specifi c location of an amino acid change is important but 
the amino acid replacement is of at least the same importance for the azole susceptibility phenotype. 
Although there are two ligand access channels present, the change of an amino acid in the opening 
in one channel is already suffi  cient for certain azole resistance phenotypes. It seems that the structural 
changes in one channel aff ect the docking of certain azole compounds for the whole protein.
Out of 130 azole-resistant isolates, 105 contained the TR/L98H mutations. It was shown that leucine 98 is 
not located close to either the active heme center or any of the two ligand access channels but is located 
on a loop that partly forms an arch-like structure that is highly conserved among the members of the 
CYP51 family of proteins (Figure 2). In a preliminary study, we have used molecular dynamic simulations 
changing the leucine to histidine in codon 98. In these studies, we observed that the fl exibility of this 
arch-like structure increased considerably, thereby narrowing the diameter of the entry of the ligand 
access channels (data not shown). These changes may result in the MAR phenotype by aff ecting the 
ligand access channels important for the docking of azole compounds.
Azole resistance profi le of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling
Figure 2. Mapping of mutations found in the A. fumigatus cyp51A gene in the CYP51A homology model. 
The two ligand access channels are indicated by arrows. The heme cofactor is black. Mutations correlated with azole resistance are purple, 
and mutations correlated with an azole-susceptible profi le are green. Mutations additionally found in azole-resistant strains are brown.
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ITZ+ isolates with other cyp51A mutations
In each of six isolates with the TR/L98H mutations, an additional mutation was found, four 
nonsynonymous mutations, namely, S52T, Q88H, N125I, and Q141H, and two synonymous mutations, 
L339L and A284A (Table 1). Introduction of these mutations into the CYP51A homology model showed 
that these mutations were not located in conserved regions of the protein but were all distributed on 
the periphery of the protein, except for two, S52T and N125I (Figure 2). S52 was located at the entrance 
of channel 2; however, the serine is replaced with an only slightly larger threonine that is similar to 
serine, an alcoholic residue with intermediate hydrophobicity. The N125I mutation represents a change 
from electrophilic asparagine to a large nonpolar isoleucine and may have a larger impact on resistance. 
However, as the isolates all contain the TR/L98H mutations and exhibit the MAR phenotype, these 
additional nonsynonymous mutations probably play only a minor or no role at all in the azole resistance 
phenotype and no diff erences in MIC values were observed between these isolates and those containing 
only the TR/L98H mutations. It is important to correlate changes in the structural integrity of the protein 
with susceptibility to azole compounds because structural changes could aff ect the docking of the azole 
molecules, with azole resistance as a possible consequence. The amino acid residues on the periphery 
of the protein generally have a lower conservation level and are not essential for the functionality of 
the protein; therefore, amino acid changes in these residues will not infl uence structural integrity. The 
structural integrity of the CYP51A protein is not changed by the two synonymous mutations L339L and 
A284A, since the amino acids are not changed. However, the possibility of changes at the RNA structural 
level due to silent mutations cannot be excluded, as synonymous mutations in RNA regulatory elements 
might alter transcription, splicing, and other regulatory processes, although there is no evidence that 
they may actually play a role in A. fumigatus.20,21 
In 12 isolates with the TR/L98H mutations, the nonsynonymous mutations S297T and F495I were found, 
and in 1 isolate with the TR/L98H mutations, only the F495I mutation was found (Table 1). Interestingly, 
although both mutations are located close to the active site of the protein, they do not seem to aff ect 
resistance, as the TR/L98H mutations already produce the MAR phenotype and no diff erences in MIC 
values were observed between these isolates and those containing only the TR/L98H mutations. Apart 
from that, although threonine is slightly larger than serine and both residues contain a hydroxyl group, 
in the case of the second observed mutation, F495I, the hydrophobic phenylalanine is replaced with a 
hydrophobic though not aromatic isoleucine. The slight diff erences are not expected to infl uence the 
binding of the external ligands, and therefore these additional mutations do not seem to aff ect protein 
function either (brown, Figure 2).
ITZ+ isolates without cyp51A mutations
In 16 azole-resistant isolates, no mutations were found in the cyp51A gene. Azole-resistant A. fumigatus 
isolates without mutations In the cyp51A gene have been reported previously in literature, which 
suggests that alternative mechanisms of azole resistance exist.2 The upregulation of effl  ux pumps has 
been described as a mechanism for azole resistance in Candida albicans previously; however, for clinical 
A. fumigatus strains, this possibility has only been described once.22,23 A selection of two of these ITZ+ 
isolates did not show any signifi cant increase in the mRNA expression levels of ABC transporter AtrF or 
multidrug resistance proteins MDR3 or MDR4 compared to ITZ- isolates (unpublished observations). 
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Therefore, in these isolates, an as-yet-unknown mechanism of azole resistance must be present. Possibly, 
the cyp51A gene could be upregulated, although no changes in the promoter region of the cyp51A 
gene were present. Further investigation is warranted to characterize the alternative mechanisms of 
resistance in these isolates.
ITZ- isolates
In 60 of 76 azole-susceptible isolates, no mutations were found in the cyp51A gene. However, in 
3 susceptible isolates, either the nonsynonymous mutation E130D, S400I or the synonymous mutation 
L252L was found. E130D and S400I are both located on the periphery of the protein and, indeed, do 
not seem to interact with azole compounds. Also, in diff erent combinations, fi ve nonsynonymous 
mutations, F46Y, M172V, N248T, D255E, and E427K, and three synonymous mutations, G98G, L358L, 
and C454C, were found in 13 azole-susceptible isolates. These mutations were also found in one azole-
resistant isolate without any other known mutation in the cyp51A gene related to azole resistance. 
These exact same mutations have been described previously in literature to be found both in azole-
resistant and -susceptible isolates.2,24 Therefore, amino acid changes found in the protein encoded by 
the cyp51A gene are not exclusively correlated with the development of azole resistance. Introducing 
the nonsynonymous amino acid alterations in the CYP51A homology model shows that these amino 
acid changes are all distributed at the periphery of the protein, not close to any of the two ligand access 
channels (Figure 2), and are not located in any of the conserved regions of the CYP51A protein. Therefore, 
no eff ect on the biological activity of the CYP51A protein or the docking of the azole compounds in the 
ligand access channels is expected. 
Due to the importance of CYP51 in antifungal drug studies, many CYP51 homology models have been 
made, e.g., C. albicans, Cryptococcus neoformans, Penicillium digitatum and Saccharomyces cerevisiae, 
by using the crystal structure of M. tuberculosis CYP51 as a template.16,25-27 Although this approach has 
several limitations, functionally important regions are conserved among this fungal CYP51 family. A wide 
diversity of amino acid changes probably not correlated to resistance has been described by others.2,24 
In this study, we showed that the use of a CYP51A homology model can be very informative in predicting 
the eff ects of these amino acid changes. Specifi c residues in the CYP51A protein are of importance for 
azole docking, and identifying the location of a mutation in the CYP51A protein can help to predict 
whether a mutation can be considered a polymorphism or whether it has a potential correlation with 
azole resistance. Taking into account the diversity of cyp51A mutations, new mutations found in the 
cyp51A gene in azole-resistant isolates should be interpreted with care. By using a CYP51A protein 
homology model, a mutation can be investigated for a correlation with azole resistance. Subsequently, 
by placing the mutation into a wild-type strain by recombinant analysis, the impact of a mutation can 
be studied at the protein level to make a conclusive correlation to azole resistance.
Azole resistance profi le of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling
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Abstract
Since 1998, the rapid emergence of multi-azole-resistance (MAR) was observed in A. fumigatus in the 
Netherlands. Two dominant mutations were found in the cyp51A gene, a 34 bp tandem repeat (TR) 
in the promoter region combined with a leucine to histidine substitution at codon 98 (L98H). In this 
study, we show that molecular dynamics simulations combined with site-directed mutagenesis of 
amino acid substitutions in the cyp51A gene, correlate to the structure-function relationship of the L98H 
substitution conferring to MAR in A. fumigatus. Because of a L98H directed change in the fl exibility of the 
loops, that comprise a gate-like structure in the protein, the capacity of the two ligand entry channels 
is modifi ed by narrowing the diameter and thereby binding of azoles is obstructed. Moreover, the L98H 
induced relocation of tyrosine 121 and tyrosine 107 seems to be related to the MAR phenotype, without 
aff ecting the biological activity of the CYP51A protein. Site-directed mutagenesis showed that both the 
34 bp TR and the L98H mutation are required to obtain the MAR phenotype. Furthermore, the amino 
acid leucine in codon 98 in A. fumigatus is highly conserved and important for maintaining the structure 
of the CYP51A protein that is essential for azole docking.
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Introduction
Invasive aspergillosis (IA) is a disease with a signifi cant mortality rate, with the opportunistic mould 
Aspergillus fumigatus as the principle etiological agent.1 It is a feared complication of immunosuppressive 
therapy mostly in patients with haematological malignancies. Patient survival is directly associated with 
timely diagnosis and prompt appropriate antifungal therapy. In medicine three groups of antifungal 
drugs are most used: the triazoles, polyenes and echinocandins. The triazoles are the main antifungal 
drugs recommended for IA as primary therapy and prophylaxis.2 The use of triazoles in the management 
of aspergillus diseases may be threatened by the emergence of acquired resistance in A. fumigatus. 
Modifi cations of the target gene of the triazoles, the cyp51A gene, has been described to be correlated 
to specifi c triazole resistance phenotypes. The cyp51A gene encodes for a CYP450-dependent enzyme, 
the 14 alpha-lanosterol demethylase, which removes the 14 alpha-methyl group from lanosterol. Triazole 
antifungals inhibit this enzyme by binding with one of the nitrogen atoms of the triazole ring to the iron 
atom of the heme group located in the active site of the CYP51 protein and thereby blocking sterol 
synthesis at the level of the sterol C-14 alpha demethylase.3 Two diff erent ligand entry channels have 
been identifi ed although it is not clear if certain antifungals exclusively use only one of the channels.4,5 
Blocking the active site of the CYP51 protein leads to the substitution of methylated sterols, ergosterol 
depletion in the fungal membrane and accumulation of toxic sterol intermediates all together causing 
inhibition of fungal cell growth.3 Specifi c mutations in this target gene of the triazoles have been 
correlated to triazole resistance for a few amino acid substitutions. For these substitutions, at glycine 54, 
methionine 220 and glycine 138, diff erent but codon-specifi c triazole resistance patterns are observed 
and all substitutions are located very close to one of the two ligand access channels.6 
In the Netherlands, the rapid emergence of multi-azole-resistance (MAR) was observed in A. fumigatus 
since 1998.7,8 MAR A. fumigatus isolates were recovered from patients with aspergillus diseases, including 
IA. Two dominant mutations were found in 94% of MAR isolates, a 34 bp tandem repeat (TR) in the 
promoter region combined with a leucine to histidine substitution at codon 98 (L98H) both in the 
cyp51A gene.8 The MAR phenotype consists of resistance to itraconazole and elevated minimum 
inhibitory concentrations (MICs) of voriconazole and posaconazole. The MAR phenotype was associated 
with treatment failure and isolates were recovered from patients with and without previous triazole 
exposure.8 There is increasing evidence that TR/L98H arises through environmental exposure of 
A. fumigatus to demethylase inhibitors (DMIs) that are commonly used for crop protection.9 Reduced 
azole drug effi  cacy against TR/L98H isolates was confi rmed in experimental models of invasive 
aspergillosis.10,11 The prevalence of TR/L98H in other countries is largely unknown although clinical 
TR/L98H isolates were recovered in Spain, United Kingdom, Belgium, France and Denmark.8 TR/L98H 
was also found in 8% of soil cultures in Denmark.8,12 
Using molecular modeling a structural homology model of the CYP51A protein was developed and 
used to investigate specifi c amino acid substitutions in the cyp51A gene.6 Mutations previously shown 
to be correlated with azole resistance, e.g., in codons G54, M220 or G138, were located in close vicinity to 
one of the two ligand access channels and are therefore thought to interfere with necessary interactions 
needed by the azole molecules to dock towards the heme centre of the protein.6 When the L98H 
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substitution was investigated in this model, it appeared to be located in a fl exible loop not near to 
any of the ligand access channels.6 Recombinant experiments have shown however that the TR/L98H 
substitutions were indeed directly correlated to the MAR phenotype.13 In what way the L98H mutation 
contributes to the MAR phenotype has not been described yet. 
The aim of the current study was to investigate the structure-function relationship of the TR/L98H 
resistance mechanism, by using molecular dynamics simulations on the leucine to histidine substitution 
in codon 98. In addition, the CYP51A homology model was used to design specifi c amino acid 
substitutions and to study their eff ect on the structure-function relationship and on the MAR phenotype. 
Amino acid substitutions were introduced by using a site-directed mutagenesis system in which any 
desired amino acid substitution can be changed in the A. fumigatus cyp51A gene.
 
Materials and methods
Molecular dynamics simulations
The structure of wild-type CYP51A protein of A. fumigatus was derived from the crystal structure of 
human lanosterol 14 alpha-demethylase (PDB code: 3I3K) by homology modeling. Both proteins share 
38% sequence identity. The three-dimensional structure has been predicted by YASARA’s homology 
modeling experiment (http://www.yasara.org). The experiment consists of building four models based 
on diff erent alignment variants. The missing loops were modelled and optimization of the structure was 
performed by molecular dynamics (MD). The model with the best Z-score was used for the presented 
studies. The point mutation was introduced using Yasara Structure software. The structure was initially 
optimized in vacuum with all backbone atoms fi xed. For all simulations the Amber99 force fi eld was 
used.14 Model coordinates will be made freely available to the community for use (www.cmbi.ru.nl). The 
MD simulations were performed using the AMBER package 15 following the standard protocol, which 
consisted of an initial minimization, followed by gradual heating of the system and equilibration of the 
system in the constant temperature of 300 K. Bond lengths involving hydrogens were constrained to 
their equilibrium values using the SHAKE algorithm which allowed adopting time steps of 2 fs. Two 
independent runs of 25 ns were performed, referred to as MD-1 for wild-type protein and MD-2 for the 
protein with L98H mutation introduced. Conﬁgurations were saved every 25 ps, yielding an ensemble 
of n = 1000 snapshots per run, after the equilibration period of 1 ns. The analysis of the trajectories was 
performed using Ptraj software, that is part of the Amber package, and VMD. 
Cyp51A site-directed mutagenesis 
In order to perform site-directed mutagenesis to introduce amino acid substitutions in the cyp51A gene 
of an A. fumigatus strain, a pUC57 plasmid containing the cyp51A gene was synthesized (GenScript 
USA Inc.). As depicted in fi gure 1, in the cyp51A cassette, 1 kb of fl anking regions were added at the 
5’ non-translated region (5’ NTR) and 3’ non-translated region (3’ NTR) to ensure successful translation. 
The Escherichia coli hygromycin B resistance gene (hph) complemented with a TrpC Aspergillus 
nidulans promoter and terminator was included in the cassette as a dominant selectable marker to 
select for recombinants independent of azole phenotype.16 The unique restriction sites SpeI and MluI 
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were introduced on both ends of the full cyp51A cassette to linearize and release the plasmid for 
transformation. Sequences were obtained from A. fumigatus strain AF293 from the CADRE genomics 
databank (http://www.cadre-genomes.org.uk). 
To introduce the 34 bp tandem repeat in the constructed plasmid, a DNA fragment containing the 
tandem repeat was amplifi ed by PCR with primers 404.13 and 404.14 (Table 1). Both PCR product and 
plasmid were digested with the restriction enzymes BglII and BbrPI and agarose gel purifi ed. The digested 
PCR product and the digested plasmid were ligated with T4 DNA ligase (Roche) during an overnight 
incubation and subsequently transformed with XL 10-Gold® ultracompetent cells (Stratagene). After 
incubation, colonies were selected and plasmid DNA was sequenced to confi rm correct incorporation 
of the 34 bp TR in the cyp51A gene cassette in the pUC57 plasmid. 
Figure 1. The cyp51A cassette was placed in a pUC57 vector for the possibility of site directed mutagenesis by mutagenic primers. 
To linearize the cyp51A cassette, restriction sites SpeI and MluI were added on both ends of the cyp51A cassette.
Table 1. Primer sequences. 
aNTR = Non Translating Region.
bhph = hygromycin-B resistance marker.
Sequence (5’-3’)
-GGAATAGACGCCGTTTACCA-
-GCCATACTGCCGGTTAAGAA-
-GTAAAACGACGGCCAGT-
-TCTCTGCACGCAAAGAAGAAC-
-ATGGTGCCGATGCTATGG-
-CTGTCTCACTTGGATGTG-
-TAGTCCATTGACGACCCC-
-ATCTTCCGTTTGGTGCTGG-
-AGATAGGCTAGAAGGAGC-
-AGTCTCCAAGGACATGCCCT-
-CAGGAAACAGCTATGAC-
cyp51A region
TR insertion
TR insertion
5’ NTRa
5’ NTR
cyp51A
cyp51A
cyp51A
3’ NTR + hphb
3’ NTR + hph
3’ NTR
3’ NTR
Primer
404.13
404.14
407.2
365.12
365.1
365.2
365.10
365.20
365.19
407.4
407.3
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Forward
Reverse
Forward
Reverse
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The QuickChange™ XL Site-Directed Mutagenesis Kit (Stratagene) was used according to protocol to 
introduce specifi c point mutations in the cyp51A cassette by site-directed mutagenesis. Primers are 
listed in table 2. All introduced mutations were checked by sequencing of the full length pUC57 plasmids 
containing the cyp51A cassette (Table 1). 
The A. fumigatus akuBKU80 strain was used as a recipient strain in the fungal transformation experiments.17 
Transformation by electroporation was carried out as described for A. nidulans and subsequently 
adapted for A. fumigatus.18,19 Concentration ranging between 0.5 and 1.0 μg of linearized cyp51A 
cassette was used for the transformation of the A. fumigatus akuBKU80 recipient strain, for each mutation 
two recombinants were analyzed that were constructed in two separate transformation reactions. 
After selection of recombinants amino acid substitutions were again confi rmed by sequencing of the 
cyp51A gene and subsequently recombinants were investigated for their antifungal susceptibility of 
itraconazole, voriconazole and posaconazole, according to the EUCAST reference method.20 Endpoints 
were recorded at 48 h by visual inspection and the MIC was defi ned as the antifungal concentration 
that resulted in 100% inhibition of growth. Southern blots were performed to confi rm size and exclude 
random genomic integration in the A. fumigatus akuBKU80 genome. For Southern blot analysis, from all 
recombinants genomic DNA was digested with either EcoRI or EcoRV, size fractionated on a 1% agarose 
gel and transferred to a Hybond-N membrane (Amersham Biosciences) by gravitational fl ow.21 The blot 
was pre-hybridized in Church buff er followed by hybridization to a cyp51A specifi c probe.22 This probe, 
a PCR fragment of the coding region of cyp51A, amplifi ed by primers 365.10 and 365.2 (Table 1), was 
labelled with 32PdATP by using the High Prime DNA labelling kit (Roche) and purifi ed with Micro Biospin 
columns (Biorad). The A. fumigatus akuBKU80 recipient strain showed the correct size of 5.6 kb for EcoRI 
and 3.1 kb for EcoRV. All recombinants showed the correct size increase to 7.3 kb for EcoRI and 4.8 kb for 
EcoRV which is caused by the addition of the hygromycin selectable marker. CYP51A mRNA levels of the 
recombinant A. fumigatus strains with diff erent cyp51A amino acid substitutions were determined as 
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Table 2. Site-directed mutagenesis primers.
Underlining indicates altered nucleotide.
Sequence (5’-3’)
-CTCAACGGCAAGCACAAGGATGTCAATGCGG-
-CCGCATTGACATCCTTGTGCTTGCCGTTGAG-
-GGGTAGTACCATCAGTTACTGGATTGATCCCTACAAG-
-CTTGTAGGGATCAATCCAGTAACTGATGGTACTACCC-
-CTCAACGGCAAGCGCAAGGATGTCAATGCGG-
-CCGCATTGACATCCTTGCGCTTGCCGTTGAG-
-CTCAACGGCAAGTACAAGGATGTCAATGCGGAAGAGG-
-CCTCTTCCGCATTGACATCCTTGTACTTGCCGTTGAG-
-CTCAACGGCAAGATCAAGGATGTCAATGCGGAAGAGG-
-CCTCTTCCGCATTGACATCCTTGATCTTGCCGTTGAG-
-TTTATTCTCAACGGCAAGCAGAAGGATGTCAATGCGGAAG-
-CTTCCGCATTGACATCCTTCTGCTTGCCGTTGAGAATAAA-
cyp51A alteration
L98H
L98H
G54W
G54W
L98R
L98R
L98Y
L98Y
L98I
L98I
L98Q
L98Q
Primer
404.1
404.2
404.3
404.4
404.5
404.6
404.7
404.8
404.9
404.10
404.29
404.30
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
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well as the akuBKU80 recipient strain. Experimental conditions were performed as described previously.23 
In brief, total RNA was isolated from 16 h cultures in 50 ml of Vogel’s minimal medium at 37°C at 200 
rpm in a 5% CO2 humidifi ed chamber. Cultures were homogenized with a MagNA Lyser Instrument 
after liquid nitrogen treatment of the harvested mycelia. RNA was extracted from the fungal lysates by 
a standard phenol-chloroform procedure and lithium chloride precipitation. First-strand cDNA synthesis 
was performed using random hexamer primers. Real-time PCR was performed for the cyp51A gene 
and the Actin gene. The change in gene expression was determined using the ratio cyp51A/Actin. 
Experimental samples were run in duplicate. All isolates were cultured twice and from each culture 
two separate cDNA amplifi cations were performed. The standard deviation of the mean value of each 
experiment was calculated (SEM).
Results 
Molecular dynamics simulations 
Codon 98 is located in a loop that connects helix B and B’ as the only hydrophobic residue among 
hydrophilic ones on the surface of this part of the protein (Figure 2). The loop is part of an important 
fragment of the CYP51A protein that consists of this loop together with short helix B’ that closely interact 
with helix F and loop BC (Figure 2). It is one of the most conserved regions in CYP51 family of proteins 
and forms a gate-like structure with open access to the heme cofactor (Figure 2).24 
Figure 2. Secondary structure of wild-type CYP51A protein with depicted in green leucine 98 subjected to substitution. 
The heme cofactor is depicted in black, the two channels are fi lled with green and in brown and blue parts of the protein are in-
dicated that are more fl exible during the molecular dynamics simulations of L98H mutated protein. Additionally the brown part 
represents the important gate of the protein that undergoes the biggest changes during the molecular dynamics simulations.
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The analysis of available structures of CYP51 and other P450 proteins showed that all of them contained 
this structural motif but the opening varied depending on the protein origin.24-27 Surprisingly, this 
opening was never reported in the literature neither its potential function as an entrance to the active 
centre of the protein. The L98H substitution takes place rather far from both hypothetical channel entries 
(Figure 2) and it is not in direct vicinity to the active centre. The striking variation by altering leucine to 
histidine in the L98H mutation was the change of hydrophobicity since histidine is a polar residue in 
contrast to hydrophobic leucine (Figure 3). In the wild-type, the hydrophobic leucine interacts with 
the opposite residue proline 124 located in the BC loop (Figure 2). These hydrophobic interactions can 
no longer occur with the substitution in codon 98 from leucine to histidine. As it was already pointed 
out, it is important to understand the role of the L98H mutation in relation to its local environment in 
the CYP51A protein. Further consequences of this mutation were obtained from a detailed study of the 
protein dynamics. In general, the calculated secondary structures of the wild-type and mutated form of 
the protein along the molecular dynamics trajectory showed that the secondary structure of the protein 
was stable within the simulation time and no drastic modifi cations were observed (data not shown). 
The fl uctuations of the C-alpha carbons around the average structure are shown in fi gure 4. The most 
fl exible regions, that can be observed with an increase of distance in ångström, covered residues 
involved in the loop formation. The fl uctuations were much larger for the mutated protein compared to 
the wild-type protein (Figure 4) specifi cally for the residues that created the BC and IH loop, highlighted 
in blue and brown in fi gure 2. Molecular dynamics simulations showed that the L98H mutation caused 
disruption of the very fi ne balance of hydrophobic versus hydrophilic surface (Figure 3) resulting in 
a much more fl exible BC loop and subsequently closure of the fi rst ligand entry channel. This is in 
agreement with evidence that the BC loop determines the opening and closing of channel 1.4,24,28 
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Figure 3. Surface representation of hydrophobic (white) versus hydrophilic (red) residues of the CYP51A protein 
in wild-type situation (a) and mutated situation (b). The residue at location 98 is depicted in green. In the circled 
area hydrophobic residues L98 and opposite to it the hydrophilic phenylalanine 124 are depicted. In the mutated 
L98H protein this fi ne balance is disturbed since histidine is hydrophilic, again depicted in circled area. As a result 
the only hydrophobic island at the bottom of BC loop tends to fold deeper into the hydrophobic core of protein.
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Another consequence of the L98H mutation is the disruption of the very important interaction of the 
heme cofactor with the residue tyrosine 121, resulting in a closer position of the introduced histidine to 
the carboxyl group of heme (Figure 5). The crystal structures of the CYP51 family showed a conserved 
pattern of interaction where the carboxylic groups of heme (COO-HEME) interacted with positively charged 
residues (lysine or arginine) and tyrosine that created hydrogen bonds directly with one of the carboxylic 
groups or through a water molecule. There were salt bridges between residue lysine 132 and COO-HEME, 
and residue arginine 369 and COO-HEME of the wild-type CYP51A structure of A. fumigatus. Additionally, 
residues tyrosine 107 and 121 were pointing towards the two carboxyl groups of the heme cofactor 
making hydrogen bonds (Figure 5a). The negatively charged carboxyl group tended to compensate 
its charge by pulling the histidine towards itself. Moreover, the side chains of residue tyrosine 107 and 
121 were relocated (Figure 5b). They fi t perfectly into a hydrophobic pocket created by residues alanine 
102, valine 106, leucine 110, threonine 111, methionine 368, leucine 494 and phenylalanine 495. As a 
consequence, the second ligand entry channel inside the protein became closed. The strong salt bridge 
of residue arginine 369 with the carboxyl group of heme cofactor remained unchanged. From crystal 
structures, it is known that residues tyrosine 107 and 121 are also involved in the triazole-binding.24 In 
conclusion, this clearly indicates that the consequences of the L98H mutation has a negative eff ect on 
exogenous ligand binding. On the other hand, the L98H mutation does not disrupt the very fi ne balance 
of hydrophobicity in the active site of the CYP51A, which is important for binding of lanosterol and 
protein activity. The area above the heme cofactor is divided into two parts, one of them is hydrophilic 
and the other hydrophobic. The lanosterol binds into the hydrophobic part which is penetrated by only 
a few hydrophilic residues namely arginine or lysine that are used to bind the OH group of lanosterol. 
Therefore only the exogenous ligands that use the access channels seem to be aff ected by the L98H 
mutation, while biological activity remains intact. 
Figure 4. The graph shows the average fl uctuation of C-alpha atoms for each residue around the average structure of the protein. 
The solid line stands for the L98H molecular dynamics trajectory and the dashed line for the wild-type 
molecular dynamics trajectory. In brown and blue parts of the protein are indicated that are more fl exible 
during the molecular dynamics simulations of L98H mutated protein. The fl uctuations are much larger for the 
mutated protein compared to the wild-type protein specifi cally for the residues creating the BC and IH loop.
114
Cyp51A site-directed mutagenesis 
Transformation by electroporation using the cyp51A cassette was performed successfully in the recipient 
A. fumigatus akuBKU80 strain. To rule out random integration of the cyp51A cassette and to control for 
correct homologous recombination of the wild-type cyp51A gene with the cyp51A cassette, southern 
blots were performed. A cyp51A cassette without any mutations was transformed to observe whether 
exchanging the wild-type cyp51A gene for the cyp51A cassette had any eff ect on azole susceptibility. The 
recombinants with the cyp51A cassette showed no changes in azole susceptibility compared to the wild-
type A. fumigatus akuBKU80 recipient strain (Table 3). As a control to check whether the cyp51A cassette is 
able to express the cyp51A gene, a G54W mutation, known from literature to be specifi cally correlated 
to itraconazole and posaconazole resistance but not to voriconazole resistance, was introduced in the 
cyp51A cassette by site-directed mutagenesis.29 Recombinants showed azole resistance specifi cally for 
itraconazole (MIC >16mg/l) and posaconazole (MIC >16mg/l) while voriconazole remained susceptible 
(MIC 0.25mg/l) (Table 3), confi rming the value of this site-directed mutagenesis system for the analysis 
of the structure-function relationship of cyp51A mutations. 
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Figure 5. Structural arrangement of heme cofactor bound by residues lysine 132, arginine 369, tyrosine 121 and 
107 in (a) the wild-type protein and (b) the L98H mutated protein after molecular dynamics simulations. Atoms 
are indicated in colours by red for oxygen, nitrogen blue, carbon grey and hydrogen white. Location of residue 
tyrosine 107 (c) in relation to the heme, in black, and the two channels, fi lled green, in the CYP51A protein.
A B
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The 34 bp TR and L98H mutations were introduced separately and in combination in the cyp51A cassette. 
The recombinants with either one of the mutations showed a slight increase in MIC compared to the 
wild-type A. fumigatus akuBKU80 recipient strain; itraconazole (MIC 1mg/l) and voriconazole (MIC 1-2mg/l) 
and posaconazole (MIC 0.5mg/l), similar to that observed by conventional homologous recombination 
experiments as described previously.13 However, only when both mutations were introduced 
simultaneously a MAR phenotype was observed; itraconazole (MIC >16mg/l) and voriconazole 
(MIC 2mg/l) and posaconazole (MIC 0.5mg/l), again confi rming the recombinant experiments described 
previously.13 Expression levels of the cyp51A gene were determined by real time PCR experiments and 
confi rmed that only the recombinants that contained the 34 bp TR showed and increased expression 
compared to the wild-type A. fumigatus akuBKU80 recipient strain (Figure 6).
Table 3. Minimal inhibitory concentrations (MIC) of recombinant A. fumigatus strains with diff erent cyp51A amino acid substitu-
tions according to the EUCAST method. For each mutation two recombinants were constructed in two separate transformation 
reactions, MIC susceptibility of one representative isolate for each mutation is shown.
TR:34 bp tandem repeat in the promoter region, ITC: itraconazole; VCZ: voriconazole; POS: posaconazole.
cyp51A substitutions
TR Coding gene
- -
- -
- G54W
+ -
- L98H
+ L98H
+ L98R
+ L98Y
+ L98Q
+ L98I
EUCAST MIC (mg/l) 48h
ITC VCZ POS
0.5 0.25 0.25
0.5 0.25 0.25
>16 0.25 >16
1 2 0.5
1 1 0.5
>16 2 0.5
>16 2 0.5
>16 1 0.5
>16 2 0.5
>16 1 0.5
Isolate
akuBKU80 recipient strain
akuBKU80 cassette
akuBKU80-G54W
akuBKU80-TR 
akuBKU80-L98H
akuBKU80-TR L98H
akuBKU80-TR L98R
akuBKU80-TR L98Y
akuBKU80-TR L98Q
akuBKU80-TR L98I
Figure 6. CYP51A mRNA levels of the recombinant A. fumigatus strains with diff erent cyp51A amino acid substitutions 
as well as the akuBKU80 recipient strain. The change in gene expression was determined using the ratio cyp51A/Actin 
measured by real time PCR. Isolates containing 34 bp TR in the promoter region are represented by the dark grey bars.
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The site-directed mutagenesis system was specifi cally able to alter any amino-acid in the CYP51A 
protein. By using the CYP51A homology model specifi c point mutations and their eff ect on azole 
resistance were investigated. Four diff erent amino acids were chosen to be introduced at codon 98 
in combination with the 34 bp TR in the promoter region: arginine (R), tyrosine (Y), glutamine (Q) and 
isoleucine (I). Arginine is a positively charged amino acid, therefore hydrophilic, and similar to histidine. 
It was expected to be attracted by the negatively charged parts of the heme group in the same way 
as histidine and therefore the recombinant was expected to give a MAR phenotype. The recombinant 
isolate containing the arginine (R) at codon 98 and TR indeed showed a similar resistance profi le to 
the TR/L98H phenotype; itraconazole (MIC >16mg/l), voriconazole (MIC 2mg/l) and posaconazole 
(MIC 0.5mg/l) (Table 3). Tyrosine is a less polar amino acid but has an aromatic ring similar to histidine, 
the MAR phenotype was however expected to be less pronounced as histidine. The recombinant 
isolate with amino acid tyrosine in codon 98 and TR was however similar to the TR/L98H phenotype; 
itraconazole (MIC >16mg/l), voriconazole (MIC 1mg/l) and posaconazole (MIC 0.5mg/l). Glutamine is a 
polar amino acid that, unlike histidine, contains no aromatic ring and the MAR phenotype was therefore 
expected to be less pronounced as histidine. The recombinant isolate with amino acid glutamine and TR 
however showed similar azole susceptibilities as the TR/L98H phenotype; itraconazole (MIC >16mg/l), 
voriconazole (MIC 2mg/l) and posaconazole (MIC 0.5mg/l). Isoleucine is a hydrophobic amino acid that 
is similar to leucine in structure and the L98I recombinant was therefore expected to have less or no 
eff ect on azole susceptibility. Unexpectedly, the susceptibility testing of the recombinant isolate with 
isoleucine and TR showed an increase in azole resistance; itraconazole (MIC >16mg/l), voriconazole 
(MIC 1mg/l) and posaconazole (MIC 0.5mg/l), similar to the TR/L98H azole phenotype as well. 
Discussion
Although modeling of A. fumigatus CYP51A has been described previously, no study investigated yet the 
dynamics of specifi c point mutations in the CYP51A homology model nor investigated the rationale of 
azole resistance caused by the L98H mutation.4,5 The amino acid changes in the cyp51A gene previously 
known from literature to be correlated to azole resistance, e.g. in codon 54, 138 or 220, have a specifi c 
impact on the azole susceptibility for certain azoles molecules.6 However these mutations are located 
in the direct vicinity of the opening of one of the two ligand access channels. The mutations have a 
direct impact on the docking of the azole molecules which does not apply for the L98H mutation. 
The TR/L98H mutation appears to have a more indirect eff ect on azole resistance as described in the 
current study and therefore represents a diff erent mechanism of azole resistance. By using molecular 
dynamics simulations the infl uence of the L98H substitution on the general structure of CYP51A was 
investigated and provided evidence for a role of this mutation in the MAR phenotype. The mutation 
mainly infl uences the fl exibility of the BC and IH loops of the protein and as a consequence the positions 
of the tyrosine 121 and tyrosine 107 side chains are changed. This causes both access channels that 
are identifi ed in the CYP51A protein to be modifi ed and prevents the binding of azoles towards the 
active heme. We have established that the general secondary structure of the protein is not altered due 
to the mutation but due to the changed fl exibility of the BC and IH loops the capacity of the ligand 
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entry channels is modifi ed by narrowing the diameter. Moreover, the relocation of the tyrosine 121 and 
tyrosine 107 that are known to be important for triazole binding, is responsible for the MAR phenotype 
although it does not aff ect the biological activity of the CYP51A protein. This is in line with evidence from 
the multi-sequence alignment, where the mutated position is occupied by histidine in Ustilago maydis 
or even by asparagine in pig or rat and the protein is still functional.30 In A. fumigatus, besides the cyp51A 
gene a cyp51B has been identifi ed. A double knockout of the cyp51 genes was never obtained and a 
cyp51A knock out showed unchanged ergosterol content and no increased expression of cyp51B.31 It 
has been postulated that cyp51B encodes for alternative functions for particular growth conditions or is 
even functionally redundant.32 This provides a possible explanation to why mutations in azole-resistant 
A. fumigatus isolates are predominantly detected in the cyp51A gene and no mutations in cyp51B have 
been proven to be correlated to azole resistance.
In order to determine whether amino acid substitutions in codon 98 can be correlated to azole 
resistance, we have developed a site-directed mutagenesis system that is specifi cally able to alter any 
amino acid change of interest in the CYP51A protein in A. fumigatus. The TR mutation, a duplication of a 
34 bp sequence in the promoter region of the cyp51A gene has been shown to increase the expression 
of CYP51A by approximately 2.5 to 8-fold.13,23 Tandem repeats in the promoter region of cyp51 genes 
are known mechanisms of azole resistance in phytopathogenic moulds.9 However, the 34 bp TR in 
the cyp51A gene of A. fumigatus is by itself not suffi  cient for the MAR phenotype, and therefore the 
substitution at codon 98 is a key alteration in this resistance mechanism. By introducing site-specifi c 
amino acid substitutions using the CYP51A homology model it becomes possible to investigate the 
structure-function relationship of amino acid alterations and, in this case, the eff ect of TR/L98H mutation 
on azole susceptibility. The constructed recombinant isolates show that the site-directed mutagenesis 
system is sound. Introduction of the cyp51A cassette showed no changes in azole susceptibility and as 
a control to check whether the cyp51A cassette, a G54W mutation, was introduced. This recombinant 
isolate showed itraconazole and posaconazole resistance but not voriconazole resistance, confi rming 
the specifi c G54W azole phenotype known from reported clinical isolates and validating the site-directed 
mutagenesis system for the analysis of the structure-function relationship of cyp51A mutations.29 In 
codon 98 four diff erent amino acid changes other than histidine were introduced simultaneously with 
the 34 bp TR. Arginine was expected to act in a similar way as histidine and the recombinant confi rmed 
this with a MAR phenotype. Tyrosine and glutamine are similar to histidine but the MAR phenotype was 
expected to be less pronounced. The recombinants however showed the same level of resistance with 
tyrosine and glutamine as TR/L98H. Isoleucine is similar to leucine in structure and the L98I recombinant 
was therefore expected to have less or no eff ect on azole susceptibility. In contrast, the susceptibility 
testing of the recombinant isolate showed an increase in azole resistance similar to the TR/L98H azole 
phenotype. Unlike the diff erent hypotheses of the amino acid changes in codon 98, all alterations in 
codon 98 decreased the azole susceptibility. This discrepancy could be explained by the fact that the 
resistant phenotype is not associated with a single mutation but with a combination of a codon 98 
alteration together with the 34 bp TR. It was previously shown and confi rmed in this study that either 
mutation alone has limited impact on the azole phenotype, but when both mutations are introduced 
simultaneously a synergistic eff ect with an azole resistant phenotype is observed. 
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When both mutations are introduced separately the MIC for itraconazole is increased to 1-2 (mg/ml), 
however combined itraconazole is greater then 16 (mg/ml). Therefore the mutations do not show an 
additive eff ect on azole resistance but a synergistic eff ect. The impact of the 34 bp insertion in the 
promoter region of the gene could therefore dominate subtle changes in azole phenotype caused by 
amino acid alterations introduced at codon 98. Introducing amino acid changes in conserved regions 
could possibly have an impact not until a 34 bp TR increases the expression of the protein by 5 to 
8-fold.13,23 Another explanation is that the current methods available to measure the azole phenotype are 
not very accurate. Both CLSI and EUCAST standards allow a 3-log two-step range of MICs corresponding 
to the best achievable precision.33 Using EUCAST methodology 51 fl uconazole MIC determinations of a 
single Candida glabrata isolate showed a range of two-2-fold dilution steps.33 As a consequence subtle 
changes in phenotype due to substitution of specifi c amino acids at codon 98 may not be detected. 
For A. fumigatus no crystal structure of the CYP51 is available and in this study a homology model 
was constructed by using the crystal structure of human lanosterol 14 alpha-demethylase. In this way 
molecular dynamic simulations can be performed and mutations can be located by pinpointing them 
in the CYP51 homology model. However, by using this method the model cannot refl ect the exact 
appearance and properties of the A. fumigatus CYP51 protein. Results originating from these studies 
need to be considered as a prediction containing uncertainties. As was shown previously by using 
the CYP51A homology model mutations in the cyp51A gene, known from literature to be correlated 
to azole resistance, could be located close to the opening of one of the two ligand access channels. 
They are thought to disturb the interactions necessary for stable docking towards the heme centre. 
The L98H mutation is however located far from both openings of the ligand access channels and the 
mechanism causing an azole-resistant phenotype must therefore take place in more subtle and indirect 
way. As was shown in the molecular dynamic simulations the L98H mutation changes the capacity of 
the ligand access channels by a change in fl exibility and thus, alterations in the protein sequence might 
aff ect dynamic properties of the molecule rather than immediate protein–inhibitor contacts as was also 
discussed by Podust et al.30 The multi sequence alignment in codon 98 show that the amino acid leucine 
in codon 98 in A. fumigatus is highly conserved. An alignment of diff erent fungi showed that 14 of 20 
fungi contained the amino acid leucine corresponding with codon number 98 in A. fumigatus. Only 
6 fungi contained a diff erent amino acid at codon 98.30 The recombinants showed that all introduced 
amino acids other than leucine in combination with the 34 bp TR decreased the azole susceptibility. This 
confi rms the importance of the presence of the highly conserved leucine in codon 98 in CYP51A for 
maintaining the structure and functionality of the ligand access channels that are used by the azoles. 
Amino acid substitutions have previously been introduced in the cyp51A gene in A. fumigatus 
by homologous recombination of PCR products or by expression of the gene by using the yeast 
Saccharomyces cerevisiae as a model system.13,34,35 In this study we present an effi  cient transformation 
system for A. fumigatus in which gene functions can be studied by introducing site-directed amino acid 
substitutions and investigate structural changes or changes in biological activity in the presence of the full 
background of an A. fumigatus genome. By introducing a dominant selectable marker such as hygromycin, 
recombinants can be selected independently from any changes introduced in azole phenotype in 
contrast to the recombinant experiments of the TR/L98H mutations performed previously.13 Thereby no
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mutations or physiological changes can be induced during selection under azole pressure and 
recombinants that did not change in expected phenotype are as well recovered and available for 
analysis. 
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Azole resistance in Aspergillus fumigatus; collateral damage of fungicide use
The aim of this thesis was to explore the epidemiology and origin of azole resistance in Aspergillus 
fumigatus in the Netherlands after a series of Dutch patients with azole-resistant invasive aspergillosis 
was reported.1 During the course of the studies more and more evidence was obtained that the 
Aspergillus fumigatus isolates did not develop azole resistance through patient azole therapy. Evidence 
that supported an alternative route of resistance development included (i) the presence of azole-
resistant aspergillus disease in azole-naïve patients, (ii) the dominance of a single resistance mechanism 
(TR/L98H), (iii) the presence of a tandem repeat which is a genomic change not found in isolates that 
have become resistant through patient therapy, but has been found in azole-resistant phytopathogenic 
molds, (iv) and the recovery of TR/L98H isolates from the environment. The hypothesis was that the 
TR/L98H resistance mechanism had emerged through exposure of A. fumigatus to azole compounds that 
are present in the environment.2 This hypothesis was investigated and indeed we were able to identify 
fi ve azole fungicides that may have caused TR/L98H to emerge. As A. fumigatus is not a phytopathogen, 
the emergence of azole resistance through the environmental route can indeed be considered as an 
unintentional side eff ect: collateral damage.
Characteristics of the environmental route of resistance development
During the past years several characteristics of the environmental route of resistance development have 
become apparent that are worrisome. Surveillance studies of azole resistance have shown that the TR/
L98H resistance mechanism has become endemic in the Netherlands.3 The prevalence of TR/L98H in 
clinical isolates varied between 0.8 and 9.5%, indicating that in some centers up to one in ten clinical 
A. fumigatus isolates is azole-resistant. Culture-based surveillance may underestimate the true prevalence 
of resistance, compared with direct detection of resistance mechanisms in clinical specimens.4 
TR/L98H was found in at least eight European countries and recently also in Asia (China and India).5,6 
Genotyping of Dutch and European TR/L98H isolates showed that these isolates are genetically more 
related to each other than wild-type controls [unpublished observations]. Genetic relatedness points 
towards a common ancestor and indicates that isolates harboring TR/L98H originated locally and 
subsequent migrated. This process has been shown for phytopathogenic molds, but is a great concern 
given the effi  cacy of asexual reproduction of A. fumigatus. This fungus is ubiquitous and found world-
wide from dessert to pole. Global migration of TR/L98H therefore can be anticipated.
A second characteristic of the environmental route of resistance development is that multiple resistance 
mechanisms may emerge in A. fumigatus and other clinically relevant molds. Although there is currently 
no evidence for the latter, we have observed two other ‘environmental’ resistance mechanism in 
A. fumigatus. In the year 2006 a 53 bp TR was found in the promoter region of the cyp51A gene of an azole 
resistant A. fumigatus isolate from a Dutch patient and also from the environment, but further spread 
has not yet been reported.7 Very recently a third TR resistance mechanism was found in Dutch clinical 
A. fumigatus isolates. The resistance mechanism consisted of a 46 bp TR in combination with two amino 
acid changes in the CYP51A protein.8 In contrast to the TR34/L98H mutation which has a primary resistance 
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against itraconazole, the TR46/Y121F,T289A isolate has a primary resistance against voriconazole. Rapid 
migration of isolates harboring this resistance mechanism was observed through the Dutch surveillance 
network and within one year 15 patients were identifi ed from six University Hospitals.8 The emergence 
and migration of this new resistance mechanism accelerates the prevalence of resistance as the 
prevalence increased from 5.3% in 2009 to 8.3% in 2010.3 Furthermore, there is no reason to believe that 
TR46/Y121F,T289A will not migrate across borders similar to TR/L98H.
A third characteristic of the environmental route of resistance development is the lack of apparent 
patient risk factors. The patient route of azole resistance development is characterized by previous or 
ongoing azole exposure and has been reported almost exclusively in patients with aspergilloma. A Dutch 
surveillance study showed that TR/L98H was the dominant resistance mechanism indicating that most 
patients will be infected through inhalation of resistant conidia that are present in the environment. In 
such a situation 64% of patients with an azole-resistant isolate had no history of previous azole exposure. 
Lack of apparent risk factors complicates patient management as any patient with aspergillus disease 
could have an azole resistant isolate. These characteristics warrant measures that may prevent new 
resistance mechanisms to emerge and halt migration. 
The origin of TR/L98H: a new hypothesis
Given the prominent and important role of azole fungicides in food production and preservation any 
measures targeted at halting the environmental route of resistance development in A. fumigatus should 
be evidence based. Although we have gained insight in the epidemiology and clinical implications of 
azole resistance, the mechanism through which resistance develops in the environment is unknown. In 
October 2010 the Dutch Center for Infectious Disease control (CiB) and the Dutch Food and Consumer 
Product Safety Authority (VWA) both advised the Dutch government to investigate the environmental 
route of resistance development in order to design strategies that prevent resistance development. 
Unfortunately, until today this much needed research has not been initiated. Indeed we believe that 
understanding the environmental route of resistance development is essential and will provide the key 
to custom made measures. 
One important unexplained issue is why the TR/L98H resistance mechanism is so dominant, as it accounts 
for over 90% of resistance mechanisms in Dutch azole-resistant clinical isolates.3,9 This observation 
has puzzled researchers. That azole exposure leads to resistance is evident, but the experience with 
the patient route of resistance development shows that multiple resistance mechanisms emerge in 
patients during azole therapy. In some patient isolates, diff erent colonies harbored diff erent azole 
resistance mechanisms.10 In the environment A. fumigatus is also exposed to azole compounds but 
we have observed only three resistance mechanisms in a period of 13 years. It could be that multiple 
resistance mechanisms will develop but only those survive that retain comparable fi tness to wild-type 
isolates. It is believed that even a slight loss of fi tness will result in disappearance of the resistant trait 
in the fi eld. We believe however that the morphotype of A. fumigatus is crucial for azole resistance 
development. We have previously suggested that during hyphal growth, which is the morphotype 
present in invasive aspergillosis, clinically relevant azole resistance is unlikely to emerge due to the fact 
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that mutated nuclei will be vastly outnumbered by wild-type nuclei.2 Only if cells that contain resistance 
mutations reproduce through asexual reproduction all conidia that develop will contain the mutations, 
thus being a very effi  cient mode of spread of resistance. Asexual reproduction takes place in cavitary 
lesions and as stated above, azole resistance develops almost exclusively in azole-treated patients 
with aspergilloma. Many cyp51A mutations have been described and there is no evidence that these 
isolates are less virulent than wild-type isolates.11 We believe that this mode of resistance development 
is nonexistent in the environment or occurs very infrequently. The presence of two genomic changes, 
including a TR, indicates that recombination must have taken place, which is most likely to occur during 
meiosis. In 2009 the sexual cycle of A. fumigatus was fi rst described by the group of Dyer.12 Numerous 
researchers had failed to identify this morphotype, which might indicate that sexual reproduction is 
very infrequent in nature. A. fumigatus requires specifi c conditions with respect to temperature and 
nutrients to allow for sexual reproduction to occur.12 It is currently unknown how frequent and in which 
natural niche sexual reproduction occurs. Our hypothesis is that sexual reproduction of A. fumigatus 
with azole pressure will cause the ‘environmental’ resistance mechanisms to develop. This probably 
occurs infrequently and explains why only three TR-resistance mechanisms have emerged in the past 13 
years. Through recombination the resistance mechanism, containing multiple genomic changes, could 
develop through a single event of through multiple sequential events. As, in contrast to the sexual cycle, 
asexual reproduction is extremely effi  cient in A. fumigatus, the resistance mechanisms will subsequently 
migrate. Such a mode of resistance development and spread explains the genetic relatedness of the 
isolates and the dominance of a single resistance mechanism.
To prove this hypothesis induction experiments during sexual reproduction should take place using 
pressure of the fi ve azole fungicides that exhibit similar molecule structure to the medical triazoles. We 
have previously performed induction experiments trough asexual reproduction but were unsuccessful 
to induce TR/L98H. Furthermore, it is important to sample in the environment for A. fumigatus 
ascospores in order to identify the niche in which these develop. It might be that there are specifi c 
conditions in the Netherlands that facilitate the development of azole resistance during sexual 
reproduction. Identifi cation of such a niche would be vital to develop eff ective preventive measures.
Clinical implications
There is increasing evidence that azole resistance is associated with treatment failure and possibly 
excess mortality in azole-resistant invasive aspergillosis.3 Early detection of resistance is of great 
importance, but also very diffi  cult and time consuming. Furthermore, the awareness of azole resistance 
and the possible clinical implications is still low, and many clinical microbiology laboratories do not 
routinely determine the susceptibility in A. fumigatus. Screening of A. fumigatus cultures for azole resistance 
using agar plates supplemented with azoles appears to be a feasible approach, but in most patients 
with invasive aspergillosis fungal cultures remain negative. Direct detection of cyp51A-mutations in 
clinical specimens has been shown to be possible,13 but the sensitivity remains a problem. As there is 
only one copy of the cyp51A-gene present in each nucleus, enhancing the DNA amplifi cation through 
for instance a nested-PCR format is required with associated risks of contamination and false positivity. 
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Also the growing number of resistance mechanisms is a concern. Diagnostic tests for detection of 
azole resistance are therefore an important goal for the near future in order to increase our diagnostic 
arsenal. In the meantime surveillance should be performed in order to know the local epidemiology. 
The initiation of a Reference Laboratory in the Netherlands by the Dutch Ministry of Health for active 
surveillance of azole resistance is an important step in systematic surveillance. This will provide insight 
in trends in resistance development in terms of prevalence and of resistance mechanisms. Given the 
migration of TR/L98H, surveillance programs should be performed at the European level. When the local 
epidemiology of azole resistance is known, local treatment guidelines can be adjusted if necessary. It is 
diffi  cult to recommend a cutoff  for adjustment of treatment guidelines, but a prevalence of 5% to 10% 
may necessitate primary therapy that includes azole-resistance. Treatment options would be liposomal 
amphotericin B or a combination of voriconazole with an echinocandin. Unfortunately there is virtually 
no data on the effi  cacy of these agents in azole resistant disease. A recent animal model did show 
effi  cacy of voriconazole and anidulafungin in disseminated azole-resistant aspergillosis.14
The concept of acquired azole resistance and a possible link with the use of azole fungicides in the 
environment has been met with disbelief and skepticism by physicians and researchers.15 With 
evidence accumulating that supports such a link it is important to bring together researchers from 
epidemiological, medical and agricultural backgrounds and to address the abovementioned research 
questions. The ultimate aim would be to maintain the medical triazoles as the most important drug class 
in the management of aspergillus diseases in humans without compromising crop protection and food 
supply.
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Summary
Aspergillus fumigatus is the most frequent cause of aspergillus diseases in humans. Antifungal agents 
of the azole class play a prominent role in the management of invasive aspergillosis (IA). Three medical 
triazoles, itraconazole, voriconazole and posaconazole, are clinically licensed for the prevention and 
treatment of aspergillus diseases. The azoles exhibit good activity against A. fumigatus, are available in 
an oral formulation, and are generally well tolerated (chapter 1). 
Although the risk of resistance due to the increased use of triazoles was considered low, we describe in 
chapter 2 the observation of itraconazole resistance rapidly emerging in clinical A. fumigatus isolates. 
A new dominant resistance mechanism, the TR/L98H, was observed in the Netherlands in six diff erent 
hospitals without evidence for a clonal spread in the year 2007. This led to the investigation of the 
Nijmegen culture collection in which all A. fumigatus isolates between 1994 and 2007 were analyzed for 
azole resistance. Itraconazole resistant isolates were detected since 2000 with an annual prevalence of 
1.7% to 6.0%. A substitution of leucine 98 for histidine in the cyp51A gene, together with two copies of 
a 34 bp sequence in tandem in the gene promoter (TR/L98H), was found to be the dominant resistance 
mechanism. The itraconazole resistant isolates also showed elevated minimum inhibitory concentrations 
of voriconazole, ravuconazole, and posaconazole. Microsatellite analysis indicated that the itraconazole 
resistant isolates were genetically distinct but clustered. Itraconazole resistance was also found in 
isolates from other medical centers in the Netherlands, which harbored the TR/L98H substitution, and 
in six isolates originating from four other countries.  The collection analyzed in chapter 2 also contained 
isolates originating from patient rooms, also exhibiting the azole resistance profi le.
Therefore we investigated in chapter 3 if A. fumigatus isolates resistant to medical triazoles are 
present in our environment by sampling the hospital indoor environment and soil from the outdoor 
environment. Itraconazole resistant A. fumigatus was cultured from the indoor hospital environment 
as well as from soil obtained from fl ower beds in proximity to the hospital but never from natural soil. 
Cross-resistance was observed for voriconazole, posaconazole, and the azole fungicides metconazole 
and tebuconazole. Molecular analysis of resistant environmental isolates showed the presence of the 
dominant TR/L98H resistance mechanism, which was identical to that found in clinical isolates and it 
showed that environmental and clinical isolates were genetically clustered apart from nonresistant 
isolates. The evidence provided in this study led to the hypothesis that patients with azole resistant 
aspergillosis might have been colonized with azole resistant A. fumigatus isolates from the environment. 
It was also shown in this chapter that the TR/L98H resistant isolates showed cross resistance for two 
azole fungicides. The fi ndings from chapter 2 and 3 suggested that the TR/L98H mutations could 
be possibly linked by environmental fungicide use. The collected evidence for this is discussed in 
chapter 4. IA due to multi-azole-resistant A. fumigatus has emerged in the Netherlands since 2000 with 
the presence of a dominant resistance mechanism (TR/L98H) that was found in over 90% of clinical azole 
resistant A. fumigatus isolates. TR/L98H isolates were also cultured from soil and compost, were shown 
to be cross-resistant to azole fungicides and were genetically related to clinical resistant isolates. The 
evidence summarized is consistent with a route of resistance development through exposure to azole 
compounds in the environment. 
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In chapter 5 the link between intensive use of fungicides and development of the dominant TR/L98H 
azole resistance mechanism was studied. Thirty-one compounds, that have been authorized for use 
as fungicides, herbicides, herbicide safeners and plant growth regulators in the Netherlands between 
1970 and 2005, were investigated for the presence of cross-resistance to medical triazoles. Five triazole 
demethylation inhibitors (DMI), propiconazole, bromuconazole, tebuconazole, epoxiconazole and 
difenoconazole, showed very similar molecule structures to the medical triazoles and adopted similar 
poses while docking the protein. These fi ve DMIs also showed the greatest cross-resistance and, 
importantly, were authorized for use between 1990 and 1996, directly preceding the recovery of the 
fi rst clinical TR/L98H isolate in the Netherlands in 1998. Through microsatellite genotyping of TR/L98H 
isolates we were able to calculate that the fi rst isolate would have arisen in 1997, confi rming the results 
of the abovementioned experiments. Similar molecule structure characteristics of fi ve triazole DMIs and 
the three medical triazoles appear the underlying mechanism of cross resistance development. The 
fi ndings in this chapter support a fungicide-driven route of TR/L98H development in A. fumigatus. 
A homology model of the CYP51A protein was developed and described in chapter 6. To obtain insight 
into azole resistance mutations, the cyp51A gene of 130 resistant and 76 susceptible A. fumigatus isolates 
was sequenced. All of the nonsynonymous mutations that were detected, apart from the mutations 
in codons G54, G138, M220 and L98, were located at the periphery of the protein, as determined by a 
structural model of the A. fumigatus CYP51A protein, and were predicted neither to interact with azole 
compounds nor to aff ect structural integrity. It was shown that the CYP51A homology model can be 
used to predict the potential correlation of a mutation in the cyp51A gene to azole resistance. 
In chapter 7 we described that molecular dynamics simulations combined with site-directed mutagenesis 
of amino acid substitutions in the cyp51A gene, correlate to the structure–function relationship of the 
L98H substitution conferring to multi azole resistance (MAR) in A. fumigatus. Because of a L98H directed 
change in the fl exibility of the loops, that comprise a gate-like structure in the protein, the capacity of 
the two ligand entry channels is modifi ed by narrowing the diameter and thereby binding of azoles is 
obstructed. Moreover, the L98H induced relocation seems to be related to the MAR phenotype, without 
aff ecting the biological activity of the CYP51A protein. Site-directed mutagenesis showed that both the 
34 bp TR and the L98H mutation are required to obtain the MAR phenotype. Furthermore, the amino 
acid leucine in codon 98 in A. fumigatus is highly conserved and important for maintaining the structure 
of the CYP51A protein that is essential for azole docking.
The relation between the use of the triazole DMIs and cross-resistance to medical triazoles in 
A. fumigatus has major implications for the assessment of health risks associated with the use of DMIs. 
In chapter 8 a general discussion is formulated about the induction and spread of the TR/L98H azole 
resistance mechanism, the evolution of azole resistance as well as the therapeutic consequences of a 
fungicide driven azole resistance. Further research should be aimed at understanding the conditions 
under which resistance mechanisms develop in the environment. Reversal of resistance development 
may be achievable by restriction of certain triazole DMIs, but laboratory population studies and genetic 
mapping would be required to predict the impact of changes in DMI-pressure. The continued use of 
DMIs with activity against opportunistic human fungal pathogens is a risk for the management of fungal 
diseases caused by these pathogens. 
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Samenvatting
Aspergillus fumigatus is de meest voorkomende oorzaak van aspergillus ziekten bij de mens. In de 
behandeling van invasieve aspergillose (IA) spelen de antifungale middelen van de azool klasse een 
prominente rol. Drie medische triazolen, itraconazol, voriconazol en posaconazol, zijn toegestaan voor 
klinisch gebruik voor preventie en behandeling van verschillende aspergillus ziekten. De azolen hebben 
een uitstekende activiteit tegen A. fumigatus, kunnen zowel oraal als intraveneus worden toegediend, 
en worden in het algemeen goed getolereerd (hoofdstuk 1). 
Ondanks het toegenomen gebruik van de triazolen werd het risico voor resistentie in het verleden 
laag ingeschat. Echter in het laatste decennium werd een snelle toename van itraconazol resistentie 
in klinische A. fumigatus isolaten geobserveerd (hoofdstuk 2). Vanuit het UMC St. Radboud werd een 
serie van negen patiënten, afkomstig uit Nederland beschreven die een aspergillus infectie hadden door 
een azool resistent A. fumigatus isolaat. Deze observatie was de aanleiding om de Nijmeegse collectie 
van A. fumigatus isolaten te onderzoeken waarbij in totaal 1912 isolaten tussen 1994 en 2007 werden 
onderzocht. Itraconazol resistente isolaten werden voor het eerst gedetecteerd in 2000 met in de 
daarop volgende jaren een stijgende prevalentie van 1.7% in 2000 tot 6.0% in 2007. Resistentie werd ook 
gevonden in isolaten die naar het UMC St. Radboud reeds waren verstuurd vanuit andere ziekenhuizen 
in Nederland. Een substitutie van leucine in codon 98 voor histidine in het CYP51A eiwit, samen met 
een insertie van een 34 baseparen tellende sequentie in tandem in de promoter regio van het gen 
(TR/L98H), bleek aanwezig te zijn in 94% van de resistentie isolaten. Microsatelliet analyse gaf aan dat 
de TR/L98H isolaten genetisch geclusterd werden. De in hoofdstuk 2 onderzochte collectie bevatte ook 
een aantal isolaten die afkomstig waren van patiëntenkamers, waarvan enkele ook azool resistent waren. 
In hoofdstuk 3 hebben we daarom onderzocht of resistente A. fumigatus isolaten aantoonbaar zijn 
in de omgeving binnen het ziekenhuis en in grond afkomstig uit de directe omgeving buiten het 
ziekenhuis. Itraconazol resistente A. fumigatus werd gevonden in monsters genomen bij het ziekenhuis 
en uit grondmonsters genomen uit plantenbakken direct buiten het ziekenhuis. Resistente A. fumigatus 
isolaten werden nooit aangetroff en in monsters afkomstig van onbewerkte grond. Kruisresistentie werd 
waargenomen voor voriconazol, posaconazol en de azool fungiciden metconazol en tebuconazol. 
Moleculaire analyse liet de aanwezigheid van het dominante TR/L98H resistentie mechanisme zien, 
die identiek was aan het resistentie mechanisme gevonden bij de klinische isolaten. De moleculaire 
analyse liet eveneens zien dat omgevings en klinische isolaten samen geclusterd werden apart van niet-
resistente isolaten. De bevindingen van deze studie suggereerden dat patiënten met azool resistente 
aspergillosis mogelijk gekoloniseerd kunnen zijn met azool resistente A. fumigatus isolaten uit de 
omgeving. In dit hoofdstuk werd tevens aangetoond dat de TR/L98H resistente isolaten kruisresistentie 
lieten zien voor twee azool fungiciden. De bevindingen uit hoofdstuk 2 en 3 leidde tot de hypothese 
dat het ontstaan van de TR/L98H mutaties in verband kan staan met het fungicide gebruik in het milieu. 
De hypothese wordt ondersteund door de volgende observaties (hoofdstuk 4): Er werd sinds 2000 
een dominant resistentie mechanisme (TR/L98H) gevonden in meer dan 90% van de klinische azool 
resistente isolaten. Dit was onverwacht omdat aspergillus ziekten niet van mens op mens overgedragen 
worden. TR/L98H isolaten werden ook gekweekt uit grond en compost, en waren kruisresistent tegen 
azool fungiciden en genetisch verwant aan klinische resistente isolaten. Tevens is een tandem repeat 
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een resistentie mechanisme dat ook in azool-resistente phytopathogene schimmels gevonden 
wordt. Het samenvattende bewijs is in overeenstemming met een route van resistentie ontwikkeling 
door middel van blootstelling van azool verbindingen in de omgeving. In hoofdstuk 5 werd de link 
tussen fungiciden en het ontstaan van het dominante TR/L98H azool resistentie mechanisme verder 
bestudeerd. Eenendertig verbindingen, die in Nederland tussen 1970 en 2005 geautoriseerd waren voor 
gebruik als fungicide, herbicide, en plantengroei regulator, werden onderzocht voor de aanwezigheid 
op kruisresistentie tegen medische azolen. Vijf triazool demethylatie inhibitors (DMIs); propiconazol, 
bromuconazol, tebuconazol, epoxiconazol en difenoconazol, hadden soortgelijke molecuul structuren 
ten opzichte van de medische triazolen en positioneerde zich hetzelfde in het CYP51A eiwit. Deze vijf 
DMIs lieten ook de grootste kruisresistentie zien en waren alle vijf geautoriseerd voor gebruik door het 
college voor de toelating van gewasbeschermingsmiddelen en biociden (CTGB) tussen 1990 en 1996, 
direct voorafgaand aan de vondst van het eerste klinische TR/L98H isolaat in Nederland in 1998. Door 
genetische evolutie van TR/L98H isolaten werd het mogelijk om te berekenen dat het eerste isolaat 
inderdaad ontstaan zou zijn in 1997. Het onderliggende mechanisme van kruisresistentie ontwikkeling 
lijkt veroorzaakt te worden door de molecuul gelijkenis van de medische azolen en deze vijf triazool 
DMIs. De bevindingen in dit hoofdstuk ondersteunen een rol voor fungiciden in het onstaan van 
TR/L98H in A. fumigatus. 
Een homologie model van het CYP51A eiwit werd ontwikkeld en beschreven in hoofdstuk 6. Om 
inzicht te verkrijgen in azool resistentie mutaties, werd het cyp51A gen van 130 resistente en 76 
gevoelige A. fumigatus isolaten gesequenced. Alle non-synonieme mutaties die gedetecteerd werden, 
afzonderlijk van de mutaties in codons G54, G138, M220 en L98, waren gelokaliseerd op de periferie van 
het eiwit, zoals vastgesteld werd met een structuur model van het A. fumigatus CYP51A eiwit. Voorspeld 
kon worden dat deze mutaties interfereren met de azool moleculen zonder invloed te hebben op de 
integriteit van het eiwit. Tevens werd aangetoond dat het CYP51 homologie model gebruikt kan worden 
om het eff ect van een mutatie in het cyp51A gen op azool resistentie te voorspellen. 
In hoofdstuk 7 werd beschreven dat moleculaire dynamica simulaties gecombineerd met specifi eke 
mutagenese van aminozuur substituties in het cyp51A gen, correleert aan de structuur veranderingen 
van de L98H substitutie, dat verantwoordelijk is voor een multi azool resistent fenotype in A. fumigatus. 
Bovendien lijkt de L98H veroorzakende aminozuur substitutie gerelateerd aan dit fenotype, zonder de 
biologische affi  niteit van het CYP51A eiwit te beïnvloeden. De relatie tussen het gebruik van de triazool 
DMIs en het ontstaan van kruisresistentie tegen medische triazolen in A. fumigatus heeft grote gevolgen 
voor de evaluatie van de gezondheidsrisico’s geassocieerd met het gebruik van DMIs. 
Hoofdstuk 8 vormt de algemene discussie over het ontstaan en de verspreiding van het TR/L98H 
azool resistentie mechanisme, de evolutie van azool resistentie en tevens de consequenties voor de 
gezondheidszorg van een omgevings route van azool resistentie. Navolgend onderzoek zou gericht 
moeten zijn op het begrijpen van de condities waaronder de resistentie mechanismen zich kunnen 
ontwikkelen in de omgeving. Omkering van resistentie ontwikkeling zou haalbaar zijn door het limiteren 
van bepaalde triazool DMIs, maar laboratorium populatie studies en genetische mapping studies zullen 
vereist zijn om het eff ect te voorspellen van veranderingen in DMI druk. De aanhoudende druk van DMIs 
met werkzame activiteit tegen opportunistische humane schimmel pathogenen is een risico voor de 
management van schimmel ziekten veroorzaakt door deze pathogenen.
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Dankwoord
Als eerste wil ik mijn co-promotor Willem Melchers bedanken. Beste Willem, op zoek naar een 
stageplek voor biomedische wetenschappen kwam ik bij jou terecht. Je sprak enthousiast over al je 
projecten, waaronder Aspergillus, maar het HPV project sprong er (toen) voor mij toch echt uit. 
Als ik een promotieplek zou gaan zoeken moest ik eerst jou bellen wat uiteindelijk een e-mail 
vanuit Stockholm werd. Een telefoongesprek was niet nodig want zelfs via de e-mail werd het mij al 
snel duidelijk......resistentie in Aspergillus zou het helemaal gaan worden!!! Twee e-mails later was mijn 
promotieplek geregeld en zie hier het resultaat. Willem; je brengt altijd de juiste mensen bij elkaar en in 
combinatie met jouw enthousiasme en motivatie is dit een van de doorslaggevende factoren geweest 
voor het succes van dit proefschrift. Dat mijn boekje leest als een spannend jongensboek is een prachtig 
compliment! Onze werkbesprekingen zitten altijd vol humor, eerlijkheid, snelle revisies en af en toe een 
wijze levensles en daarnaast krijgen we het ook nog voor elkaar om mijn data te bespreken. Laten we 
deze succesvolle formule voortzetten!
Daarnaast ben ik natuurlijk mijn promotor Paul Verweij ook veel dank verschuldigd. Tot grote verbazing 
van Willem schudde ik jou pas voor het eerst de hand tijdens de rondleiding die ik bij het starten van 
mijn promotie onderzoek kreeg. Dit betekende echter niet dat het project nog niet in volle gang 
gezet was. Samen met jouw contacten binnen de Mycologie kreeg dit promotie onderzoek een ware 
vliegende start. Als er een beurs beschikbaar was waarvoor ik in aanmerking kwam werd de aanvraag 
altijd ingediend, mijn dank hiervoor want ik heb een prachtig CV kunnen opbouwen. Ondanks dat de 
revisies niet als eerste terugkwamen, heb je ze wel altijd tot op de laatste komma’s gelezen, ook hiervoor 
mijn dank!   
Mijn twee paranimfen; Arjan en Stefanie
Arjan, dat jij mijn paranimf zou worden wist ik na ongeveer 1 week na het starten van mijn promotie 
al. We kregen samen een kamer toegewezen en het duurde niet lang voordat iemand langskwam om 
onze deur dicht te doen… er werd namelijk te hard gelachen! Ondanks dat je niet op mijn artikelen 
staat heb je altijd de tijd genomen om mij te helpen en van advies te voorzien.....ook als ik er niet op zat 
te wachten was dit het geval, en juist ook hiervoor mijn dank. Daarnaast wil ik ook jou, Marloes, Elise en 
Linde bedanken voor de altijd warme ontvangst bij jullie thuis, ik ben blij dat ik op mijn beurt jullie kon 
helpen door op de meiden te passen. 
Stefanie, onze eerste echte kennismaking was tijdens het rondje Ooij dat wij samen liepen, de enige keer 
dat ik jou eruit heb kunnen lopen! Nu lopen we samen bij HUF, jij echt hardlopend in de voorhoede en ik 
ergens in de achterhoede. Of het nu tijdens een AAA meeting, een HUF weekend of een vakantie is, wij 
zijn de beste kamergenoten! Onze Vlaams Nederlandse miscommunicatie blijft een eeuwige bron van 
hilariteit waardoor we voorlopig nog niet uitgepraat zijn. Met eerlijkheid, humor en zelfspot weten 
we elkaar altijd weer op het juiste pad te houden als we hier vanaf dreigen te raken. Bedankt voor je 
waardevolle vriendschap.
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Alle collega’s van de Mycologie research wil ik graag bedanken. Ton en Hein, gelukkig wist ik jullie 
namen al snel wel uit elkaar te houden en als het warm genoeg is sluit ik me graag aan bij jullie 
koffi  epauze buiten, altijd gezellig! Ton, bedankt voor alle uitleg over de schimmels en het paraat staan 
voor studenten, je bezit unieke kennis en daar mag je heel erg trots op zijn. Hein, bedankt voor het 
opkweken van de gehele collectie op de itra buizen en de fungicide MICs, het bleek van onmisbaar 
belang voor dit proefschrift. Dorien, ondanks dat je al een tijd niet meer bij ons werkt heb ik een hele 
fi jne samenwerking met jou gehad. Gelukkig hebben we dit om weten te zetten in borrelavondjes in 
de stad, en misschien gaat het komende zomer dan toch echt een keer lukken om met mooi weer af te 
spreken! Jan, ik was verbaasd dat jij, ondanks mijn teleurstelling van mijn gedwongen kantoorvertrek, 
me toch vol enthousiasme beneden ontving. De verhalen uit Schaijk waren altijd erg vermakelijk en ik 
heb mijn mening over dorpsjongens echt drastisch bij moeten stellen! Dewi, ik weet niet waarom, maar 
als wij samen in een auto stappen gaat het altijd mis, met groot licht van Schaijk naar Nijmegen om 
vervolgens je trein te missen..... maar op de fi ets door Milaan achter Eva aan was trouwens minstens even 
spannend! Bedankt voor je interesse en voor alle gezelligheid. Simone, veel succes met het afronden 
van je promotie, jij bent inmiddels ook bijna klaar! Rita, you made sure things never got boring at the 
Mycology. You have worked very hard on your animal experiments so I hope to see all those eff orts back 
in nice papers. Amir, you are very motivated, polite and you work hard, good luck with all your projects!
Natuurlijk wil ik ook alle (ex)-collega’s van de Moleculaire Diagnostiek bedanken: Bart, Cindy, Gonneke, 
Judith B, Judith K, Karin, Muriël, Paul en Sandra. Ondanks mijn Mycologie onderzoek zat ik het meest op de 
Moleculaire labs. Dat betekende dat ik in de praktijk dus ook bij jullie werkbesprekingen zat en (gelukkig)
ook met de Moleculaire uitjes meeging. Bedankt voor alle gezelligheid en het vieren van alle publicaties 
onder het genot van een stuk taart! Daarnaast natuurlijk ook bedankt voor alle hulp met de bestellingen, 
inzetten van platen of andere praktische labzaken. Om als onderzoeker in het lab van de Moleculaire 
Diagnostiek te mogen werken is pure luxe. Ondanks enige ‘planningswrijving’ die kan ontstaan is verder 
altijd alles aanwezig. Dank hiervoor! Judith K, bedankt dat ik met de methoden uit Madrid meteen aan 
de slag kon en daarnaast ben je altijd bereid om mee te denken of te helpen wat ontzettend fi jn is 
geweest! Aangezien ik als MMMio aan de slag ga zal ik veel meer bij jullie dagelijkse werk aanwezig zijn. 
Ik hoop dat deze samenwerking net zo goed zal verlopen!
De roulerende Moleculaire Diagnostiek en Virologie collega’s, Secretariaat MMB, Nel, John, Twan, Theo, 
Diane en Rob wil ik natuurlijk ook allemaal bedanken. De pauzes zijn altijd een goed moment om vooral 
ook de zaken buiten het werk te bespreken. Bedankt voor jullie gezelligheid, openheid en interesse in 
mijn promotie of juist de zaken daarbuiten. Als ik iets nodig had was er altijd iemand om te helpen; er 
kon nog iets uit het magazijn gehaald worden of de autoclaaf werd nog speciaal aangezet. Ontzettend 
bedankt allemaal! Judith T, bedankt voor de altijd verhelderende lunchpauzes, en daarnaast regel je ook 
nog een auto! Geweldig!
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Graag wil ik ook een paar collega’s van het NCMLS bedanken. Kjerstin, bedankt dat ik altijd terecht kon 
op jouw bench in de toren om te preppen, ik wens je heel veel succes in Utrecht. Jan, inmiddels werk je 
niet meer in de toren maar zitten we samen op de ‘fl explekken’. Ik denk dat we een goede en gezellige 
samenwerking tegemoet gaan! Ben, mijn dank is groot voor onze gelukte Southern Blot. Het was echt 
damage control voor gevorderden, ik heb nooit meer zoiets meegemaakt! Veel succes met alles wat er 
op je pad komt.
De studenten, Robert, RobbertJan, Anne en Rob, die aan het Aspergillus werk hebben meegewerkt 
wil ik natuurlijk ook ontzettend bedanken. De hoogrisico projecten komen vaak op jullie bord dus 
bedankt voor jullie inzet bij de vele experimenten die jullie hebben uitgevoerd. Daarnaast zijn er ook 
een aantal profi elwerkstuk-studenten geweest die ik wil bedanken voor hun interesse en inzet. Indi, Tim, 
Tommie en Jakobijn veel succes met jullie eigen opleiding! Behalve dat ik studenten heb begeleid ben ik 
natuurlijk zelf als student ook begeleid. Dit heeft uiteraard de basis gevormd voor mijn eigen lab- en 
onderzoeksvaardigheden en ik ben blij dat ik altijd goede stagebegeleiders getroff en heb. Daarom wil ik 
graag Yvonne Biermann en Ulrike Schmidt (Intervet, Boxmeer), Dennis van Hamont (Gynaecologie, UMC 
St Radboud) en Judith K (jawel!) bedanken. 
Also thanks to my supervisors of my internship in Stockholm at the Karolinska Institute; Fredrik Eriksson, 
Panos and Pavel Pisa and also the groupmembers Anki, Kajsa and David. My last internship made it very 
clear for me to decide to start my own PhD. Thank you for having a great time in your group, taking me 
to Göteborg for the half marathon, borrowing skiing clothing etc. basically having a good time, tack så 
mycket!
Emillia, thank you for all your eff orts in teaching me the basics of transformation in Aspergillus in your lab 
in Madrid. My own transformation project back in the Netherlands turned out to be the biggest job of 
my whole PhD, and it feels great to have accomplished this. This could not have been possible without 
your help. Gracias por todo!!
Beste Gert, Els en Viviane, als ik niet op jullie locatie in Wageningen welkom was geweest voor mijn 
transformatie experimenten had een belangrijk deel van mijn promotiewerk niet door kunnen gaan. 
Bedankt voor het openstellen van jullie lab! Gert, bedankt voor je bijdrage in de aanvraag voor de 
ESCMID grant. 
Dear Anna, the bioinformatics work that you have done for my PhD turned out the be very 
important. The papers would not have had the same impact without your contribution and in addition 
the 3D pictures look amazing! We were able to publish three articles and we can look back on a great 
collaboration! Thank you very much!
142
HUF, het dankwoord zou niet compleet zijn zonder jullie te noemen. Toen Stefanie een paar jaar geleden 
over HUF begon dacht ik dat ze een gaatje in haar hoofd had…. om 8 uur  ‘s ochtends op je vrije zaterdag 
door een bos rennen! Wie bedenkt dat nou… inmiddels ren ik al bijna 2 jaar met jullie mee en tot mijn 
eigen verbazing heb ik inmiddels zelfs een halve marathon uitgelopen (met dank aan Ilse en Karin). De 
verbazing mag nog groter zijn dat ik het ook echt leuk vind! Dit heeft zeker te maken met de bijzondere 
groep mensen die jullie zijn. Bedankt voor al jullie interesse en gezelligheid tijdens alle HUF activiteiten!!
Een promotie traject zonder de nodige ontspanning kan ik niemand aanraden. Dan kom ik al snel bij 
de mannen en aanhang terecht (Edwin, Frank, Theo en Jelle). Als HLO doorstomers kwamen wij op de 
universiteit al snel bij elkaar om onder het genot van een kop koffi  e commentaar te geven op alles waar 
wij het eventueel niet mee eens zouden kunnen zijn (heerlijk). Al snel was de traditie geboren om na het 
tentamen te gaan borrelen (10 uur ‘s ochtends een kroeg zoeken!!). Inmiddels is de kwantiteit van ons 
samenzijn wat teruggeschroefd vanwege de afstand. De kwaliteit zeker niet want deze afstand geeft ons 
genoeg redenen om naar Stockholm, New York en jawel…. ook Maastricht af te reizen. Geef ons brood, 
wijn en spelen of in ons geval een brood, wijn en YouTube en we vermaken ons de hele avond, ik vind 
het prachtig hoe simpel het kan zijn. Ik hoop dat er nog vele avonden en reizen volgen!
Brenda, bedankt voor alle motiverende sms’jes, kaartjes of telefoontjes tijdens de afgelopen 
jaren. Ik heb het altijd ontzettend gewaardeerd. Kathrin, I cannot imagine surviving Jägargatan 
without you, a crazy time it was! And then both starting a PhD in Nijmegen; there was always 
something to discuss over lunch. Thank you for standing by me and joining me in Argentina. 
Carolina, I never thought that someone living on the other side of the world could live such a similar 
life. Thank you for all the hospitality that I received during my trip to Argentina, indeed it is nothing like 
that in Sweden or the Netherlands. I hope to continue our online chats and I cannot wait to return!
Dat hier nu een prachtig proefschrift ligt heb ik mede te danken aan thuis. Papa en Mama, jullie 
hebben mij altijd geleerd om er hard voor te werken en vooral om met plezier te werken. Daarnaast 
besef ik me heel goed dat de kansen die ik heb gekregen er voor jullie niet altijd waren. Ik waardeer het 
dus des te meer dat dit voor mij wel het geval is en jullie altijd voor mij klaar staan! De afgelopen jaren 
hebben jullie vaak gezegd dat het jullie helemaal niet om de titel gaat maar dat het veel belangrijker is 
dat ik een fi jn persoon ben. Bedankt hiervoor, daardoor weet ik mijn prioriteiten altijd weer in de juiste 
volgorde te zetten. Stijn, fi jn dat jij mijn broer bent. Onze trip naar NY was super en ik kan jouw humor 
altijd waarderen. Nicole, jij heel erg bedankt voor de gezelligheid bij ons thuis, ik ben blij dat jij erbij bent.
Papa, Mama en Stijn, de afgelopen jaren zijn niet makkelijk geweest, maar ook dat zal zeker zijn plek gaan 
vinden. En voor nu...... laten we ervan genieten!
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